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ZUSAMMENFASSUNG 
Marker sind Substanzen, die als Indikatoren für eine Exposition, einen metabolischen 
Zustand oder einen Effekt herangezogen werden. Metabolomics und Metabolite 
profiling-Ansätze gewinnen in der Markerforschung zunehmend an Bedeutung. Meta-
bolomics ermöglicht die Identifizierung von Markern für den Lebensmittelverzehr, die 
in Zukunft unter anderem in epidemiologischen Studien zur Ergänzung und Über-
prüfung traditioneller Ernährungserhebungsmethoden Verwendung finden werden. In 
der Konsequenz können Zusammenhänge zwischen Ernährung und Gesundheit im 
Allgemeinen, sowie ernährungsabhängigen Erkrankungen im Speziellen, besser be-
schrieben werden. Außerdem können mittels Metabolomics auch Marker identifiziert 
werden, die im klinischen Rahmen eine Diagnose, Prognose oder Überwachung von 
Behandlungsmaßnahmen für eine Erkrankung ermöglichen, wie z.B. bei Typ 2 
Diabetes mellitus. Von besonderem Interesse sind dabei Marker, die eine frühzeitige 
Diagnose, das heißt vor der Manifestation von Symptomen, ermöglichen. Ziel der 
vorliegenden Arbeit war es, die Verwendung von GC-MS basierten Metabolite 
profiling-Ansätzen zur Identifizierung von Markern für den Lebensmittelverzehr und 
den Gesundheitsstatus zu prüfen. Einen besonderen Schwerpunkt bildeten dabei 
volatile organische Verbindungen und Zuckerverbindungen, die in Urin- und 
Plasmaproben einer Querschnittsstudie mit 300 Probanden sowie einer humanen 
Interventionsstudie mit Diabetikern, Prädiabetikern und Gesunden analysiert wurden. 
Bei der bisherigen Suche nach Markern für den Lebensmittelverzehr lag das Augen-
merk vor allem auf nicht-volatilen Metaboliten. Um das Potential des Volatiloms zu 
eruieren, wurden Urinproben einer Querschnittsstudie mithilfe einer ungerichteten 
HS-SPME-GC×GC-MS Methode analysiert und darin beispielhaft nach Markern für 
den Kaffeekonsum gesucht. Aus dem Urinprofil mit 138 volatilen Verbindungen wur-
den sechs plausible Kandidaten identifiziert, von denen sich 3,4-Dimethyl-2,5-furan-
dion als der robusteste Marker erwies. Mittels einer Korrelationsanalyse anhand von 
Verzehrsdaten weiterer Lebensmittel wurde darüber hinaus gezeigt, dass das Volati-
lom eine vielversprechende Quelle neuer Marker für den Lebensmittelverzehr ist. 
Zucker lassen sich aufgrund ihrer strukturellen Ähnlichkeit häufig nur unzureichend 
chromatographisch trennen, daher werden in humanen Matrices bisher mehrheitlich 
nur wenige bekannte Zuckerverbindungen erfasst. Im Rahmen dieser Arbeit wurde 
eine semi-gerichtete GC-MS Zuckerprofiling-Methode entwickelt, mit der gezeigt 
werden konnte, dass das humane Zuckerprofil im Urin und im Plasma erheblich kom-
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plexer ist, als bisher beschrieben und angenommen. Verschiedene Zuckerverbin-
dungen, wie beispielsweise Psicose oder Trehalose, über deren Herkunft und Vor-
handensein im Urin oder in Plasma fast nichts bekannt ist, wurden nachgewiesen. Im 
Urin zeigten sich darüber hinaus Unterschiede in der Maltosekonzentration in 
Abhängigkeit vom Geschlecht sowie dem prä- und postmenopausalen Status, die 
vermutlich im Zusammenhang mit der vaginalen Mikrobiota stehen. Die Assoziation 
der Zuckerprofile mit dem Lebensmittelverzehr ermöglichte zudem die Identifizierung 
neuer und Bestätigung bekannter Marker, beispielsweise für den Verzehr von 
Avocado und Milchprodukten, sowie für Alkoholkonsum.  
Im Plasma von Gesunden, Prädiabetikern und Diabetikern wurden nach einem 
oralen Glucosetoleranztest deutliche Unterschiede im Zuckerprofil festgestellt. 
Interessanterweise zeigten eine Reihe neuer Zuckerverbindungen markante 
postprandiale Unterschiede abhängig vom Gesundheitszustand. Beispielsweise 
zeigte Trehalose ein ähnliches Profil wie die insulinabhängige Glucose. Jedoch ist 
weder über den Mechanismus noch zur Herkunft dieser Zucker etwas bekannt.  
Bereits die bisherigen Ergebnisse des Zuckerprofilings in Urin und Plasma zeigten, 
dass zusätzliche Zuckerverbindungen, wenn auch in sehr geringer Konzentration, 
vorhanden sind. Daher wurde die eindimensionale Methode zu einer 
zweidimensionalen GC×GC-MS-Methode mit verbesserter Sensitivität und Trennung 
weiterentwickelt, was nun die Erfassung von 84 statt 55 Zuckerverbindungen in Urin 
ermöglicht. Erste Auswertungen der Messdaten einer Interventionsstudie mit Äpfeln 
zeigten, dass diese Methode die Identifizierung von potentiellen Markern für den 
Verzehr von Äpfeln ermöglicht. Die Ergebnisse verdeutlichen, welches Potential in 
der umfassenden Analyse von Zuckern, einschließlich seltener Verbindungen, steckt.  
GC-MS basierte Metabolite profiling-Ansätze, wie hier für das Volatilom und das 
Zuckerprofil gezeigt, sind geeignete Methoden für die Identifizierung von Markern 
des Lebensmittelverzehrs und des Gesundheitsstatus. Die Identifizierung bisher 
unbekannter Verbindungen, die Weiterentwicklung der Zuckeranalytik zu einer 
quantitativen Methode und insbesondere die Validierung der identifizierten Marker 
bezüglich ihrer Eignung, den Lebensmittelverzehr bzw. den diabetischen Status 
akkurater zu erfassen, sind zukünftige Ziele. Besonders herausfordernd ist es dabei, 
die mechanistischen Zusammenhänge aufzuklären, insbesondere im Hinblick auf 
Herkunft, Vorhandensein und Funktion der detektierten Zuckerverbindungen im 
menschlichen Metabolismus. 
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SUMMARY 
Markers are compounds that can be used as indicators of an exposure, a metabolic 
state, or any other effect. Metabolomics and metabolite profiling approaches for 
marker discovery will increasingly gain significance. In the context of food, diet, and 
health, these approaches allow among others the identification of dietary intake 
markers, which can complement and verify traditional dietary assessment methods in 
epidemiologic studies. Consequently, the investigation of associations between diet 
and health status in general, and also in particular diet-related diseases will be 
improved. Compared to classical biomarker studies, metabolomics enables a more 
comprehensive investigation of clinical markers for diagnosis, prognosis and 
monitoring of diseases, such as type 2 diabetes mellitus. Especially, early diagnosis 
in pre-disease states, where symptoms are not yet evident, are of particular interest. 
The aim of this thesis was to evaluate the application of GC-MS based metabolite 
profiling approaches for the identification of markers for dietary intake and health 
status. In this respect, volatile organic compounds and sugar compounds were 
analyzed to discover marker candidates in urine and plasma samples from a cross-
sectional study with 300 participants, as well as from a human intervention study with 
diabetic, prediabetic and healthy participants. 
In the past, the search for markers of dietary intake mostly focused on non-volatile 
metabolites. To explore the potential of the volatilome, urine samples of a cross-
sectional study were analyzed aiming to exemplary identify markers of coffee 
consumption using an untargeted HS-SPME-GC×GC-MS method. Six marker 
candidates were identified from a profile of 138 volatile organic compounds with the 
most robust represented by 3,4-dimethyl-2,5-furandione. Moreover, the correlation 
with the general dietary intake data highlighted the volatilome as a particularly 
interesting source for the detection of new dietary markers. 
The chromatographic separation of sugar compounds is often insufficient due to the 
high structural similarities. Therefore, in most studies common and well-known sugar 
compounds are analyzed in human body fluids. Within the scope of this thesis, a 
semitargeted GC-MS sugar profiling method was developed, which revealed a more 
complex sugar profile, both in urine and plasma, than described so far or expected. 
Rare sugar compounds such as psicose and trehalose were detected. However, the 
knowledge about their origin and presence in urine or plasma is limited to date. 
Moreover, the maltose concentration in urine was shown to be dependent on sex and 
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menopause status (pre- and post-menopausal) – a relationship with the vaginal 
microbiota is suggested here. In addition, the association of the urinary sugar profile 
with dietary intake data enabled the identification and confirmation of several new 
and also known marker candidates as for example, for consumption of avocado, 
dairy products and alcohol. 
The plasma sugar profiles of healthy, prediabetic and diabetic volunteers after an oral 
glucose tolerance test could be clearly distinguished, independent of glucose. 
Remarkably, a variety of sugar compounds showed marked postprandial differences 
dependent on health status. For example, trehalose showed a profile similar to the 
insulin-dependent profile of glucose. However, the origin and underlying biological 
mechanism for those sugar compounds remain to be elucidated.  
During the application of the one-dimensional GC-MS sugar profiling method to urine 
and plasma samples, it became evident that even more sugar compounds might be 
present, although in low concentrations, but were not detected due to limitations of 
the analytical method. Therefore, the one-dimensional method was transferred into a 
two-dimensional GC×GC-MS method. Improved sensitivity and separation finally 
enabled the detection of 84 instead of 55 sugar compounds in urine. The two-
dimensional method was applied in an intervention study with apples, and revealed 
marker candidates for apple consumption for future validation. Overall, the results 
illustrate the benefit of a comprehensive analysis of sugar compounds in urine and 
plasma, including minor and rare sugar derivatives. 
The GC-MS based metabolite profiling approaches addressing the volatilome and the 
sugar profile, respectively, were demonstrated to be promising approaches for the 
identification of markers for dietary intake and health status. Future work should 
address the identification of unknown compounds, the adaptation of the GC×GC-MS 
sugar profiling method for quantitative purposes, and especially the validation of the 
identified marker candidates with respect to their suitability to more accurately assess 
dietary intake or diabetic state. High priority should also be given to the biochemical 
mechanisms and the origin of the compounds as well as their physiological or 
pathophysiological function in human metabolism. 
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ABBREVIATIONS 
ANOVA  analysis of variance 
APCI   atmospheric pressure chemical ionization 
BSA   benzenesulfonic acid 
BSTFA  N,O-bis(tri-methylsilyl)trifluoroacetamide 
CAR   carboxen 
CE-MS  capillary electrophoresis coupled to mass spectrometry 
CI   chemical ionization 
CV   coefficient of variation 
CW   carbowax 
C18   octadecylsilyl derivatized silica column 
1D   first dimension 
2D   second dimension 
2D   two-dimensional 
dc   internal diameter 
df   film thickness 
DVB   divinylbenzene 
ECD   electron capture detector 
EI   electron ionization 
FAME   fatty acid methyl ester 
FFQ   food-frequency questionnaire 
FID   flame ionization detector 
FoodBAll  Food Biomarker Alliance 
GC   gas chromatography 
GC×GC  comprehensive two-dimensional gas chromatography 
GMD   Golm Metabolome Database 
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HbA1C   glycated hemoglobin 
HDL   high-density lipoprotein 
HLB   hydrophilic lipophilic balances 
HMDB  Human Metabolome Database 
HPLC   high pressure liquid chromatography 
HS   headspace 
IFG   impaired fasting glycaemia 
IGT   impaired glucose tolerance 
IS   internal standard 
L   length 
LC   liquid chromatography 
LDL   low-density lipoprotein 
LLE   liquid-liquid extraction 
MRI   Max Rubner-Institut 
MSI   Metabolomics Standard Initiative 
MS/qMS  mass spectrometry/quadrupole mass spectrometer 
MSTFA  N-methyl-N-(rimethylsilyl)trifluoroacetamide 
m/z   mass-to-charge ratio 
NIST   National Institute of Standards and Technology 
NMR   nuclear magnetic resonance spectroscopy 
OGTT   oral glucose tolerance test 
PA   polyacryl 
PAN   polyacrylonitrile 
PCA   principal component analysis 
PDMS   polydimethylsiloxane 
PLS   partial least squares 
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QC   quality control 
RI   retention index 
RT   retention time 
SIM   selected ion monitoring 
SPE   solid-phase extraction 
SPME   solid-phase micro extraction 
S/N   signal-to-noise 
TIC   total ion current 
TLC   thin layer chromatography 
TMCS   trimethylchlorosilane 
TMS   trimethylsilyl 
TOF   time-of-flight 
TPR   templated resin 
T1DM   type 1 diabetes mellitus 
T2DM   type 2 diabetes mellitus 
VOC   volatile organic compounds 
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1 INTRODUCTION 
1.1 Metabolomics 
1.1.1 Principle and definitions 
Metabolomics is a comprehensive analytical approach aiming at an unbiased 
analysis of the entirety of metabolites occurring in a biological system at a certain 
time point, namely the metabolome [1]. In essence, a biological system is everything 
that lives or lived or a sample thereof. Metabolites are organic, low molecular weight 
molecules (<1500 Da) in a biological system, which originate from endogenous 
metabolism, host-associated microbial communities, exogenous sources (e.g. 
environment) and are detectable [2, 3]. Metabolomics can be applied to analyze the 
metabolic state of a biological system (human, animal, plant, microorganisms etc.) 
comprehensively. In this thesis, only human biofluids were analyzed. Existing 
definitions of metabolomics are not consistent; the following are, however, commonly 
used. In metabolomics, several approaches can be distinguished with fluid transitions 
between them: 
• Targeted analysis aims at a precise quantitative analysis of selected known 
metabolites and is in most cases driven by a specific biochemical question 
(hypothesis-driven). Accordingly, specific sample preparation and purification 
adjusted for the respective applications as well as highly sensitive and robust 
methods are necessary [1, 4]. 
• (Targeted) Metabolite profiling aims at the absolute or relative quantitative 
analysis of metabolites (known or unknown) from a selected biochemical 
pathway or a specific substance class. The approach can be hypothesis-
driven or hypothesis-generating. Sample treatment can be specific for a 
substance class [1, 2, 4]. 
• Untargeted metabolite profiling/untargeted metabolomics aims at the 
relative quantitative, non-selective, and universal analysis of all or as many 
metabolites (known or unknown) as possible in a given biological sample. The 
approach often does not have an a priori question, and therefore is 
hypothesis-generating. Accordingly, sample preparation is unspecific in order 
to capture as many metabolites as possible [1, 2, 4]. 
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• Metabolite fingerprinting classifies samples based on their metabolite 
pattern (“fingerprint”). This screening approach does not differentiate between 
individual metabolites [1, 2, 4]. 
Metabolomics takes a snap-shot of the metabolism at a given time point, aiming to 
enable investigation of the physiologic state of an organism, diagnosis of diseases or 
metabolic disturbances, investigation of the influence of a certain treatment on an 
organism, or identification of marker candidates [2, 5, 6]. Especially in marker research, 
metabolite profiling, or untargeted metabolomics approaches are meant to identify 
potential metabolites of interest, which later might be applied for specific purposes 
using targeted analyses [7]. For these purposes metabolomics approaches are 
usually performed to compare metabolite profiles of groups (treated vs. control; 
healthy vs. diseased) and to apply statistical methods to identify differentiating 
metabolites [2, 5, 6]. Another important application of untargeted metabolomics 
approaches is to improve our understanding of the entire living organism at the 
molecular level (systems biology), meaning the biochemical and biological 
mechanisms in a complex system, together with the other “omics” approaches such 
as genomics, transcriptomics or proteomics [2]. Metabolomics is at the endpoint of the 
“Omics cascade”, reflecting “what has happened and is happening”, and thus is 
closest to the phenotype [2]. Therefore, it enables the most functional insight into the 
biological processes in a living organism, and the influence of or the response to 
stimuli are amplified in comparison to genomics, transcriptomics and proteomics [8]. 
According to the Human Metabolome Database (HMDB, version 4.0), the number of 
detected, expected and predicted human metabolites totals more than 114 000 
(detected metabolites: ~21 700, expected metabolites: ~82 000; predicted 
metabolites: ~9 500) [9]. The metabolome consists of chemically highly diverse 
compounds with a wide range of polarity, solubility, and volatility – including but not 
limited to carbohydrates, secondary natural products, lipids, amino acids, terpenoids, 
steroids, aromatic compounds, and many more [10]. Additionally, these metabolites 
occur in a wide concentration range (7-9 orders of magnitude, pmol-mmol) [11]. 
Therefore, it is impossible to cover the whole metabolome with just one analytical 
technology [2, 3, 8]. With the aim to detect as many metabolites as possible, analytical 
technologies should fulfill the following criteria: non-selective, universal, robust, 
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sensitive, suitable for high-throughput analyses (especially for large studies), and 
sufficient separation performance [1-3]. 
1.1.2 Important aspects for metabolomics experiments 
Experimental design 
A typical workflow for a metabolomics study in nutritional research is depicted in 
Figure 1.1. The first and most important step is the experimental design, because the 
data can only be as informative as the experimental design allows [2, 12]. Therefore, 
unwanted variation (biological or technical/pre-analytical and analytical) has to be 
minimized and controlled. The choice of study design (observational vs. intervention 
study) and also its standardization (e.g. control and blinding, confounding factors, 
compliance etc.) are important [12]. For example, in the case of an intervention study, 
usually the influence of the high intrinsic biological variation due to many factors 
(among others sex, age, diet, life style, genetic background, hormonal changes, 
diurnal rhythms) has to be limited, while in the case of an observational question 
often the broad variation of a population is of interest. Generally, dependent on the 
study design, in order to obtain valid and statistically significant results for the 
investigated question, a large number of individual samples/participants is desirable 
[2, 6, 10, 13]
. For example, for observational studies, a minimum of 100 participants is 
necessary to cover a broad population, while a minimum of 5-10 well characterized 
participants might be sufficient for an intervention study (better power calculation). 
Another relevant decision is the choice of the sample matrix for the investigation. 
Metabolomics analyses have been performed with many biological matrices and 
body fluids, such as urine, blood plasma or serum, feces, saliva, sweat, breath, or 
tissue samples. Attention should be paid to the following points: i) invasiveness of 
sample collection (e.g. urine vs. tissue) [14]; ii) biological question, availability of 
metabolites in a certain matrix (e.g. volatiles in breath vs. blood); iii) interference of 
matrix components with analytical technology (e.g. anticoagulants for plasma) [12]; iv) 
containers for samples and storage of samples until analysis (e.g. breath vs. urine) [1, 
2, 14]; v) necessity of normalization (pre- or post-analytical; e.g. in the case of 
differentially diluted urine samples due to maintenance of water homeostasis) [12]; vi) 
influence of the background, for example macromolecules interfering with analysis 
(e.g. breath vs. blood) and vii) the sample preparation in general. 
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Figure 1.1. Typical workflow for human metabolomics experiment including experimental design, sample preparation, data acquisition, 
data preprocessing, statistical analysis, identification and biological interpretation (modified from [15]). 
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Sample preparation 
Some of the stated points are also relevant for the next step in metabolomics 
experiments, the sample preparation. The sample preparation aims to lose as few 
metabolites as possible from a complex matrix, to avoid degradation or changes in 
metabolite levels, and to receive a sample that is compatible with the chosen 
analytical technology [2, 3]. Degradation of metabolites via enzymatic and non-
enzymatic reactions have to be prevented using an inactivation or quenching step 
(e.g. freezing with liquid nitrogen, adding cold methanol, or adding acid and boiling) [2, 
6, 8, 10]
. Interferences by components of the matrix should be minimized; therefore, for 
example blood plasma or serum samples are usually subjected to a protein 
precipitation. Typically applied sample preparation methods are dilution, liquid-liquid 
extraction (LLE), solid-phase extraction (SPE), solid-phase micro extraction (SPME) 
or microwave-assisted extraction. The solvent applied for the extraction process, e.g. 
in the case of LLE, has a huge influence on the coverage of the metabolome and can 
introduce a bias with respect to some metabolite classes (polar vs. unpolar 
solvents) [2, 13]. To minimize pre-analytical variation due to sample collection, storage 
and preparation, all samples have to be treated consistently throughout the 
experiment [13]. 
Data acquisition 
The three main methodologies applied in the untargeted metabolomics field are 
nuclear magnetic resonance spectroscopy (NMR), and mass spectrometry (MS) 
either coupled to liquid chromatography (LC) or gas chromatography (GC). Other 
more rarely applied technologies are for example direct injection MS or capillary 
electrophoresis coupled to MS (CE-MS) [2]. Each of these technologies has its own 
advantages and disadvantages with respect to its application in metabolomics. NMR 
enables i) a fast and non-destructive sample preparation with high-throughput; ii) a 
fast, highly reproducible, robust and non-discriminating quantification of metabolites; 
and iii) includes information on chemical structure. However, sensitivity and coverage 
of metabolites (only middle to highly concentrated metabolites detectable) is limited 
and identification based on chemical shifts of the signals is difficult in complex 
mixtures [2, 15]. In contrast, MS based methods allow a highly sensitive and selective 
detection and identification, especially in combination with a separation technology 
such as GC or LC. Disadvantages include a destructive and more complex sample 
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preparation and clean-up and also the possibility of discrimination against some 
metabolites or whole substance classes [2, 15]. While LC-MS enables the detection of 
the highest number of metabolites, GC-MS has the highest reproducibility with 
respect to retention time and mass spectra and is less susceptible to matrix effects 
and ion suppression than LC-MS [16]. However, GC-MS necessitates derivatization of 
metabolites to increase thermal stability and volatility [2, 16]. Each of these methods 
has an implicit bias with respect to metabolite coverage, therefore a combination of 
different methodologies enables a more comprehensive investigation of the 
metabolome [2]. To minimize intra-analytical variation, blank samples, internal 
standards (IS) and quality control (QC) samples are useful tools [2, 16]. Blank samples 
allow the assessment of artefacts due to derivatization reagents, solvents or in the 
case of chromatography due to the column. Internal standards and QC samples 
enable supervision of the data acquisition and performance of the equipment, and 
also the determination of the overall precision of the method. Additionally, QC 
samples can be used for correction of drift and batch effects [12]. Randomization of 
the sample order during the measurement is recommended to minimize the 
introduction of bias due to instrumental drifts [12]. 
Data preprocessing 
After the data acquisition the raw data has to be converted to a form enabling further 
data analysis (data preprocessing). The commonly high number of samples and the 
huge number of metabolites detected per sample result in highly complex and large 
data sets requiring dedicated software programs for data preprocessing. Typical 
steps during data processing include baseline correction, noise filtering, peak 
detection, automatic annotation, peak alignment, deconvolution, drift correction, or 
normalization. Each step has to be well-conceived because every individual step can 
introduce undesired and uncontrolled post-analytical variation and can have 
fundamental influence on the results of the statistical analysis [10, 12].  
Statistical analysis 
Usually, a combination of univariate and multivariate statistics is applied to 
distinguish between groups. In the case of univariate statistic (e.g. t-test, analysis of 
variance (ANOVA) or correlation analysis) each feature is analyzed individually, while 
for multivariate statistic (e.g. principal component analysis (PCA), partial least 
squares (PLS) or clustering) all features are analyzed simultaneously [15]. As a first 
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step, statistical analysis aims to identify interesting features or patterns in the data 
due to the biological context. Such biological relevant features or patterns might, in a 
second step, enable the generation of a hypothesis for further investigations [10]. 
Important aspects with respect to statistical analysis are: i) each statistical approach 
has certain assumptions (e.g. normality, homogeneity of variances); ii) potential 
confounding variables have to be taken into account (e.g. sex or age); iii) proper 
validation strategies for results [12]; and iv) the problem of multiple testing due to the 
large number of features in metabolomics experiments. If a large number of features 
are analyzed at the same time, the likelihood of coincidental false positive 
associations is increased [15]. 
Metabolite identification and biological interpretation 
One of the biggest bottlenecks in metabolomics studies is the identification of 
metabolites. As a result of advanced analytical technologies more and more 
metabolites can be detected, however many of these remain unknown and cannot be 
easily and directly identified [12]. Therefore, usually the statistical analysis is carried 
out and only relevant metabolites are subsequently identified, if possible. Different 
approaches for identification are conceivable: i) extensive databases with spectral 
information; ii) MS/MS or NMR experiments for structure elucidation; or iii) in the case 
of chromatographic separation the peak position together with retention indices (RI; 
only for GC) can give hints about the structure of a compound. For GC-MS in the 
case of electron ionization (EI), which produces highly reproducible mass spectra, 
extensive spectral libraries already exist. Spectral library databases such as the 
FiehnLib or the National Institute of Standards and Technology (NIST) libraries 
include mass spectra and alkane- or fatty acid methyl ester (FAME)-based RI’s. Once 
relevant metabolites, distinguishing between a control group and a diseased or 
treated group, are identified, the last important step starts: the biological 
interpretation, which aims to find a mechanistic and contextual biological relationship 
between metabolites and the biological outcome. 
The workflow of a human metabolomics experiment emphasizes that the whole 
metabolome cannot be covered by one sample preparation and/or analytical 
technology. Any sample preparation or analytical technology introduces a certain 
bias with respect to the coverage of the metabolome. Although sample preparation is 
usually as unspecific and general as possible, the high diversity in chemical 
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properties of the metabolites makes some losses unavoidable. For example, an 
extraction with a hydrophilic solvent often is only effective for polar substance classes 
and as a result excludes most unpolar substance classes. Another point is that some 
substance classes with very characteristic properties such as volatile organic 
compounds (VOC) need dedicated sampling approaches and analytical methods. 
With respect to the analytical technology, often a compromise between the detection 
of as many different metabolites and substance classes as possible and the 
resolution of some specific substances showing a high structural similarity, such as 
isomeric sugar compounds, has to be made. Therefore, for some selected metabolite 
classes or pathways, dedicated targeted comprehensive metabolite profiling 
approaches are desirable for highly resolved insights into the metabolome. 
1.1.3 Technical aspects of GC-MS based metabolite profiling approaches 
The development of capillary columns in GC enables the highest separation power 
and highest chromatographic resolution in comparison to other chromatographic 
techniques such as thin layer chromatography (TLC) or high pressure liquid 
chromatography (HPLC) [17]. Additionally, coupling with MS enables a high selectivity 
and sensitivity, and also the possibility to identify unknown metabolites. Moreover, 
the separation of chromatographically coeluting peaks using individual masses is 
achievable. Therefore, GC-MS represents an indispensable tool for untargeted 
metabolomics and metabolite profiling approaches [17].  
Gas chromatography (GC) 
The basic principle of GC is the separation of an analyte mixture through partition 
between a mobile gaseous phase (typically Helium) and a stationary phase (columns 
with different characteristic properties). Therefore, analytes have to be transferable to 
the gaseous phase (i.e. sufficient vapor pressure) and thermally stable. While volatile 
metabolites (such as many ketones, aldehydes, esters, furan and pyrrole derivatives, 
sulfides, isocyanates, isothiocyanates or hydrocarbons) can be directly analyzed, 
semi- and non-volatile metabolites (such as mono- and disaccharides, sugar 
phosphates, amino acids, fatty acids, small peptides, long chain alcohols, inositols, 
amines, amides, alkaloids, or organic acids) have to be derivatized to increase 
volatility and thermal stability [12]. 
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VOC are important constituents of the metabolome [2, 18]. With respect to sample 
preparation and injection of volatile metabolites dedicated approaches are 
necessary. Conventional sample preparation approaches such as extraction or SPE 
are not feasible due to incomplete extraction or losses during concentration steps, 
and additionally, solvents might interfere with analyte elution (i.e. solvent front) [2]. 
Therefore, headspace (HS) techniques are applied, such as static or dynamic HS or 
HS-SPME [17]. Headspace refers to the gaseous phase above solid or liquid matrices 
[19]
. In the case of static HS-GC, an aliquot of the equilibrated headspace above a 
sample matrix is injected into the GC, while in dynamic HS-GC or “purge-and-trap”, 
the sample is continuously and exhaustively extracted before desorption in the GC 
[17, 19]
. Another simple and cost-effective HS sampling techniques, which is often 
applied in metabolomics is SPME, which integrates sample collection, extraction and 
concentration in one solvent-free step [18, 20]. A fused-silica fibre situated in a hollow 
needle is coated with a stationary phase, resembling a syringe assembly. The fibre 
can either directly be immersed in a liquid sample (direct immersion) or in the HS 
above the sample (HS-SPME), during this time VOC are either adsorbed or absorbed 
on the stationary phase. HS-SPME is a complex multiphase equilibrium. In addition 
to the equilibrium between sample and HS (similar to static HS-GC), there is the 
equilibrium between HS and stationary phase of the fibre [17, 18]. Similar to static HS 
the following parameters are important for method optimization: extraction 
temperature and time, salting-out effect, agitation of sample, equilibration time, phase 
ratios (sample/HS; HS/stationary phase), film thickness of stationary phase 
(influences equilibration time and sensitivity) and interactions between analytes and 
matrix [17, 18]. To achieve high precision and reproducibility, a strict standardization of 
sample preparation and conditions is necessary, especially if extraction is performed 
under non-equilibrium conditions [18]. Untargeted metabolomics and metabolite 
profiling approaches aim to detect as many compounds as possible, therefore 
stationary phases with a low selectivity are desirable [21]. Many GC-based 
metabolomics studies recommend a mixture of DVB/CAR/PDMS (divinylbenzene/ 
carboxen/polydimethylsiloxane) as stationary phase for the fibre to detect a variety of 
VOC of a broad range of volatility and polarity [21-23]. 
Most primary metabolites such as amino acids, organic acids, sugars, lipids and 
alcohols require derivatization to increase volatility and thermal stability before GC-
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MS analysis. Derivatization should be fast, simple, efficient, reproducible and if 
possible automated via an autosampler to reduce batch effects (e.g. degradation or 
variability in ratios of partially derivatized metabolites) [12, 17]. A number of 
derivatization methods exist such as silylation, acylation, alkylation/esterification and 
many more. However, most GC-MS based untargeted metabolomics or metabolite 
profiling methods apply a two-step derivatization including an oximation followed by 
silylation [2, 12, 16, 17]. Oximation, either performed with hydroxylamines or 
alkoxyamines, prevents cyclization of sugar isomers, decarboxylation of α-
ketocarboxylic acids, and keto-enol tautomerism. Reducing sugar compounds 
equilibrate in aqueous solutions between their open-chain and cyclic α- and β-
semiacetal form. If only silylation is performed, this results in six and more derivatives 
(Figure 1.2) [2, 12], which in turn leads to a more complex chromatogram and 
separation problems. Therefore, oximation or methoximation is performed, arresting 
reducing sugars in their open-chain form and leading to only two isomers (syn and 
anti; Figure 1.2).  
Following methoximation, typically a trimethylsilylation is performed, often using 
reagents such as N-Methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA) or N,O-
Bis(trimethylsilyl)trifluoroacetamide (BSTFA). During silylation active hydrogen in 
functional groups (such as OH, COOH, NH or SH) is replaced by trimethylsilyl(TMS)-
groups. However, silylation is a reversible process, even traces of water or humidity 
might cause degradation. Consequently, taking care of evaporation of extracts before 
derivatization and close systems while handling derivatization reagents (i.e. working 
under inert gas) is necessary [2, 12]. Limitations of derivatization procedures are: i) it 
causes longer and more complex sample preparation and can introduce additional 
variance; ii) in the case of some compounds degradation or rearrangement reactions 
are possible (e.g. arginine to ornithine or glutamate to pyroglutamate); iii) especially 
for amino acids a partial silylation can occur, leading to multiple derivatives; iv) due to 
reactions of the silylation reagent with itself or solvents, artifacts can be formed; and 
v) it can lead to altered compound compositions in the samples (e.g. via 
contamination or faster/selective reaction with certain substance classes) [2, 12, 17, 24]. 
However, derivatized compounds show more distinct MS spectra in comparison to 
the corresponding underivatized compounds and an improved sensitivity and 
selectivity is observable [2, 17]. An important reason, why trimethylsilylation with and 
1 INTRODUCTION  
11 
 
without oximation/methoximation are mainly used is that extensive EI-MS spectral 
libraries exist (e.g. NIST or FiehnLib). 
 
Figure 1.2. Mutarotation of glucose in aqueous solution and methoximation (modified 
from [12]). 
Coupling with mass spectrometry 
The combination of GC with MS is very advantageous and additionally, the coupling 
of capillary columns with MS is easily realized [17]. For MS, ions are generated from 
molecules in the ion source at temperatures between 200-300 °C, then separated 
according to their mass-to-charge ratio (m/z) in the mass analyzer and finally 
detected in the detector; all this happens under high vacuum conditions 
(10-7-10-5 mbar) [12]. Two regularly applied MS techniques in metabolomics are 
quadrupole MS (qMS; Figure 1.3) and time-of-flight MS (TOF-MS) [2]. The qMS uses 
four parallel metal rods with direct and alternating currents as mass filter, so that at a 
given setting and time period only ions with a certain m/z have a stable trajectory and 
can pass the quadrupole rods towards the detector. The current is continuously 
changed over time to analyze the desired mass range; this results in slow scan rates 
dependent on scan speed and selected mass range [2, 12, 17]. For TOF-MS, ions are 
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accelerated in an electric field; their velocity and the transit time through a drift region 
depend on their mass. Therefore, high acquisition rates (up to 500 spectra/s) are 
possible and the whole mass range is acquired simultaneously; it can be operated 
both in nominal and high mass resolution [2, 12]. However, TOF-MS are comparably 
sensitive and cost-intensive [17]. In the last years, Q-TOF-MS and Orbitrap are 
emerging MS to be coupled with GC. Q-TOF-MS permits to determine parent and 
fragment ions along with their isotopic abundance with high mass accuracy and thus, 
is especially useful for identification purposes [17]. Similarly, Orbitrap enables even 
higher mass resolution and accuracy, also providing information on MS/MS spectra, 
however acquiring data at high resolution will lead to reduced number of 
scans/peak [12]. 
qMS, which were utilized in this thesis, can be operated both in scan mode and 
selected ion monitoring (SIM)-mode. Untargeted metabolomics approaches mainly 
operate in scan mode due to the possibility to record more comprehensive 
information for metabolites and therefore better identification. SIM mode is an 
interesting alternative for targeted or metabolite profiling approaches aiming to 
identify and quantify targeted substances or substances of certain substance 
classes [12]. Advantages of SIM mode are i) lower limits of detection due to longer 
dwell times of selected m/z; ii) better separation of metabolites and especially better 
separation from matrix compounds; and iii) better accuracy and precision due to 
more data points, which are equally distributed over the peaks [12, 14]. Nonetheless, 
SIM mode necessitates prior knowledge of the measured compounds 
(i.e. characteristic m/z for certain metabolites or whole substance classes) and is 
more of a targeted nature or semitargeted, if the monitoring of a whole substance 
class is the aim [14]. In consequence, the coverage of the metabolome is naturally 
restricted. 
In general, ions for GC-MS measurement are mostly generated by EI or chemical 
ionization (CI) [2, 12, 17]. EI, a hard ionization method with extensive and highly 
reproducible fragmentation patterns, is the ionization technique of choice [2, 4, 12, 17]. 
Gaseous compounds are bombarded with electrons and as a result radical cations 
are formed, which are then extensively fragmented. 70 eV are used for EI, even 
though for the ionization of most molecules 10-15 eV would be enough, however the 
ionization efficiency and in consequence, the sensitivity would be limited [12, 17]. The 
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resulting highly reproducible and extensive fragmentation patterns can be used for 
identification of metabolites using existing commercial EI-MS spectral libraries, some 
of which already include mass spectra and RI’s of more than 99 000 compounds 
(NIST17, National Institute of Standards and Technology, Gaithersburg, MD, US). 
However, the following limitations exist:  
• missing molecular ions complicate identification of unknown compounds not 
listed in spectral databases 
• fragmentation ions are often unspecific and difficult to interpret 
• structural isomers very often exhibit highly similar EI spectra necessitating 
chromatographic separation for an unambiguous identification (e.g. in the case 
of sugar compounds) [12, 17] 
The additional use of CI, a soft ionization technique, might enable overcoming some 
of the limitations with respect to identification. In the case of CI, the energy 
transmitted to the analyte molecules is low, therefore the formed molecular ion is 
relatively intensive, and less fragmentation occurs [12]. However, CI results in less 
efficient ionization and a loss in sensitivity. Additionally, spectra obtained in different 
labs are not as comparable and therefore, building databases of mass spectra is 
complicated. Nonetheless, the more intensive formation of the molecular ion is 
advantageous for the calculation of the molecular formula of unknown compounds 
and, together with fragmentation patterns obtained by EI-MS, might enable a more 
reliable structure elucidation. However, in the case of structurally highly similar 
isomers (e.g. sugar compounds), even this will not enable unambiguous 
identification. Such challenges might be overcome by using enhanced separation 
capacity, as it can be achieved for example with comprehensive two-dimensional gas 
chromatography (GC×GC). 
Comprehensive two-dimensional gas chromatography (GC×GC) 
The fundamental principal of GC×GC is the separation of all analytes on two columns 
with different stationary phases. The peak capacity, a tool to evaluate 
chromatographic separation and column efficiency, is increased in a multiplicative 
way in comparison to one-dimensional GC (ntotal = n1 × n2) [17]. A comprehensive two-
dimensional separation has to fulfill the following criteria according to Giddings et 
al. [25]:  
1 INTRODUCTION  
14 
 
• All analytes of a sample have to undergo two or more essentially 
different/independent separation mechanisms (orthogonality criterion). 
• Analytes that were separated in the first dimension (1D), have to remain 
separated in the second dimension (2D) (modulation criterion). 
The set-up of the GC×GC-qMS systems applied in this work are depicted in 
Figure 1.3.  
 
Figure 1.3. Set-up of the GC×GC-qMS systems applied in this work. 
In general, two columns with different stationary phases are serially connected, with 
the so-called modulator lying in between. To fulfill the orthogonality criterion, the 
choice of stationary phases in the 1D and 2D is essential. Often a column with an 
unpolar stationary phase is chosen for the 1D-separation, which is based on vapor 
pressure, and a column with a polar or medium-polar stationary phase is chosen for 
the 2D-separation, where additionally polar interactions with the stationary phase, 
such as hydrogen bridge bonds or dipole-dipole interactions, play a role [12, 17]. Non-
orthogonal column combinations with a polar stationary phase in the 1D and an 
unpolar one in the 2D are less common, but can be advantageous for certain 
applications, such as for polar and/or ionogenic analytes or for VOC analysis [12, 26-28]. 
The modulator fractionates and focusses the eluate from the 1D-column, transfers 
and reinjects it for further separation on the 2D-column [12, 28-31]. In general, thermal 
and differential flow modulators can be differentiated:  
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• Thermal modulators (jet-based cryogenic modulator, utilized in this work): 
Part of the column is placed in the air streams of two jets (cold and hot jet). 
The cold jet continually emits a cold air stream and focusses the analytes in a 
narrow band. Possible modulator gases are nitrogen, carbon dioxide or 
compressed (dried) air; the choice depends on volatility of analytes and cost. 
The hot jet emits fast, hot pulses to mobilize and reinject the analytes on the 
separation length of the 2D-column [12, 17, 28, 32]. 
• Differential flow modulators: Utilizes a six-way-valve and a second flow 
controller and so far is rarely applied in praxis, because the technical 
development and optimization of differential flow modulators is still emerging. 
The eluate of the 1D is collected in a loop or chamber and after switching the 
valves transferred and reinjected fast on the 2D-column via the additional flow 
controller unit [12, 17, 28, 32]. 
Thermal modulators are preferred, because in addition, they enable effective 
focusing of analytes in narrow bands, leading to narrow peaks with optimal peak 
shape and increased sensitivity [12, 17, 28, 29, 32]. However, the technical realization and 
hardware is more complex and cost-intensive in comparison to flow modulators. 
Especially, in the case of highly volatile analytes liquid nitrogen is necessary as 
modulator gas. The duration of each fractionation of the 1D-eluate, the so-called 
modulation period, is typically between 2-8 s. The separation on the 2D-column has 
to be completed within the modulation period or, in other words, before the next 
fraction is reinjected. Wrap-around occurs if analytes elute from the 2D-column one 
modulation period later than they were reinjected on the 2D-column. The reverse 
effect, so-called breakthrough, describes the effect of highly volatile analytes, which 
are not sufficiently fractionated in the modulator. 
Peaks eluting from the 1D-column have peak widths between 6-25 s and have to be 
modulated at least 3-4 times to fulfill the modulation criterion and ensure that the 
separation of the 1D is maintained. As mentioned above, the modulation creates 
narrow peaks in the 2D with peak base widths of 50-200 ms enabling improved 
signal-to-noise-ratios and higher sensitivity [12, 17, 28, 29, 32]. To accurately reconstruct 
these narrow peaks, a minimum of 8-15 data points is required, which necessitates 
fast detectors [12, 17, 33]. Detectors fulfilling this requirement are the flame ionization 
detector (FID), the electron capture detector (ECD) or the MS detector, which 
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enables additional structure elucidation. Especially TOF-MS, with data acquisition 
rates of up to 500 Hz, are often applied. However, qMS systems with fast scanning 
properties are cost-efficient and robust alternatives, although the mass range is 
limited [31, 33]. 
Processing of GC×GC-MS data is more complex in comparison to one-dimensional 
GC-MS data and dedicated software and algorithms are needed. Each 
chromatogram consists of numerous, short, consecutive 2D-chromatograms, which 
have to be rearranged for the usual 2D-depiction as a contour plot (Figure 1.4). 
Additionally, the modulation process leads to multiple peaks per analyte [12], which 
have to be recombined. A huge data volume is the result of measuring a few hundred 
analytes using a GC×GC-MS approach with each analyte having multiple modulation 
peaks.  
Two different approaches to handle GC×GC-MS data have been described so far: 
• Peak-feature based approach: For this approach the peak information (e.g. 
retention time, RI, peak height/area, mass spectral information, library 
matching, etc.) is extracted similarly to the traditional one-dimensional data 
processing. The demodulation, meaning the combination of multiple 
modulation peaks belonging to the same analyte, is performed with dedicated 
software. The final result is one textual peak list per raw data file with 
considerably smaller size, which can be used for further processing steps such 
as drift/batch correction and alignment [12]. 
• Peak-region feature approach: For this approach the two-dimensional (2D) 
contour plot is utilized to extract information based on methods developed for 
pattern recognition, which have been implemented in commercial software 
packages (GC Image, GC Image LCC, Lincoln, NE, US). The information of 
2D-peaks (i.e. 2D-peak contour) and 2D-chromatographic regions, which 
describe a chromatographic region not necessarily including only one 
compound, can both be utilized to generate a template describing the pattern 
of all detectable compounds. This template includes mass spectral 
information, information about the 2D-retention search space and the absolute 
and relative position within the pattern of detectable 2D-peaks and 2D-
chromatographic regions. It can be utilized both to integrate raw data files and 
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for alignment purposes. Additional steps such as drift/batch correction may be 
performed subsequently [12]. 
 
Figure 1.4. Raw data processing of GC×GC-qMS files, including both peak-feature 
and peak-region based approaches (modified [34]). 
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1.2 Applications of metabolite profiling approaches in nutrition and 
health 
1.2.1 Investigating associations between nutrition and health – general aspects 
There is an increasing incidence of diet-related diseases worldwide, which will 
become even more relevant in the future [35]. On the one hand, an unbalanced diet 
can promote or even cause a disease or metabolic disorder, and on the other hand, 
the general health status or even existing diseases can be positively influenced 
through nutrition and the intake of specific foods, food constituents or essential 
nutrients [36-39]. An important goal in nutritional research is to estimate relative risks 
between dietary factors and the occurrence of diseases [38]. Further, especially the 
early diagnosis of diseases or metabolic disorders is crucial because their onset can 
effectively be prevented or at least delayed by preventive measures during early 
developmental stages. For example, in the case of type 2 diabetes mellitus, diet and 
life style changes during the prediabetic state are successful in preventing the onset 
of diabetes.  
Observational studies are employed to examine relationships between nutrition and 
diseases or health status [38, 39]. For these investigations, the measurement of the 
dietary intake is essential. Dietary intake data is then correlated with clinical 
parameters and/or the occurrence of diseases such as cancer, cardiovascular 
disease or diabetes to find potential associations. However, a correlation does not 
imply a causal relation. Consequently, intervention studies are often performed in 
addition to substantiate the influence of dietary factors (e.g. polyphenol-rich, Western 
diet, Mediterranean diet, essential nutrients or special food components) on the 
human body and health status [40]. However, three main limitations lead to substantial 
variation, which in turn complicates finding unambiguous and reliable associations 
between health status and nutrition:  
• Uncontrollable conditions and incomplete standardization: 
Uncontrollable conditions and also incomplete standardization in human 
studies complicate the interpretation of research findings in nutritional 
studies [41]. Uncontrollable conditions include factors, such as genetics 
(polymorphisms, phenotypic variations), environment, life style, age, and sex. 
All of these factors can have a considerable influence on the individual 
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response to a certain food and therefore, might in part confound results [41, 42]. 
Yet, at least in part, some of these confounders, e.g. sex and age, might be 
accounted for in the applied statistical approach. Incomplete standardization 
with respect to study design variables (e.g. compliance, additional food intake, 
wash-out and run-in phases during studies) or, depending on the research 
question and study design, the incomplete characterization of the study 
population (e.g. genetic polymorphisms or individual gastrointestinal 
microbiota) can have a considerable influence on the outcome of a study [36, 38, 
41, 42]
. It is not possible to account for incomplete standardization, e.g. for 
compliance, in statistical approaches. The resulting high variation necessitates 
large participant collectives to attain the statistical power to discover small 
effects and detect reliable associations between nutrition and health [38, 43]. 
• Assessment of dietary intake: 
Next to standardization and variations in phenotypes, dietary assessment 
methods add significantly to the variation of the data with considerable random 
and systematic errors [38, 39, 43]. In general, in dietary assessment, the actual 
diet, i.e. consumption within the last 24 hours, and the habitual diet, i.e. 
consumption over a longer time period (e.g. several months or a year), are 
differentiated. During epidemiologic studies, food frequency questionnaires 
(FFQ) are often applied to assess the habitual diet via the frequency of 
consumption and typical portion sizes, which is an easy and cost-effective way 
to assess diet [43]. 24 h recalls are structured interviews assessing the 
consumption of food and beverages during the last 24 hours, which uses 
picture booklets of typical portion sizes to estimate the consumed amount, like 
FFQ. Therefore, both are prone to errors in estimating the consumed amount, 
while in the case of weighed records, participants record the detailed amounts 
of consumed food and beverages in a diary. However, weighed records might 
influence and change the behavior of participants and compliance might be a 
problem due to the time effort. Retrospective methods, such as FFQ and 24 h 
recall, require a good memory, with respect to both choice and amount of 
food. While in the case of FFQ daily variations in consumption and possibly 
changed dietary habits during the study period may lead to erroneous data, 
particularly spontaneous snacks might be forgotten during 24 h recalls. Next to 
this unintentional misreporting, all self-reported dietary assessment methods 
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are prone to intentional misreporting, with respect to both choice and amount 
of food, due to social desirability and approval, e.g. underreporting in the case 
of perceived unhealthy food or overreporting for perceived healthy food [43]. 
The studied population might also have an influence on misreporting, e.g. it 
was observed that overweight participants are more prone to underreporting 
energy intake than others [39, 43]. Accurately assessing dietary intake is 
essential in investigating associations between diet and health status [44]. 
• Complexity of the consumed food and its potential effects: 
Other problems related to the traditional dietary assessment instruments are 
the details in the asked questions during a FFQ or 24 h recall. Equally 
important is the dependency on comprehensive food composition and nutrient 
databases to calculate the total energy intake, the nutrient intake, or the intake 
of other non-nutrients from the estimates of dietary intake [38, 39]. These food 
composition and nutrient databases are limited with respect to the enormous 
complexity of compounds occurring in food. While calculating the intake for 
macro- and even some micronutrients is possible, calculating other potentially 
bioactive compounds (such as secondary plant metabolites) is almost 
impossible due to incomplete data for such compounds in these databases [38, 
45]
. Additionally, neither FFQ nor 24 h recalls differentiate between different 
varieties (e.g. orange and blood orange) due to missing details in the asked 
questions. However, factors such as variety, environment (e.g. place of 
growth, seasonal changes, weather differences), processing (e.g. fertilization, 
cooking, baking, etc.) or storing can have considerable influence on food 
composition [45, 46]. Therefore, another source of error is due to the calculation 
based on average amounts of compounds in a specific food. Furthermore, the 
complexity of more than thousand compounds in a food item complicates 
both, the determination of associations of only one specific compound (e.g. a 
flavonoid) or of a certain diet (e.g. Mediterranean diet) with an observed health 
effect. Any diet consists of a whole variety of potentially bioactive compounds, 
all of which might be individually or together responsible for a health effect in a 
large number of biochemical pathways [42, 44, 47, 48]. 
Metabolomics and metabolite profiling approaches might facilitate the detection of 
associations between health status, diseases and nutrition by addressing and 
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circumventing some of the abovementioned limitations. In this respect, metabolomics 
and metabolite profiling approaches might support research in nutrition and health:  
• by accurately and comprehensively describing the human metabolism and 
metabolic phenotypes, including the metabolic effect of individual genetic 
polymorphisms [36, 41, 49]; 
• by complementing traditional dietary assessment methods and using dietary 
intake markers [38, 40, 46]; 
• by uncovering associations between human nutrition, metabolism and health 
status [49] and consequently, by understanding mechanistic relations between 
nutrition, metabolism and health status [36, 37, 49, 50]; 
• and by comprehensively describing the components of the diet itself [40].  
In general, metabolomics can help improving the so far incomplete knowledge and 
understanding of the metabolism itself, the alterations in metabolism in the case of 
diseases, the biochemical function of different metabolites and also the interaction 
between nutrition and health status [36, 42, 47, 49]. The discovery of new diagnostic 
biomarkers especially for pre-disease states might be facilitated by metabolomics. 
However, the implementation and success of the abovementioned points is not trivial 
due to the complexity and interplay of many factors and will take great effort in the 
coming years [36, 42, 47, 49]. 
The terms biomarker and marker are sometimes used synonymously and sometimes 
they are differentiated. Additionally, there are many different classification systems 
for biomarkers causing ambiguities concerning the use of these terms, their 
validation and subsequent application [50-53]. A summary of different definitions and 
classifications can be found in Supplemental Table S1.1. In general, a marker is 
reflecting or “marking” an exposure, a status, a function, an effect or a risk factor and 
therefore, is always applicable [53]. A biomarker, as defined by the WHO is a 
chemical, its metabolite, or the product of an interaction between a chemical and 
some target molecule or cell that is measured in the human body [54]. The WHO 
differentiates three subclasses of biomarkers [55]: 
• Biomarker of exposure: an exogenous substance, its metabolite, or the 
product of an interaction between a xenobiotic agent and some target 
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molecule or cell that is measured in a compartment within an organism and 
can be related to exposure [54, 55]. 
• Biomarker of effect: a measurable biochemical, physiological, behavioral, or 
other alteration in an organism that, depending on the magnitude, can be 
recognized as associated with an established or possible health impairment or 
disease [55]. 
• Biomarker of susceptibility: an indicator of an inherent or acquired ability of 
an organism to respond to the challenge of exposure to a specific chemical 
substance [55]. 
Often the term biomarker (of effect) is used more specifically for surrogate endpoints 
in clinical settings to predict future events, and to indicate normal biological 
processes, pathogenic processes, or pharmacologic responses [44, 53]. Dietary or 
nutritional markers reflect an exposure to the intake of a food constituent, the entire 
food or maybe even a dietary pattern, and they are measured objectively in biological 
specimen [44, 48, 53]. Although the term biomarker is often used for dietary markers in 
the literature, a differentiation between biomarkers (clinical setting – biomarkers of 
effect) and markers of food intake and dietary exposure (biomarkers of exposure) is 
made in this thesis. 
1.2.2 Markers for dietary intake 
An accurate assessment of dietary intake is crucial in investigating associations 
between diet and disease, as both qualitative and quantitative changes in food can 
strongly influence the risk for diet-related diseases [50, 51]. Due to concerns with 
respect to validity and quantitative accuracy of the traditional dietary assessment 
methods, dietary markers detected in body fluids like urine, blood or even hair are of 
utmost interest. In future, dietary markers might facilitate a more objective and pre-
cise measurement of dietary intake, especially if used in conjunction with traditional 
dietary assessment [56]. In this respect, dietary markers are not meant to replace, but 
to complement the traditional dietary assessment methods. Most foods consist of 
thousands of compounds, which theoretically all represent potential markers of intake 
of the respective food. Some of the compounds will be excreted unchanged from the 
human body dependent on the consumed amount [39, 45], while others are 
transformed via phase I or II metabolism (e.g. oxidation, glycosylation, glu-
curonidation or sulfonation) resulting in an even higher number of metabolites [40, 41].  
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Next to the objective measurement of the true intake itself [44, 48], dietary markers 
might be used to ensure and monitor compliance of participants in a long-term 
intervention study or in patients during treatment (e.g. abiding dietary instructions) [44, 
48]
, as a tool to assess biological effect of nutrition and susceptibility to nutritional 
effects [50] or to assess and calibrate the measurement error and, therefore validating 
results from traditional dietary assessment instruments [38, 40, 44, 46]. Application of 
validated and established markers, such as doubly labelled water for total energy 
intake or 24 h urine nitrogen for protein intake, revealed considerable differences to 
total energy and protein intake measured with traditional dietary assessment 
methods. In these studies, comparing traditional dietary assessment and established 
markers, the uncertainties connected with traditional dietary assessment methods 
lead to weaker observed effects and a loss of statistical power, explaining that often 
no relation between diet and health status is detected or that results are contradictory 
[38, 43]
. So far however, only a few dietary markers are established and validated. A 
few examples of marker candidates for dietary consumption are listed in Table 1.1. 
Therefore, new dietary markers have to be identified and validated in the future to 
cover a broader spectrum of food intake, provide a deeper understanding of 
metabolic dynamics and enable the detection of associations between nutrition and 
health status [38, 45-47, 50]. 
In general, it is important to perform both, marker discovery and marker validation. 
Two possible strategies for marker discovery exist: hypothesis-driven or data-
driven [44, 48, 72]. Most of the markers that are already in use were discovered using 
the hypothesis-driven approach, which necessitates a priori knowledge of the 
potential marker. Markers are usually either compounds of the food itself, their 
metabolites after digestion, absorption and/or metabolism or endogenous metabolites 
that increase as a result of altered metabolic pathways (e.g., serotonine metabolism 
after alcohol intake [73]) [48]. Food components can be metabolized in three different 
ways [48]:  
• digestion of larger food components into simple nutrients in mouth, stomach 
and small intestine, so that they can be absorbed (typically lipids, 
polysaccharides, proteins);  
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• further transformation by host tissues (liver and kidneys) through 
biotransformation in phase I and II metabolism (xenobiotics such as 
polyphenols, alkaloids, carotenoids, volatiles, flavors and so on); 
• processing by gut microbiota in the large intestine.  
Table 1.1. Examples of dietary marker candidates. 
Food or food group Marker compound/s Matrix References 
protein intake 24 h nitrogen urine [38] 
total sugar intake fructose+sucrose urine [57-60]
 
alcohol ethylglucuronide, ethylsulfate, ethanol urine, blood, breath [61-63]
 
wholegrain wheat and 
rye intake 
alkylresorcinols urine, blood [64]
 
citrus fruit, particularly 
orange 
proline betaine urine [65]
 
red meat O-acetylcarnitines urine [66]
 
chocolate (solid or 
drink) 
6-amino-5-(N-methylformylamino)-1-
methyluracil, theobromine, 7-methyl-
uric acid 
urine [67]
 
coffee trigonelline, cyclo(isoleucylprolyl) urine, blood [68]
 
Allium vegetables 
(onion, garlic) N-Acetyl-S-(2-carboxylpropyl)cysteine urine 
[69]
 
dairy products galactose, lactose urine [70, 71]
 
 
Increasing databases (such as FooDB, HMDB or Phenol-Explorer) will be important 
ways to find information on food composition and typical metabolization in future. And 
subsequently, allow building hypotheses for discovery of potential marker 
compounds.  
On the other side, the growing numbers of metabolomics investigations, which show 
changes in metabolite profiles as a result of the diet, enable data-driven approaches 
for marker discovery [44, 48, 72]. For this, either samples from controlled dietary 
intervention studies or samples from cross-sectional or longitudinal studies can be 
used [48, 72]. In the case of controlled dietary interventions, either a single meal/food is 
given (acute study) and samples collected postprandially for up to 48 hours or a 
meal/food is consumed for a longer period (from a few days up to six months) and 
samples from the beginning and end of the period are compared e.g. with a control. 
In the case of a cross-sectional or longitudinal study, participants are grouped into 
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low and high intake according to self-reported intake and metabolites are compared 
via statistical approaches or correlation analysis with self-reported intake and 
statistical approaches are performed. On the one hand, observational studies have 
the advantage of more robust markers due to the availability of a background diet, 
however, on the other hand they have the disadvantage of using self-reported intake 
for the grouping of participants, which is prone to misreporting [48, 72]. One of the 
major disadvantages of the data-driven approach via untargeted metabolomics is that 
a marker can only be used, if it is possible to elucidate its structure. This is one of the 
major limitations of metabolomics approaches in general (section 1.1.2). 
More and more markers are discovered nowadays by metabolomics approaches (see 
tables in [48]). However, marker validation, which is necessary before application of 
any marker in an epidemiologic study or in a clinical setting, has been performed 
rarely, if at all [44, 52, 72, 74]. This is due to the fact that so far no standard procedure or 
guideline for validation of dietary markers exists. In the FoodBAll (Food Biomarker 
Alliance) Consortium, a multidisciplinary team developed a first scheme for validation 
of dietary markers [74]. Validation in an independent study is a crucial step and is 
meant to ensure that a marker is enabling appropriate results for its intended purpose 
[52, 72, 74]
. Dragsted et al. [74] proposed eight criteria for validity of markers of food 
intake, the first five criteria relate to biological and interpretative validity and the last 
three criteria relate to the validity of the applied analytical method. Variability in the 
consumed amount of food, determined via a dietary marker, can be a result of 
differences in absorption, distribution, metabolism and excretion due to factors such 
as age, sex, genetics, life style (e.g. smoking, alcohol consumption, drugs), health 
status, background diet, individual gut microbiota or variable amounts of the marker 
compound or its precursor in the food itself [44, 50, 74]. Additionally, the stability of the 
marker compound might be influenced by sample collection, processing or storage 
[44, 50, 74]
. The aim of the eight criteria for validation is to ensure a more objective and 
precise measurement of the markers of intake. In the following section the eight 
criteria are described and explained as suggested by Dragsted et al. [74]; a deeper 
discussion of their applicability, advantages and disadvantages can be found in the 
general discussion section: 
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• Plausibility (biological and chemical): 
Plausibility means that a causal explanation for the increase of a putative 
dietary marker after intake of a certain food or food group exists [44, 53, 74]. Next 
to the occurrence of a putative marker in the targeted food, knowledge on 
variability (e.g. based on variety, growth conditions, etc.), on food chemistry 
(e.g. process-derived components) as well as bioavailability, digestion, 
distribution, metabolism and excretion play an important role for the 
evaluation of plausibility [44, 46, 48, 74]. In this respect, food metabolite profile 
databases are highly desirable, but at the moment only in a limited way 
available. Databases such as FooDB are being set up at the moment and will 
be important resources in the future [9]. Dragsted et al. [74] include in this 
criterion also the question of specificity of a marker, meaning for example the 
occurrence and amounts of the marker metabolite in other food and also the 
amounts and frequency of consumption of such food. 
• Dose-response: 
For the quantitative estimation of the intake, the excretion of the putative 
marker should be a fixed proportion of the intake [44, 74]. The dose-response 
relationship is important to determine the potential range of intake, from limits 
of detection due to high baseline levels or low bioavailability to saturation 
effects (e.g. vitamin C) [44, 48, 72, 74]. Evaluation of dose-response has to be 
performed in a controlled intervention study with a well-defined food and 
different amounts of intake, where no background diet could possibly 
influence the excreted amount of the putative marker [44, 48]. Nonetheless, a 
cross-sectional study or longitudinal study with different intakes can be used 
as well, but with less certainty (due to bias through background diet or usage 
of self-reported intake).  
• Time-response: 
Time-response addresses the kinetics (absorption, distribution, metabolism 
and excretion) of the putative marker in the human body with respect to its 
biological half-life. And consequently, whether the putative marker enables 
the detection of intake over hours, days, weeks, months or even years (short- 
vs. medium- vs. long-term markers) [74]. Both, the time-response after one 
meal, and also the time-response after repeated meals (i.e. reproducibility of 
response, e.g. accumulation effects, cumulative increase of excretion due to 
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induced or inhibited enzymes or altered excretion) are important to be 
assessed within controlled intervention studies to decide on the best sampling 
time and biological sample [74]. Most often highly polar compounds have a 
short physiological half-time (excretion within 24 h) and therefore, most likely 
reflect short-term or acute dietary intake [44, 48]. Long-term or habitual dietary 
intake might be best reflected by lipophilic compounds e.g. in blood or other 
less often investigated sample matrices such as hair, fat tissue or nail 
clippings [44, 48].  
• Robustness: 
The term robustness addresses a number of factors that might confound the 
results and interpretation of a putative marker; it concerns among others the 
specificity of a marker. For the evaluation of robustness both controlled 
dietary interventions (controlled habitual diet; marker for one specific food, a 
food group or a whole dietary pattern [39, 46]), cross-sectional studies in free-
living populations (suitability in different populations, interactions with other 
food or food matrices/background diet, amounts and frequency of 
consumption of such food) as well as metabolite profile databases of food 
components (occurrence and amounts of the marker in other food, variability) 
are necessary [44, 48, 72, 74]. The potential influence of other food components or 
the putative marker itself on the absorption, distribution, metabolism and 
excretion might be a relevant factor. However, these kinds of influences so far 
have been rarely investigated [74].  
• Reliability: 
The reliability of a putative marker to indicate the true dietary intake should be 
confirmed by comparison with a gold standard or reference method for a 
different marker indicating dietary intake for the same food. These 
conformation studies are best carried out under highly controlled conditions. 
Another way to prove the reliability of a putative marker would be the 
comparison with traditional dietary assessment methods. However, this has to 
be done with care, as it will be unclear, whether a putative marker lead to 
different results than the traditional dietary assessment method, because of 
its unsuitability and unreliability (i.e. not specific for a certain food or not 
chemically or biologically stable), or whether it is due to the biased dietary 
assessment using self-reported intake [44, 74]. 
1 INTRODUCTION  
28 
 
• Stability: 
Suitable protocols for sample collection, processing and storage should be 
developed and chemical stability (possible oxidation or pH-instability) and 
biological stability (metabolization via enzymes in the matrix) should be 
ensured by performing degradation tests [72, 74]. 
• Analytical performance: 
This criterion includes the overall validity of the analytical method, including 
but not limited to precision, accuracy, detection limits, inter- and intra-batch 
variability (repeatability), practicality [53, 72, 74]. The aim of this criterion is to 
assess whether a qualitative or quantitative analysis is feasible using the 
putative marker. Validation of the analytical method with a validated method, 
a reference method or by using reference materials is desirable.  
• Inter-laboratory reproducibility: 
Results and data should be comparable, when the putative marker is 
measured by different laboratories [72, 74]. 
1.2.3 Identification of markers for health status exemplified by diabetes 
In contrast to the subtle changes in metabolism through the diet, the onset and 
development of a disease may cause massive metabolic changes, detectable even 
though the metabolome is of course influenced by a multitude of factors, such as sex, 
age, diet, lifestyle, individual microbiota or drugs [53]. The growing number of 
chronical diseases such as obesity, diabetes, cardiovascular disease and in part 
cancer caused by metabolic dysregulations is nowadays a growing worldwide 
problem [75]. Diseases and inborn errors of metabolism cause characteristic 
alterations in metabolism, which are often apparent before clinical symptoms become 
evident [76]. The detection of early stages of diseases is of high importance, because 
this could enable more efficient treatments, prevention, a slower clinical progression 
and lower rates of mortality [76]. A whole number of diseases were investigated for 
early stage diagnosis such as cancer, diabetes, cardiovascular diseases or inborn 
errors of metabolism. However, not only early stage diagnosis is important, but also 
the classification and progression of the disease or prognosis of treatment success 
are highly relevant in clinical research [76]. Through the detection of several hundreds 
of metabolites at the same time, metabolomics and metabolite profiling approaches 
enable an efficient monitoring of perturbations in specific endogenous metabolites, 
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representing the complexity of key and potentially disease-related metabolic 
pathways [75-77]. Therefore, metabolomics can reveal crucial information related to the 
health status [77]. The comparison of metabolite profiles of perturbed and unperturbed 
metabolic pathways will enable deeper knowledge of underlying physiological and 
pathophysiological mechanisms of disease development and also identification of 
targets for treatment [75, 76]. Metabolomics has an immense potential for identification 
of biomarkers predicting the onset of diseases, their severity and progression, 
therefore enabling diagnosis, monitoring and therapy of diseases [15, 75-77]. Although 
the investigation of clinical biomarkers using metabolomics has been going on for a 
while, there is still a lot to be done, especially with respect to validation and 
application of these markers in a clinical setting, similarly as described above for 
nutritional markers [77]. 
Measurements of a static state in metabolism to determine health state has been the 
objective of many investigations, but in the last years, also the measurement of 
metabolism while challenging homeostasis has gained interest. In general, the 
metabolism is able to respond to internal and external stimuli in a dynamic way via a 
complex network of multiple mechanisms, pathways and interactions; thereby 
maintaining homeostasis [78]. Challenges such as dietary intake (acute exposition 
with e.g. high fat, high sugar, high caloric or high salt) or physical activity cause 
changes in metabolite concentrations that are related to physiological processes. A 
healthy organism is able to respond adequately to, and compensate these changes 
caused by stressors or other expositions by flexible metabolic adaptation via different 
feedback mechanisms, the buffer capacity of the homeostasis and, if necessary 
repair mechanisms [78-80]. A chronical exposure towards an unbalanced diet will 
cause a reduced, impaired or even a loss in flexibility of the metabolic responses and 
thereby cause the development of diseases such as diabetes, hypertension or 
cardiovascular disease [78-80]. Therefore, the flexible balancing reaction of the 
metabolism in response to an external challenge can determine the individual health 
status, the predisposition for diseases and enable an early diagnosis of many 
chronical diseases [40, 41, 78-80]. In the end, in comparison to measuring a static state, a 
challenge of homeostasis might be a more informative way for diagnosis via 
biomarkers, as it might enable a detection of more subtle and relevant effects that 
precede a disease, identify an individual predisposition towards certain diseases, or 
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predict the capacity of an organism to withstand stress [78, 79]. Untargeted 
metabolomics and metabolite profiling approaches are highly suited to monitor the 
time course of metabolites in body fluids after a challenge tests e.g. with an acute 
high intake of glucose, fructose, fat, salt or similar. An additional advantage and 
challenge at the same time is that the normal and healthy range of individual 
responses towards such challenges is broad, thereby enabling the classification of 
humans into metabotypes with similar phenotypic regulations in metabolism [40, 79, 81]. 
The key example of a challenge test is the traditionally used oral glucose tolerance 
test (OGTT) for the diagnosis of impaired glucose tolerance and diabetes. Here a 
patient receives a drink containing 75 g glucose and blood samples are taken before 
and during the test to determine how quickly glucose is cleared from the blood. 
Diabetes mellitus and its related ensuing serious, life-threatening complications are 
one of the most significant global health problems, resulting in a large social, financial 
and health system burden across the world [82-85]. In year 2017, about 451 million 
adults (age 18-99 years) lived with diabetes worldwide, this number is expected to 
increase to 693 million by 2045 using a conservative estimation [86]. Almost half of all 
people living with diabetes are undiagnosed and moreover, an estimate of 374 million 
people lives with impaired glucose tolerance (IGT). Diabetes mellitus is a group of 
metabolic disorders characterized by prolonged high blood glucose levels as a result 
of either a relative or an absolute insulin deficiency. Insulin is the main anabolic 
hormone of the body, regulating among others, especially blood sugar level. It is 
produced by β-cells of the pancreatic islets or islets of Langerhans in the pancreas. 
Insulin promotes the absorption of glucose from the blood into liver, fat and skeletal 
muscle cells, where glucose is either used for energy production via glycolysis or 
converted to glycogen via glycogenesis or to fats via lipogenesis for storage. 
Therefore, blood glucose levels change even after food intake only within a narrow 
range (4,5-6,7 mmol/L). As a result of absolute or relative insulin deficiency, glucose 
is not absorbed properly into body cells, and therefore, prolonged high levels of blood 
glucose are observed (Table 1.2 for WHO definitions [87]). There are three main types 
of diabetes mellitus and pre-disease states [87]: 
• Pre-disease states: IGT and impaired fasting glycaemia (IFG) 
Both are intermediate conditions between the healthy and diseased state, and 
are connected with a high risk for the development of type 2 diabetes mellitus. 
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IFG is defined by a consistently increased fasting blood glucose level, while 
IGT is defined by both increased fasting and 2-hour glucose. 
• Type 1 diabetes mellitus (T1DM): absolute insulin deficiency 
As a result of pathological alterations of the pancreatic islet β-cells, most often 
caused by autoimmune reactions in juvenile age, physiological insulin 
concentrations cannot be maintained. Symptoms such as excessive excretion 
of urine (polyuria), thirst (polydipsia), constant hunger, weight loss and fatigue 
may occur suddenly.  
• Type 2 diabetes mellitus (T2DM): relative insulin deficiency/insulin 
resistance 
Even though insulin concentration is mostly normal at the beginning the body 
is unable to effectively/properly respond to insulin. In later stages, a lack of 
insulin may also develop. Symptoms are similar to T1DM; however, they are 
less pronounced and progression is insidious. As a result, diagnosis often 
happens several years after the onset, when complications are already 
evident. T2DM was also called adult-onset diabetes, as it occurred in the past 
mainly in people over 40 years. However, recently it is occurring increasingly 
frequently also in younger people. The genetic predisposition, lifestyle factors 
such as a high fat, high sugar and high caloric diet, obesity and physical 
inactivity play a role in the development of T2DM. 
• Gestational diabetes: occurring during pregnancy 
Gestational diabetes is marked by hyperglycaemia with blood glucose levels 
above normal but below those of diabetes. A consequence is an increased 
risk of complications during pregnancy and at delivery and additionally an 
increased risk for the women and their children to develop T2DM in the future. 
Table 1.2. WHO diagnostic criteria and blood glucose levels [87]. 
Condition Fasting glucose 
(mmol/L) 
2-hour glucose 
(mmol/L) 
HbA1C                           
(%)1 
Healthy <6.1 < 7.8 < 6.0 
IFG ≥ 6.1 < 7.0 < 7.8 6.0-6.4 
IGT < 7.0 ≥ 7.8 6.0-6.4 
Diabetes mellitus ≥ 7.0 ≥ 11.1 ≥ 6.5 
1glycated hemoglobin 
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90-95% of people with diabetes mellitus have T2DM [85]. Here, and also in the case of 
IGT and IFG, preventive measures such as lifestyle changes and especially weight 
reduction are viable options to ensure diabetes is never manifesting or even to cure 
T2DM during early stages. With the measurement of blood glucose, glucose in urine 
and glycated hemoglobin (HbA1C) established indicators of diagnostic, progression 
and therapy monitoring are available [85]. Nonetheless, as mentioned above about 
half of the people with diabetes remain undiagnosed for years [86] and as a result 
develop severe complications such as diabetic retinopathy, diabetic nephropathy, 
diabetic neuropathy and diabetic angiopathy. Those long-term complications are 
mostly caused by the hyperglycaemia itself. Therefore, research for biomarkers of 
especially the prediabetic state and also biomarkers for the assessment of the risk to 
develop complications is of high importance. Metabolomics and metabolite profiling 
approaches may contribute to this field of work. 
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2 SCOPE AND AIM OF THIS THESIS 
Research on markers for both dietary intake and health status using untargeted 
metabolomics and metabolite profiling approaches are emerging topics in nutrition 
and food sciences. Markers of dietary intake will in the future objectively complement 
the traditionally applied dietary assessment methods (such as FFQ or 24 h-dietary 
recall), which often lead to biased results due to intentional or unintentional 
misreporting. Furthermore, traditional clinical markers for diseases are most often 
indicators, when symptoms already are evident. New markers of health status or 
markers of disease will especially aim towards an early diagnosis of pre-disease 
states, where preventive measures are feasible options. Metabolomics with its ability 
to detect several hundreds of metabolites at the same time is a perfectly suitable tool 
for marker discovery. However, sometimes details within specific substance classes 
are overseen, due to the compromise between covering as many substance classes 
as possible at the same time and the necessity of dedicated sampling approaches for 
specific substance classes or groups. Therefore, dedicated metabolite profiling 
approaches might be a useful complement to untargeted metabolomics. Additionally, 
often the narrower perspective of metabolite profiling approaches will enable deeper 
elucidation and interpretation of a biological question within a specific metabolic 
pathway. Therefore, within this thesis, the application of dedicated GC-MS based 
metabolite profiling approaches (investigating volatile organic compounds and sugar 
compounds) for the discovery of markers for both dietary intake and health status 
was evaluated.  
From everyday experience, it is known that urine smells differently after the ingestion 
of for example asparagus or coffee. And even with closed eyes, just smelling will 
enable humans to differentiate between lemons and strawberries. Although odorous 
volatile organic compounds are highly specific for foods, they have so far scarcely 
been targeted as potential markers of dietary intake. Coffee as a highly aromatic 
drink is a promising food to investigate the potential of volatiles as dietary markers. A 
HS-SPME-GC×GC-MS profiling method for volatile compounds was applied to 
identify markers of coffee consumption in urine samples of a cross-sectional study. 
With respect to sugar compounds, so far attention was mostly paid to well-known 
sugar compounds, although numerous sugar compounds and isomers occur in 
nature, some of them highly specific for certain foods. Even in studies regarding 
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diabetes, a disease that is characterized by a disturbed carbohydrate metabolism, 
mainly glucose was of interest so far. Consequently, within this thesis, a dedicated 
GC-MS based metabolite profiling approach for sugar compounds was developed, 
optimized and applied towards identification of dietary markers within a cross-
sectional study and also within an intervention study with an OGTT in healthy, 
prediabetic and diabetic volunteers. 
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Robust Markers of Coffee Consumption Identified Among
the Volatile Organic Compounds in Human Urine
Carina I. Mack, Bjo¨rn Egert, Erica Liberto, Christoph H. Weinert, Achim Bub,
Ingrid Hoffmann, Carlo Bicchi, Sabine E. Kulling,* and Chiara Cordero
Scope: The human volatilome has gained high interest for the discovery of
potential biomarkers of diseases. However, knowledge about the diet as a
crucial factor affecting the volatilome is scarce. Therefore, the search for
disease biomarkers, as well as the potential use of volatiles as dietary markers
is so far limited. The aim of this study is to investigate the association of the
diet with the urinary volatilome with the special task to find potential markers
of coffee consumption in 24 h urine samples from the Karlsruhe
Metabolomics and Nutrition (KarMeN) study.
Methods and results: Acidified urine samples are analyzed using an approach
combining headspace solid phase microextraction (HS-SPME) sampling with
untargeted GC×GC-MS. Overall, 138 reliably occurring volatiles are detected.
To account for the unequally concentrated urine samples, results of six
different commonly used normalization methods are compared. Statistical
analysis evidences six potential markers of coffee consumption, the most
promising being 3,4-dimethyl-2,5-furandione. A correlation analysis between
the 24 h dietary recall data and the urinary volatilome reveals further
promising associations.
Conclusion: The human urinary volatilome is highly affected by the diet,
enabling access to a high level of information about potential diet-related
biomarkers. Therefore, it is a very promising source for further investigations
on dietary markers.
1. Introduction
Volatile organic compounds (VOCs) are formed by several chem-
ical and biochemical processes and are therefore omnipresent
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in the environment.[1,2] VOCs play im-
portant roles in many different aspects
of life such as aroma components of
food, animal or plant hormones and
pheromones, microbial products, com-
bustion, or industrial processes. These
exogenous volatiles can easily enter the
human body via diverse paths (e.g., in-
halation, ingestion, dermal absorption,
and resorption in the gut), are distributed
between different compartments of the
body, and are excreted via diverse paths
(e.g., exhalation, excretion, and secre-
tion). At the same time the human body
itself can produce a variety of VOCs en-
dogenously through normal or abnormal
physiologic processes or even through re-
siding commensal microorganisms.[2–6]
The combination of these exogenous and
endogenous VOCs emitted by the hu-
man body are defined as the human
volatilome, which can be measured in
various specimen such as breath, skin
emanations, sweat, saliva, blood, urine,
or feces.[3,6,7] So far, the highly com-
plex interplay between the various fac-
tors that influence the volatilome are
not well understood.[4,5,8–11] Nonetheless, there is a growing inter-
est to exploit the volatilome for early diagnosis of diseases[4,5,12] or
metabolic disturbances such as, among others, cancer[9,13,14] and
diabetes.[15,16] However, identifying distinguishable VOC profiles
representing the healthy and diseased status is complicated by
the huge interindividual variability caused by many factors such
as genetic background, life style, diet, age, sex, physiologic dif-
ferences in metabolism, or residing commensal bacteria.[4,5,8–11]
Therefore, it is necessary to understand the interplay between
and the impact of these influencing factors on the human
volatilome.
Every-day experience demonstrates that diet may have a ma-
jor (and sometimes olfactorily well-perceivable) impact on the
urinary volatilome. So far, only a few systematic investiga-
tions of this phenomenon have been performed,[17–21] but it is
likely that VOCs could be valuable for nutritional research. For
example, with respect to epidemiologic studies where under-
and/or overreporting complicate interpretation of results along
the diet-health/disease-trajectory, valid dietary markers would be
extremely useful.[22] While nonvolatile metabolites in urine as
potential dietary markers have been in the focus of nutrition
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research for some years, so far little attention has been paid to
volatile metabolites.[23]
Breath and skin emanations are objects of several studies as
they can be sampled easily and noninvasively.[5,7,9] Urine, as an-
other readily accessible specimen, has gained popularity in the
last years.[24,25] It has the additional advantage of preconcentra-
tion in the kidneys and of being more easily storable than, for ex-
ample, breath or skin emanations. Even so, a huge disadvantage
of urine is the differently diluted excretion, which necessitates
(pre- or post-analytical) normalization. There are many normal-
izationmethods that can be applied, among others normalization
on creatinine, osmolality, specific gravity, urine volume, mass
spectral total useful signal (MSTUS),[26] or probabilistic quotient
normalization (PQN).[27] So far, a scientific consensus on the eval-
uation and application of these methods is still missing.[28–31]
Coffee, with more than 800 volatile constituents or
flavorants[17] and more than 150 million bags (weighing
60 kg) consumed worldwide in 2016,[32] is an important and
promising food to study the informative potential of its volatiles
as dietary markers. Wagenstaller et al.[17] already described an
increase of some VOCs in urine after the ingestion of coffee
in an acute intervention study with a targeted method based
on a limited population (n = 14). Otherwise markers for coffee
consumption are mainly from among nonvolatile metabolites.[23]
This study aims to identify potential markers of coffee con-
sumption in 24 h urine samples from a selected subset of the
observational Karlsruhe Metabolomics and Nutrition (KarMeN)
study.[33] Urinary VOCs were sampled by headspace solid phase
microextraction (HS-SPME) and analyzed by two-dimensional
gas chromatography coupled with a quadrupolemass spectrome-
ter (GC×GC–qMS). Different normalizationmethods on urinary
VOC responses were tested to achieve a higher confidence level
in results interpretation. Additionally, through the use of a 24 h
dietary recall the association of diet with the urinary volatilome
was investigated apart from coffee consumption.
2. Experimental Section
2.1. Study Design and Subjects
A subset of 24 h urine samples from the cross-sectional study
KarMeN, performed at the Max Rubner-Institut in Karlsruhe,
Germany (2011–2013), was analyzed. The study design and ex-
amination procedures were described elsewhere.[33] The study
was approved by the ethics committee of the State Medical
Chamber of Baden-Wu¨rttemberg (F-2011-051) and was in accor-
dance with the 1964 Helsinki declaration and its later amend-
ments. The study was listed at the German Clinical Study Regis-
ter (DRKS00004890) and has the WHO universal trial number:
U1111-1141-7051. The subset consisted of 97 apparently healthy
participants (18–80 years), of these 53 were male and 44 female.
According to the conducted 24 h dietary recall, 48 participants
drank coffee in the 24 h of urine collection (coffee consumers)
and 49 participants did not drink coffee during that period (non-
consumers). The subset was chosen randomly among coffee con-
sumers and non-consumers of the KarMeN population with the
precondition that about half of the coffee consumers and non-
consumers, respectively, were male and the other half female.
Additionally, for each, consumers and non-consumers, a uniform
distribution of age was intended. For participant characteristics
of the subset see Table 1.
Participants collected a 24 h urine sample in urine contain-
ers that were kept cooled throughout the collection period. The
urine volume was recorded. A urine portion was centrifuged at
1850 × g at 20 °C and aliquoted. Aliquots were frozen at –20 °C
for 1 day, and afterward cryopreserved at –196 °C until analysis.
A quality control (QC) sample was prepared by mixing fresh spot
urine samples of four male and four female volunteers shortly
before the measurement series, then it was aliquoted and frozen
for a short period at –20 °C until analysis.
The food consumption (in g d–1) of each participant during
the 24 h of urine collection was assessed in a personal inter-
view using the 24 h dietary recall method and the software EPIC-
Soft,[34,35] now renamed into GloboDiet.
2.2. Volatile Profiling of Urine Samples Using
HS-SPME–GC×GC–qMS
2.2.1. Sample Preparation and HS-SPME Sampling Conditions
A short screening with different fibers (polyacrylate (PA), poly-
dimethylsiloxane (PDMS), polydimethylsiloxane/divinylbenzene
(PDMS/DVB), and divinylbenzene/carboxen/polydimethyl-
siloxane (DVB/CAR/PDMS)) as well as comparing sample
preparation either with β-glucuronidase (Helix Pomatia,
100 000 units mL–1, pH: 4.5–5; Sigma–Aldrich) or with addi-
tion of a pH modifier, i.e., HCl, was performed, before setting
the method sampling protocol (see Section 1.1.1, Supporting
Information).
Table 1. Participant characteristics.
Characteristics of participants Total Non-consumers Coffee consumers
Women (n = 22) Men (n = 27) Women (n = 22) Men (n = 26)
Age (years), mean 49.2 45.9 50.3 50.6 49.6
Age (years), range 18.9–80.4 18.9–77.4 20.2–74.3 22.7–80.4 21.2–79.5
Body mass index (kg m−2), mean 24.1 21.5 25.2 24.7 24.6
Coffee consumption (g d−1), mean 255.9 0 0 506.4 526.4
Coffee consumption (g d−1), range 0–1330 0 0 50–1330 110–1320
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The solid phase microextraction (SPME) fiber chosen for uri-
nary VOCs samplingwas theDVB/CAR/PDMSwith df 50/30 µm
and 2 cm length. A set of six fibers, all from Supelco (Bellefonte,
PA), was conditioned before use as recommended by the manu-
facturer and tested for response standardization.
For each 24 h urine sample, a headspace crimp top vial (22mL)
was filled with 5mL of deionized water to enable an efficient heat
transfer toward the inert glass insert of 6 mL volume used for
urine sampling. The reduced headspace volume enabled achiev-
ing adequate sensitivity for effective VOCs monitoring. To the
6 mL insert, 0.16 ± 0.001 g of NaCl was added together with
800 µL of urine sample. A total of 200 µL of HCl (1 mol L–1) was
finally added to lower the pH, before capping the vial and mixing
with a Vortex unit. QC sample aliquots and study samples were
prepared in the samemanner. QC samples were used for the cor-
rection of batch or drift effects. Each day, 11 study samples, three
QC samples, and one blank sample (consisting only of the in-
ternal standard solution) were prepared and analyzed. All study
samples were measured twice.
For each run, 2 µL of internal standard solution (10 ppm tride-
cane in dibutylphthalate) was placed into a 22 mL glass vial for
preloading onto the fiber for 30 min at 65 °C (standard-in-fiber
procedure[36]), at the same time and temperature the urine sam-
ple was pre-equilibrated. Then, the fiber was exposed to the urine
sample for 60 min at 65 °C. Afterwards, the fiber was introduced
into the injector of the GC×GC system at 250 °C and thermally
desorbed for 5 min.
2.2.2. Instrumental Setup for HS-SPME–GC×GC–qMS
HS-SPME–GC×GC–qMS analysis was performed on an Agilent
6890 unit coupled to an Agilent 5975C MS detector (Agilent, Lit-
tle Falls, DE), equipped with an MPS-2 multipurpose sampler
(Gerstel, Mu¨lheim a. d. Ruhr, Germany) and a two-stage KT 2004
loop-type thermal modulator (Zoex Corporation, Houston, TX)
cooled with liquid nitrogen. Data were acquired by Agilent MSD
ChemStation ver. E.02.01.00. In the Table S1, Supporting Infor-
mation, the different GC parameters including modulation pa-
rameters and the different MS parameters for the GC×GC–qMS
measurement are shown.
2.2.3. Data Processing
Processing of raw data was performed using GC Image GC×GC
Software version 2.5 (GC Image, LLC Lincoln NE). The sequen-
tial workflow described by Magagna et al.[37] was slightly mod-
ified and applied. After file import, rasterization, colorization,
baseline correction, 2D-peak detection, and integration, a tem-
plate with known analytes (targeted 2D peaks) was built using
GC Image standard workflow.[37,38] Targeted peaks were identi-
fied by EI–MS fragmentation pattern (NIST MS Search algo-
rithm, ver. 2.0, National Institute of Standards and Technology,
Gaithersburg, MD; with Direct Matching threshold 900 and Re-
verse Matching threshold 950) with those collected in commer-
cial (NIST2014 and Wiley7n) and in-house databases. As a fur-
ther parameter to support identification, linear retention indices
based on n-alkanes were considered and experimental values
were compared with tabulated NIST reference indices. The tar-
get template consisting of 63 known volatiles was matched to
all 2D-chromatograms and results (positive matches) saved (GC
Project) to enable further processing.
Processed runs were then used to generate an untar-
geted/targeted (UT) template, following the UT fingerprint-
ing principles,[37,38] including all reliable 2D peaks (known
and unknown reliable peaks) that matched in all-but-one chro-
matograms of the set. The fully automated procedure is imple-
mented in a dedicated software ambient named GC Investigator.
The algorithm performs a comprehensive pair-wise peak match-
ing and alignment of all 2D chromatograms based on retention
times in both chromatographic dimensions and EI–MS fragmen-
tation pattern (mode for preferred reliable peaks: most relaxed).
After application of the UT template to all samples
(GC Project), the resulting 2D chromatograms were super-
vised and checked for the correct alignment of all reliable peaks.
A preliminary data matrix with 172 features was obtained for
which an analyte-specific batch correction was performed based
on the measured QC samples. Afterward, analytes were evalu-
ated with respect to their repeatability in QC samples (corrected
interday coefficient of variance [CV] > 35% were excluded) and
the occurrence of 2D peaks in heavily crowded chromatogram
regions, leading to a final data matrix consisting of 138 peak
features.
Before statistical analysis, missing values were replaced
analyte-wise by half of the minimal value, which is a realistic
value as they are mostly a result of the signal intensity being be-
low the LOD. Afterward, normalization for the differential con-
centration of urine samples was carried out. For comparative rea-
sons, not normalized data and data normalized using osmolality,
creatinine, urine volume, MSTUS, and PQN were used. While
scaling factors for osmolality, creatinine and urine volume are
based on physiologic properties, those derived fromMSTUS and
PQN are data driven with the objective to prevent the impact of
sample concentration variability. MSTUS is similar to normal-
izing on total signal, but uses only a subset of ions/features in-
stead of including all measured ions (total ion count (TIC), which
would also include noisy or specimen-specific ions/features) for
a more reliable normalization.[26] PQN adjusts each sample of a
metabolite profile according to the most probable dilution fac-
tor with regard to a reference sample to achieve a virtual overall
concentration.[27] The reference sample could be either a selected
biological study sample or a calculated median metabolite profile
based on all measured biological samples, respectively. In recent
publications,[31,39] when urine volume was used as the normal-
ization reference, signal response was normalized by dividing by
the urine volume and as this led to an increased biological vari-
ance, it was concluded that urine volume normalization is not
appropriate.[31,39] However, compared to the direct proportional-
ity between creatinine content or osmolality and the overall urine
concentration, the urine volume is inversely correlated to the con-
centration of urine analytes (see Figure 1). Consequently, divid-
ing by urine volume should lead to an increased variation con-
trary to the intention of normalization. A physiologically more
reasonable option based on the principles of human renal phys-
iology may be to normalize signal intensities by multiplication
with urine volume. For comparison, both methods were applied
in this manuscript (urine volume div and urine volume mult).
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Figure 1. Normalization methods. A) Scatter plots of the different normalization methods including Spearman correlation coefficient. B) Violin plot
for the CV’s of all volatiles after the different normalization methods have been applied, grouped by inter- (CV over all study samples) and intra-group
(CV within the two groups of coffee consumers and non-consumers) variation. The contour of the violins shows regions of data density, density is the
highest where the violin is the broadest.
After assessment of data quality, some technical replicates
were excluded. For the replicates, the mean was calculated and
further statistical analysis and data interpretation were carried
out on the resulting seven data matrices, one for each differ-
ent normalization methods, as well as on the raw data with no
normalization.
2.3. Statistical Analysis
Statistical analysis was carried out using JMP (version 13, SAS In-
stitute Inc., Cary, NC, 1989-2007). Data matrices were built with
97 study samples (48 coffee consumers and 49 non-consumers)
and 138 UT peak features.
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Figure 2. Workflow for the raw data processing and statistical analysis for potential coffee markers.
2.3.1. Comparison of Normalization Methods
In a first step, the overall impact of the different normalization
methods on the data set was assessed using a correlation anal-
ysis. For this, Spearman correlation coefficients were calculated
for the scaling factors used to normalize the data. In a second
step, the CVs for all the 138 VOCs in all study samples and as
well in the two groups of coffee consumers and non-consumers
were calculated before and after application of all normalization
methods.
2.3.2. Potential Markers of Coffee Consumption
First, an analysis of variance (ANOVA)-based response screen-
ing analysis including correction for multiple testing[40] was per-
formed to identify volatiles differentiating the two groups of
coffee consumers and non-consumers. The workflow included
a first ANOVA with correction for multiple testing, a second
ANOVA, and post hoc tests (each depending on the distribu-
tion and homogeneity of variance). The ANOVA based response
screening was performed for the data without normalization,
and the normalized data sets (creatinine, osmolality, urine vol-
ume div, urine volume mult, MSTUS, and PQN). Only signifi-
cant volatiles showing a median fold change > 1.5 for at least
one of the normalization methods were considered. Second, a
correlation analysis using Spearman correlation coefficients was
performed to consider the potential dose-response relation be-
tween the coffee consumption and the volatiles. Therefore, Spear-
man correlation coefficients of the volatiles with the amount of
consumed coffee were calculated before and after normalization.
Significance of the correlation was tested and only those reported
that remained significant after Bonferroni correction, which in
this case corresponded to ρ > 0.35. In Figure 2, a workflow for the
raw data processing as well as the statistical analysis is depicted.
2.3.3. Relevance of Age or Sex for Potential Markers of Coffee
Consumption
The possible influence of sex or age on the potential markers
of coffee consumptions was evaluated. A Wilcoxon test was per-
formed to ascertain the influence of sex, while Spearman corre-
lation coefficients were calculated for the age effect.
2.3.4. Other Potential Volatile Markers Related to Food
Consumption
To get a further impression on the usability of volatiles as po-
tential markers for food consumption in general and the associ-
ation of the diet with the urinary volatilome, the food consump-
tion during the 24 h of urine collection (overall 81 different food
consumption and nutrient intake variables, see ref.[41]) was cor-
related with the detected volatiles in 24 h urine samples before
and after normalization. Only Spearman correlation coefficients
with ρ > +0.35 for at least three normalization methods and
with more than 25 participants who ate certain food items were
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considered further. Occurring negative correlations of VOCs in
urine with some food items were not considered at this stage
because they could be related to endogenous metabolism and
their relationship would be of a complex nature. Additionally, a
Wilcoxon test was performed (lowest against highest tertile) for
the normalization methods with the highest Spearman correla-
tion coefficients.
3. Results
3.1. Analytical Characteristics
As a first step, different stationary phases of the fiber and sam-
ple treatment used for SPME were screened. Comprehensive ap-
proaches for selection of the fiber, sample treatment, and extrac-
tion conditions can be found elsewhere.[13,14,25,42–45] InTable 2, the
number of detected 2D peaks is compared for the different fibers
as well as the different sample preparations tested, including a
blank sample with only glucuronidase and buffer. In Figures S1
and S2, Supporting Information, GC×GC–MS chromatograms
for all fibers as well as the different sample preparations are de-
picted. The possibly gentler treatment with β-glucuronidase (He-
lix pomatia,100 000 units mL–1, pH: 4.5–5; Sigma-Aldrich) was
excluded as the measurement of the blank enzyme sample re-
vealed high abundance of VOCs (see Table 2 and Figure S2, Sup-
porting Information). Enzyme preparations are usually isolated
from living organisms (e.g., Helix pomatia) and can be complex
mixtures. Therefore, it is highly recommendable to measure the
blank enzyme before applying it to metabolomics studies.
Our short comparison gave the best result, i.e., the highest
number of detected 2D peaks, for theDVB/CAR/PDMSfiber and
the acidic treatment with HCl, which is in good agreement with
literature evidences.[14,43,45] Therefore, these conditions were cho-
sen for the analysis of the 24 h urine samples of the KarMeN
study. Overall, 138 reliable 2D peaks were detected (at least in
70% of study samples) of which 63 were identified (targeted an-
alytes). Repeatability of the measurement series was satisfactory
with 66% of the volatiles having a CV < 25% in the batch cor-
rected QC samples (see Table S2, Supporting Information).
3.2. Comparison of Normalization Methods
In Figure 1A, the scatter plots and Spearman correlation coeffi-
cients are shown for the different normalization methods. The
associations between the normalization methods are of different
Table 2. Comparison of detected 2D peaks for different fibers and different
sample preparations.
DVB/CAR/PDMS PDMS/DVC PDMS PA
NaCl + HCl (1 mol L−1) + urine 656 628 411 429
NaCl + buffer + β-glucuronidase
+ urine
640
NaCl + buffer + β-glucuronidase
+ water
440
type and strength. While normalization based on creatinine and
osmolality is highly correlated (ρ = 0.901) and thus almost equiv-
alent in this specific dataset, the effects of other normalization
methods are obviously different and may lead to less comparable
datasets and thus, at least in part, different results. Additionally,
the inverse relationship of urine volume with the overall urine
concentration and the other normalization methods can clearly
be observed. In Figure 1B, the inter- and intra-group variation be-
fore and after the application of the different normalizationmeth-
ods is depicted in a violin plot. The densest region of the CV’s was
at similar values (CV 50%) before normalization and after nor-
malization using creatinine, osmolality,MSTUS, and PQN. Inter-
estingly, calculating total peak feature excretion per 24 h (urine
volume mult) leads to a similar densest region, whereas normal-
ization by dividing by urine volume (urine volume div) showed a
broader distribution of CV’s and the highest density lay at higher
CV’s (CV 125%).
3.3. Potential Markers of Coffee Consumption
The results of the ANOVA-based response screening (see
Figure 3) and correlation analysis, as well as the potential influ-
ence of sex and age are summarized in Table 3. For the response
screening, listed volatiles had a median fold change higher than
1.5 or, in case of the correlation analysis, a Spearman corre-
lation coefficient above 0.35. In case of the ANOVA-based re-
sponse screening, further volatiles were found to distinguish be-
tween coffee consumers and non-consumers, but these volatiles
were increased in non-consumers and additionally showed only
a weak median fold change (see Table S3, Supporting Infor-
mation). Therefore, they are not discussed in this paper. The
most interesting volatile marker candidate was 3,4-dimethyl-2,5-
furandione, which was present in significantly higher levels in
the samples of coffee consumers independent of the normaliza-
tion method. This metabolite showed the highest fold changes
(6.61–8.19) and correlations (ρ = 0.606–0.683). The other po-
tential markers for coffee consumption were 2-methylfuran,
guaiacol (i.e., 2-methoxyphenol), 2-/3-methylbutanoic acid, and
2-vinylfuran. The compounds exhibited a significant difference
only for some of the different normalization methods (see
Table 3). In case of methylbutanoic acid, both the 2-methyl- and
3-methylbutanoic acid isomer are coeluting, therefore, we report
them as a sum parameter. To elucidate whether only 2-methyl-,
only 3-methylbutanoic acid, or both are potential marker candi-
dates, the raw data was reintegrated using a peak region over the
coeluting isomers including two quantifier ions (m/z 57 and 60).
This enabled a distinction of these two isomers. After applying
the different normalizationmethods and performing aWilcoxon-
test as well as a correlation analysis with the coffee consumption,
it becomes clear that both isomers were equally increased after
coffee consumption (see Figure S3, Supporting Information).
In Figure S4, Supporting Information, both boxplots from the
ANOVA screening as well as scatterplots from the correlation
analysis are shown. 2-Methylfuran and 2-vinylfuran were found
to significantly differ between males and females at least in one
of the normalization methods, but not all. Median fold changes
ranged between 1.18 and 1.38, therefore we believe the influence
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Figure 3. Results of the ANOVA based response screening for all normalization methods. FDRLogWorth = –log(p-value). Black line indicates p-value
threshold of 0.05. • Higher in coffee consumers; ◦ higher in non-consumers.
of sex to be negligible. Guaiacol showed a rather weak correlation
with age in case of two normalization methods.
3.4. Other Potential Volatile Markers Related to Food
Consumption
With the aim to demonstrate the general capability of volatiles
as potential markers of food consumption and to show the rel-
evant associations of the diet with the urinary volatilome, we
performed an additional Spearman correlation analysis with the
food variables reported in the 24 h dietary recall during the 24 h
of urine collection with the volatiles detected in these samples.
Although the 97 participants were chosen with the specific aim
to find markers of coffee consumption (see Section 3.3), we were
able to detect further associations between volatile compounds in
urine and dietary intake (see Table 4).
4. Discussion
4.1. Analytical Characteristics
Using the optimized HS-SPME–GC×GC–qMS method, we de-
tected 138 volatile compounds reliably and reproducibly in
97 (24 h) urine samples of the KarMeN study. The 63 identified
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Table 3. Results for potential markers of coffee consumption. In the first part “ANOVA screening”, the median fold changes for those volatiles that were
tested as significantly differentiating between coffee consumers and non-consumers after the post hoc tests are listed. The second part “Correlation
analysis” lists the significant Spearman correlation coefficients of volatiles with the amount of consumed coffee after Bonferroni correction. The third
part “Influence of sex” lists the significant p-values for a Wilcoxon test with males and females. The fourth part “Influence of age” lists the significant
correlations of volatiles with age. If no value is included it was not tested as significant for this volatile or normalization method.
3,4-Dimethyl-2,5-furandione 2-Methyl-furan Guaiacol 2-/3-Methyl-butanoic acida) 2-Vinylfuran
ANOVA screening (median fold change) No normalization 7.81 1.83 1.55b) 1.69 1.68
Creatinine 7.08 1.35 – – 1.46
Osmolality 6.61 1.42 – 1.39 1.33
Urine volume div 8.19 – – – –
Urine volume mult 7.31 1.49 – – 1.52
MSTUS 7.36 1.76 1.51b) 1.48 1.58
PQN 8.15 1.68 – 1.66 1.51
Correlation analysis (correlation coeff. ρ) No normalization 0.683 0.541 0.486 – 0.432
Creatinine 0.657 0.431 – – –
Osmolality 0.673 0.493 0.360 – 0.359
Urine volume div 0.606 0.404 0.384 – 0.364
Urine volume mult 0.686 0.526 0.430 – 0.401
MSTUS 0.682 0.559 0.515 – 0.406
PQN 0.682 0.557 0.524 – 0.449
Influence of sex (p-values) No normalization – – – – –
Creatinine – 0.0242 – – –
Osmolality – – – – –
Urine volume div – – – – –
Urine volume mult – 0.026 – – –
MSTUS – – – – 0.0362
PQN – – – – –
Influence of age (p-values) No normalization – – –c) – –
Creatinine – – 0.352 – –
Osmolality – – –c) – –
Urine volume div – – – – –
Urine volume mult – – –c) – –
MSTUS – – –c) – –3
PQN – – 0.338 – –
a)2- and 3-Methylbutanoic acid are coeluting compounds; b)Tukey HSD as post hoc test, all other volatiles and normalization methods used Steel–Dwass as post hoc test;
c)Correlations were tested as significant, but ρ <│0.3│.
VOC include different substance classes, among others alco-
hols, aldehydes, ketones, carboxylic acids, furan derivatives, ter-
penoids, and phenols. It is noteworthy that the 24 h urine sam-
ples were cryopreserved at –196 °C for 3–4 years and stored
for a short period (3 months) at –80 °C before they were mea-
sured. Although investigations on the influence of storage con-
ditions on the volatilome of urine advice not to store sam-
ples longer than 6–9 months at –80 °C,[44,46] we observed a
complex profile of VOCs in measured 24 h urine samples.
Nonetheless, it is to be expected that very volatile compounds
will successively be lost even at cryopreservation temperatures
(–196 °C). However, this will occur for all urine samples in
a similar manner and therefore, a relative comparison as per-
formed in this study is still feasible. Even after 3–4 years of
cryopreservation, semi- and less volatile compounds are well
detectable.
4.2. Normalization
In literature, many comparisons about the advantages and disad-
vantages of normalization methods can be found.[31,39] The most
often applied criteria for comparing normalization methods is
the number of distinguishing metabolites between groups. If
considered exclusively, this criterion is highly questionable as
a higher number of potential biomarkers does not necessarily
prove the validity of these potential markers. Therefore, objective
methods for the evaluation of normalizationmethods are needed.
Some publications proposed application of multiple evaluation
criteria (among others reduction of intra-group variation or con-
sistency of identified markers).[28,29] Additionally, experimental
design, the dataset, and the underlying research question are
important criteria for selecting a normalization method.[29] The
proposed schemes[28,29] are sophisticated approaches, but they
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Table 4. Further associations of volatile compounds with dietary intake. The number of participants having ingested a certain food variable (ning), the
Spearman correlation coefficients for all normalization methods and the p-values of the additionally performed Wilcoxon test (lowest against highest
tertile) using the in bold highlighted normalization method with the highest ρ are listed.
Food variable Volatile compound ning No normal-
ization
Creatinine Osmolality Urine
volume div
Urine
volume mult
MSTUS PQN Wilcoxon
Bread sum 2-Pentylfuran 93 0.452 – – 0.370 – 0.439 0.387 <0.0001
Cereal and cereal products 2-Pentylfuran 65 0.420 – – 0.372 – 0.383 0.379 <0.0001
Polysaccharides 2-Pentylfuran 97 0.436 – – – – 0.459 0.420 <0.0001
Baked goods Octanoic acid 47 – 0.421 0.422 – – 0.378 – 0.0005
Dairy products sum Octanoic acid 85 0.394 0.363 – – – 0.408 0.432 0.0010
Milk sum Octanoic acid 70 0.370 – – – – 0.379 0.397 0.0002
Fat sum 2-Pentylfuran 80 – – 0.357 – – 0.375 0.373 0.0002
2(3H)-Furanone,
5-ethenyldihydro-5-methyl-
80 0.356 – – – – 0.416 0.404 0.0002
Sausage products p-Cymene 50 0.437 0.353 – – – 0.467 0.447 <0.0001
Calamenene 50 0.379 – – – 0.380 0.386 0.391 0.0039
Non-alcoholic beverages sum Benzaldehyde 97 0.370 0.431 0.455 – – 0.405 0.397 <0.0001
4-Methylbenzaldehyde 97 – 0.391 0.414 – – 0.362 – <0.0001
Butylbenzoate 97 – 0.446 0.541 – – 0.446 0.371 <0.0001
(14) 97 – 0.397 0.437 – 0.408 – – <0.0001
(162) 97 – 0.368 0.405 – 0.384 – – 0.0003
Butyrolactone derivative 97 – 0.415 0.485 – 0.489 – – <0.0001
(236) 97 – 0.383 0.415 – 0.425 – – 0.0003
1-Dodecanol 97 – 0.381 0.467 – 0.440 – – <0.0001
Phthalic acid derivative 97 – 0.423 0.528 – 0.503 – – <0.0001
Phthalic acid derivative 97 – 0.424 0.501 – 0.482 – – <0.0001
Di-tert-butyl-phenol 97 – 0.418 0.456 – 0.457 – – <0.0001
Dibutylmaleate 97 – 0.394 0.505 – 0.426 – – <0.0001
Alcoholic beverages Ethanol 31 0.569 0.526 0.525 0.544 0.565 0.541 0.551 <0.0001
Carrot (149) 29 0.379 0.459 0.464 – 0.412 0.393 0.407 0.0001
(122) 29 – 0.469 0.458 – 0.375 0.369 0.378 0.0003
(78) 29 0.354 0.541 0.527 – 0.389 0.417 0.436 <0.0001
Methylsalicylate 29 – 0.420 0.435 – – 0.355 0.367 0.0225
Fruit sum 4-Methylbenzaldehyde 78 0.369 0.390 0.406 – 0.380 – 0.359 0.0014
(38) 78 – 0.4082 0.4485 – 0.4196 – – <.0001
(40) 78 – 0.4179 0.4565 – 0.4087 – – <.0001
(43) 78 – 0.3838 0.4175 – 0.3659 – – 0.0002
(68) 78 – 0.3889 0.4048 – 0.3634 – – 0.0008
Trimethyl-2-cyclohexenone 78 – 0.3703 0.4052 – 0.3539 – – 0.0008
(89) 78 – 0.4147 0.4073 – 0.3651 – – 0.0001
(98) 78 – 0.4378 0.4773 – 0.3981 – – <.0001
Apples raw (24) 36 – 0.3953 0.4161 – 0.3799 – – <.0001
(49) 36 – 0.3906 0.4203 – 0.3784 – – <.0001
(58) 36 – 0.3636 0.3964 – 0.3874 – – <.0001
Nuts and seeds (68) 25 – 0.3557 0.3537 – 0.3518 – – 0.0008
necessitate a deep understanding of the implemented statisti-
cal and bioinformatical methods for their application. Addition-
ally, if the implementation of these statistical and bioinformatical
methods is not performed by oneself, complete transparency can
hardly be guaranteed.
We applied six normalization methods (creatinine, osmolal-
ity, urine volume div, urine volume mult, MSTUS, and PQN),
not with the aim of choosing one over another, but to objectively
compare results with respect to their intrinsic similarity, their
ability for reduction of inter- and intra-group variation and dif-
ferences and similarities in the identified potential markers for
coffee consumption (discussed in Section 4.3). For all applied
normalization methods, correlations in different strength were
observed (see Figure 1A). Therefore, statistical group compari-
son can be different depending on the applied normalization. All
normalization methods as well as no applied normalization had
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comparable variation (see Figure 1B), with the exception of nor-
malization on urine volume div, which caused a higher inter-
and intra-group variation. This is in agreement with other re-
ports in recent literature[31,39] and confirms our assumption that
normalizing on 24 h urine volume by division does not lead to
an equalization of the differentially diluted urine samples, but
to a higher variation due to its inversely proportional relation-
ship with the overall urine concentration. Thus, the normaliza-
tion on urine volume div cannot be recommended. Nevertheless,
from the physiological point of view, urine volume can indeed
be considered as a meaningful normalization reference for 24 h
urine samples, because it allows the calculation of the total excre-
tion of metabolites—which may, in case of an untargeted analy-
sis and using the normalization on urine volume mult, be ex-
pressed as signal intensity per day, which is proportional to the
excreted amount per day. This allows investigating associations of
24 h dietary intake and corresponding urinary metabolite excre-
tion in the same 24 h. Twenty-four hour urine collections are not
easily applicable in most studies and therefore, spot urine sam-
ples are taken instead, which necessitate normalization methods
other than urine volume. On the other hand, as shown in Fig-
ure 1B, normalization using creatinine, osmolality, MSTUS, or
PQN was obviously equally appropriate at the global level. Fur-
ther, any normalization based on creatinine, osmolality, or urine
volume is probably not appropriate if the urinary metabolite pro-
files of apparently healthy people and those with impaired renal
function will be compared.
4.3. Potential Markers of Coffee Consumption
Using the ANOVA-based response screening and the correla-
tion analysis, six potential markers for coffee consumption were
found, 3,4-dimethyl-2,5-furandione, 2-methylfuran, guaiacol,
2- and 3-methylbutanoic acid, and 2-vinylfuran (see Table 3). Only
3,4-dimethyl-2,5-furandione was found to be significant with all
normalization methods, while the other potential markers were
only significant for some of the normalization methods. For the
normalization on urine volume div, which even introduced vari-
ation to the data, only 3,4-dimethyl-2,5-furandione was found to
be significant. Applying normalization can reduce overall varia-
tion and therefore enable marker identification, but unsuitable
normalization can as well introduce additional and artificial vari-
ation and is therefore a potential source of errors. However, bio-
logically highly relevant markers, as 3,4-dimethyl-2,5-furandione
(see Figure 3), will be found independent of the normalization
method. Therefore, comparing the influence of different normal-
ization methods on a dataset is a worthwhile and useful step.
3,4-Dimethyl-2,5-furandione is the most promising of the
found potential markers for coffee consumption (see Figure 3).
It had by far the highest median fold changes and correlation
coefficients, additionally neither sex nor age showed any influ-
ence on the urinary levels of this VOC. Most likely, 3,4-dimethyl-
2,5-furandione is a product of the roasting process of coffee
beans. It was described in the headspace of roasted Robusta cof-
fee beans[47] and brews prepared with these beans,[48] but not in
the headspace above green Robusta coffee beans.[47] Next toCoffea
canephora (Robusta coffee), 3,4-dimethyl-2,5-furandione was as
well detected in extracts from Coffea arabica varieties of different
geographic origins.[49] Therefore, 3,4-dimethyl-2,5-furandione as
potential marker of coffee consumption is plausible. However,
roasting processes are applied to many foods and 3,4-dimethyl-
2,5-furandione was also found in roasted chicory,[50] Ugandan
vanilla beans (but not bourbon vanilla beans),[51] caramel,[52] and
in flue-cured tobacco leaves,[53] affecting specificity of this po-
tential marker candidate. Most of the mentioned foods are con-
sumed rarely or in small amounts and the influence of smoking
would have to be evaluated separately, because the KarMeN par-
ticipants were all nonsmokers. Nonetheless, with high median
fold changes (6.61–8.19), no overlap of the boxes in the boxplots
of coffee consumers versus non-consumers (see Figure S4, Sup-
porting Information) and good correlations (ρ = 0.606–0.683) in
a cross-sectional study with participants on an unrestricted diet,
3,4-dimethyl-2,5-furandione remains a highly interesting and ro-
bust potential marker of coffee consumption. This is especially
true because this marker was identified even though coffee is
drunk inmany different ways and recording details of coffee con-
sumption are not part of a 24 h dietary recall. Not recorded details
of coffee consumption are i) differentiated amounts of different
coffee beverages (among others filtered coffee, instant coffee bev-
erages or espresso), ii) brewing habit (e.g., amount and length),
iii) degree of dilution with milk to some extent, iv) coffee variety
(Arabica, Robusta, etc.), and v) the roasting process, its intensity,
and the grounding. All these factors may be causal for the broad
scattering of data points that can be observed in the scatter plots
(see Figure S4, Supporting Information) and for this reason, cor-
relation coefficients can only be indicators of associations in this
case. An assessment and validation of the quantitative use of this
marker is not feasible in this study, due to the unrestricted diet
and the unknown details of coffee consumption. The quantita-
tive application should be evaluated in a separate intervention
study controlling these potential confounding factors. So far, 3,4-
dimethyl-2,5-furandione seems to allow a robust, qualitative as-
sertion about general coffee consumption.
The other significantly different VOCs (2-methylfuran, guaia-
col, 2-methyl- and 3-methylbutanoic acid, and 2-vinylfuran) be-
tween coffee consumers and non-consumers had weaker effects
(median fold changes < 1.9, ρ < 0.56). The influence of sex and
age on these potential markers seems to be of negligible impor-
tance, as only in some of the normalization methods slight ten-
dencies for differences in sex or age were observed (see Table 3).
2-Methylfuran, guaiacol, 3-methylbutanoic acid, and 2-vinylfuran
were detected in roasted coffee and are—such as 3,4-dimethyl-
2,5-furandion—a result of coffee roasting,[47,49,54] therefore they
can be viewed as plausible markers. Specificity is similarly ques-
tionable due to their formation during roasting processes.
2-Methylfuran, 2-vinylfuran, and 2-methyl- and 3-
methylbutanoic acid are formed during heating of glucose,[55]
while guaiacol is formed from the thermal or microbial degra-
dation of lignin or phenolic acids such as ferulic acid.[56] Once
ingested with the coffee, potential volatile markers will enter the
blood stream similarly to other food components.[12] From there,
they are transported to various organs for elimination (e.g., to
the lungs, where some are exhaled with the breath).[12] Others,
such as the found potential markers of coffee consumption are
removed in the kidneys and excreted with urine. Before excretion
via urine often biotransformation in the liver (phase I and II
metabolism) occurs. In this study, however, an acidic hydrolysis
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of urine samples was performed to increase the number of
observed VOC’s, therefore, no assertion about potential phase II
conjugation is possible.
Wagenstaller et al.[17] described guaiacol and 3-methylbutanoic
acid to increase after coffee consumption in a targeted analy-
sis of selected VOCs of urine samples obtained from 14 volun-
teers. 3,4-Dimethyl-2,5-furandion, our most relevant VOC, was
not measured. Wagenstaller et al.[17] observed further VOCs to
increase after coffee consumption, such as among others 4-
vinylguaiacol and β-damascenone. These VOCs were also iden-
tified in our analysis, while others might have remained uniden-
tified or were not detected. However, they were all below the sig-
nificance threshold for marker candidates of coffee consumption
in our statistical analysis. Most likely due to the more controlled
conditions in an intervention study, the small number of volun-
teers and the measurement of spot urine samples in comparison
to the KarMeN cross-sectional study with 97 participants on an
unrestricted diet and the usage of 24 h urine samples, Wagen-
staller et al.[17] were able to detect a larger number of potential
marker candidates of coffee consumption. However, our identi-
fied markers may be considered as more robust against all kinds
of potentially interfering factors (e.g., other food consumption)
and are based on a broader population.
4.4. Other Potential Volatile Markers Related to Food
Consumption
The aim of the correlation analysis between the 24 h dietary in-
take data and the VOCs in 24 h urine was to explore the potential
of using VOCs as dietary markers, not a comprehensive evalua-
tion of further potential dietary markers. In the literature, VOCs
have gained major interest for the diagnosis of diseases and al-
though many authors assume that the volatilome is influenced
by our diet,[4,5,7,9,12] specific reports are still mostly missing. Our
study shows that dietary intake has noticeable associations with
the urinary volatilome. Even though this study was specifically
designed to investigate the consumption of coffee and therefore
the strongest associations were observed with coffee, we were
nonetheless able to observe further interesting correlations (see
Table 4). Next to these positive correlations some negative correla-
tions (ρ = –0.3514 to –0.4522) were observable. Due to theirmore
difficult interpretation with respect to food consumption and be-
cause most of the volatiles were not identified, they are not dis-
cussed here. Some of the positive correlations seem plausible, ex-
emplary mentioned here: i) 2-pentylfuran is a known constituent
of the volatile profile of bread;[57] ii) octanoic acid is a known
constituent of milk and other dairy products; iii) p-cymene and
calamenene are typical constituents of different culinary herbs
applied for taste and as antimicrobial agent in sausages;[58–61] or
iv) ethanol is part of alcoholic beverages. All these plausible di-
etary marker candidates highlight the future potential of investi-
gations of the volatilome in this respect.
5. Concluding Remarks
Acidified urine samples of the KarMeN study showed a rich VOC
profile with 138 reliable volatiles (untargeted and targeted ana-
lytes) within samples collected from coffee consumers and non-
consumers. Storage for 3–4 years at –196 °C preserved the uri-
nary volatilome information, enabling effective and consistent
fingerprinting by HS-SPME–GC×GC–qMS, even without any
particular storage containers designed with respect to preserva-
tion of VOCs. The urinary volatilome is suitable for the iden-
tification of dietary markers, which could be illustrated by six
identified potential markers of coffee consumption, the most
promising being 3,4-dimethyl-2,5-furandione. These potential
markers are plausible, but due to their likely formation via roast-
ing processes, their specificity is not ensured and necessitates
future validation in further studies. Nonetheless, these markers
were found in 24 h urine samples of 97 participants of an ob-
servational study on an unrestricted diet. The fact that this was
possible, despite not recording details of coffee consumption in
a 24 h dietary recall, underlines the robustness of the marker
candidates. Applying five different normalization methods gave
similar results. With the exception of normalization on urine vol-
ume by dividing by it (urine volume div), all other normalization
methods showed similar variation in the data as no normaliza-
tion method. Nevertheless, markers that are highly relevant and
show huge biological differences, such as in case of 3,4-dimethyl-
2,5-furandione, will be identified independent of normalization
procedures. The additionally performed correlation analysis with
the general food consumption during the 24 h of urine collection
enabled us to illustrate the future potential of VOCs as dietary
markers. Our data highlights the substantial impact of dietary
intake on the urinary volatilome, therefore in future work, it is
necessary to investigate these associations in more detail, also
with respect to their influence on potential disease biomarkers.
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1. Materials and methods 
1.1. Volatile profiling of urine samples using HS-SPME-GC×GC-qMS 
1.1.1.  Screening of fibres and comparison of sample preparation 
The following four different fibre stationary materials were compared: polyacrylate (PA), 
polydimethylsiloxane (PDMS), polydimethylsiloxane/divinylbenzene (PDMS/DVB) and 
divinylbenzene/carboxen/polydimethylsiloxane (DVB/CAR/PDMS). For the comparison of 
different stationary phase materials, aliquots of the same urine sample were used and 
sample preparation and HS-SPME sampling conditions were as described for the final 
measurement series (see main paper section 2.2.1), meaning 0.16 g NaCl, 800 µL urine 
sample and 200 µL HCl (1 mol/L) with 30 min pre-equilibration at 65 °C, 1 h fibre exposure 
at 65 °C and 5 min desorption at 250 °C. 
For the comparison of enzymatic hydrolysis with the acidic hydrolysis, the same urine 
sample as above was prepared with β-glucuronidase using the DVB/CAR/PDMS fibre for 
HS-SPME under the same conditions as described above. For enzymatic hydrolysis 0.16 g 
NaCl was weight out, 800 µL of urine, 800 µL of sodium acetate buffer (pH 5) and 20 µL of 
β-glucuronidase (Helix Pomatia, ≥100000 units/mL, pH: 4.5-5) were added and mixed. 
Afterwards, HS-SPME sampling was carried out as described above. To evaluate the 
potential influence of volatiles originating from the β-glucuronidase and the buffer, a blank 
sample using water instead of urine was also measured. 
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1.1.2. Instrumental setup for HS-SPME-GC×GC-qMS 
Table S1. GC, modulation and MS parameters for measurement of volatiles using HS-
SPME-GC×GC-qMS. 
Parameter Setting / value 
GC parameters 
Carrier gas Helium 
GC mode Constant flow 
Initial column head pressure 276.4 kPa 
Liner type Splitless, straight, for SPME, Ultra Inert 
1D column SolGel WAX; 1L = 30 m plus; 1dc = 0.25 mm; 1df = 0.25 µm 
Modulator column Inert column used in modulator and to transferline L = 1 m; 
dc = 0.1 mm 
2D column Mega OV1701; 2Lsep = 1.0 m; 2dc = 0.10 mm, 2df = 0.10 µm 
Column connector SilTite MicoUnion (SGE) 
GC temperature ramp 40 °C (1 min) → 3 °C/min → 240 °C → 8 °C/min → 260 °C 
(9.83 min). Run time: 80 min. 
Injection mode split 
Split ratio 1:5 
Gas saver 2 min then 20 mL/min 
Injection temperature 250 °C 
Interface temperature 320 °C 
Modulation parameters 
Modulator type Cryogenic, liquid nitrogen-based, loop-type 
Modulation period (PM) 4 s 
Hot jet temperature ramp 220 °C → 3 °C/min →320 °C 
Hot jet duration 350 ms 
MS parameters 
Ion source temperature 230 °C 
Ionization mode EI (70 eV) 
MS Mode Scan 
Scan speed 12.500 amu/s 
Scan range 0-45 min: m/z 40-240 
45 min-end: m/z 40-320 
Data acquisition frequency 30 s-1 
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2. Results 
2.1. Analytical characteristics 
2.1.1. Fibre and sample preparation comparison 
 
Figure S1. HS-SPME-GC×GC-MS chromatograms of a urine sample using different fibre 
stationary phases. 
 
Figure S2. HS-SPME-GC×GC-MS chromatograms of a urine sample using different 
sample preparations. 
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2.1.2. Measurement serie – analytical characteristics 
Table S2. Summary of all measured known and unknown volatiles, median peak volume 
and minimum to maximum range in study samples (not normalized), frequency in all study 
samples, and intra-day repeatability bevor and inter-day repeatability after batch correction 
in QC samples. 
Volatile compound 
Median 
peak 
volume 
Minimum 
peak 
volume 
Maximu
m peak 
volume 
Frequenc
y (%) 
Intra-
dayuncorr 
(mean) 
Inter-
daycorr 
 (10) 1.10E+05 3.2E+04 7.3E+05 95.9 10.7 10.1 
 (11) 1.05E+05 2.3E+04 6.1E+05 97.9 22.8 23.2 
3-Methyl-2-heptanone 1.68E+05 5.4E+04 1.0E+06 88.7 18.7 17.4 
 (14) 1.31E+05 3.7E+04 2.4E+05 100.0 26.0 23.5 
4-Isopropylbenzaldehyde 8.94E+05 6.7E+04 1.0E+07 94.8 23.1 22.6 
 (24) 1.44E+05 2.5E+04 8.5E+05 95.9 15.8 19.5 
 (26) 2.44E+05 8.2E+04 9.4E+05 100.0 30.3 27.0 
 (30) 2.63E+05 1.0E+05 1.4E+06 100.0 24.5 24.0 
 (32) 1.85E+06 2.0E+05 1.2E+07 100.0 13.1 15.1 
 (33) 1.32E+06 1.3E+05 7.2E+06 100.0 9.7 10.6 
 (34) 3.32E+05 4.4E+04 3.3E+06 92.8 13.8 13.8 
 (35) 7.87E+05 5.1E+04 4.5E+06 100.0 15.2 16.0 
 (38) 1.68E+06 3.8E+05 6.9E+06 100.0 11.0 10.1 
 (39) 1.07E+06 5.4E+05 1.9E+07 100.0 23.5 20.2 
 (40) 1.06E+06 3.7E+05 4.2E+06 99.0 14.4 15.3 
 (41) 2.19E+06 6.7E+04 1.4E+07 80.4 8.2 7.0 
 (42) 9.48E+06 5.1E+06 1.2E+07 100.0 20.7 19.3 
 (43) 5.65E+06 1.8E+06 1.8E+07 100.0 16.5 15.0 
 (44) 3.63E+05 5.2E+04 4.1E+06 100.0 28.2 30.9 
 (49) 4.15E+05 5.8E+04 2.3E+06 100.0 9.6 10.0 
 (50) 1.08E+07 7.2E+06 1.6E+07 100.0 14.4 13.2 
 (51) 3.01E+05 1.2E+05 6.6E+05 92.8 15.6 16.7 
 (53) 8.77E+05 3.4E+04 4.3E+06 97.9 21.2 18.8 
 (54) 1.67E+05 5.0E+04 9.5E+05 97.9 28.4 24.4 
 (58) 5.09E+05 5.7E+04 2.5E+06 100.0 21.2 27.7 
 (65) 4.31E+05 2.7E+05 7.9E+05 100.0 16.6 15.1 
 (68) 5.00E+06 4.8E+05 2.0E+07 100.0 19.9 18.8 
 (69) 2.05E+05 6.0E+04 7.7E+05 91.8 15.2 14.7 
 (75) 2.30E+05 4.1E+04 1.3E+06 99.0 22.3 27.1 
 (78) 3.27E+05 8.7E+04 3.0E+06 99.0 12.1 13.1 
 (82) 1.03E+06 1.1E+05 6.1E+06 78.4 21.5 17.8 
 (83) 1.46E+05 5.1E+04 4.0E+05 100.0 34.3 32.1 
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Table S2 continued.       
 (84) 1.41E+06 1.0E+05 1.1E+07 99.0 16.3 16.7 
 (85) 7.92E+05 1.9E+05 2.2E+06 97.9 14.8 13.6 
 (86) 1.27E+05 4.7E+04 3.0E+05 94.8 11.3 11.2 
 (87) 2.09E+05 2.9E+04 1.2E+06 99.0 28.3 31.7 
 (88) 1.96E+05 6.4E+04 5.1E+05 99.0 20.0 19.8 
 (89) 3.21E+05 2.5E+04 4.8E+06 93.8 15.5 14.5 
 (90) 2.25E+05 3.0E+04 1.5E+06 94.8 15.4 14.3 
 (91) 2.01E+05 3.1E+04 9.2E+05 99.0 16.7 19.6 
 (92) 2.69E+05 6.4E+04 1.4E+06 94.8 24.9 21.6 
 (94) 3.91E+05 5.6E+04 3.1E+06 99.0 29.4 24.9 
 (95) 1.81E+05 5.8E+04 1.6E+06 97.9 37.3 30.9 
 (98) 1.39E+05 4.8E+04 3.3E+05 97.9 18.4 16.8 
2-Vinylfuran 9.60E+04 3.2E+04 7.0E+05 94.8 35.7 30.7 
 (104) 2.41E+05 2.2E+04 2.5E+06 94.8 28.2 28.7 
 (118) 4.08E+05 5.0E+04 2.4E+06 100.0 14.6 18.5 
 (122) 3.08E+05 5.7E+04 3.4E+06 93.8 15.2 15.1 
 (128) 5.48E+05 8.6E+04 4.2E+06 96.9 14.1 13.3 
 (141) 1.44E+05 3.0E+04 9.2E+05 95.9 21.4 25.2 
 (142) 4.70E+05 7.4E+04 2.0E+06 97.9 23.1 22.1 
 (144) 8.98E+05 7.5E+04 3.3E+06 86.6 20.1 20.3 
 (149) 1.14E+05 3.3E+04 4.0E+06 79.4 23.6 19.7 
 (153) 1.27E+05 2.9E+04 6.0E+06 74.2 18.2 19.7 
 (159) 2.41E+05 3.8E+04 2.1E+06 89.7 11.9 11.5 
 (162) 1.90E+05 7.3E+04 6.8E+05 83.5 19.4 20.6 
 (174) 1.64E+05 3.4E+04 1.7E+06 80.4 31.7 27.5 
 (178) 2.10E+05 6.5E+04 1.5E+06 96.9 30.7 26.6 
 (183) 1.40E+05 3.3E+04 1.2E+06 70.1 25.3 22.6 
 (190) 2.83E+05 4.4E+04 1.5E+06 97.9 31.9 31.9 
 (197) 1.81E+05 3.1E+04 2.0E+06 88.7 30.8 28.3 
 (209) 1.56E+05 6.0E+04 3.3E+06 81.4 23.0 20.2 
 (212) 1.01E+05 2.8E+04 8.3E+05 72.2 31.9 32.5 
 (218) 1.53E+05 8.1E+04 3.2E+05 99.0 22.2 20.9 
 (220) 9.75E+04 3.1E+04 2.6E+05 100.0 32.7 32.5 
 (221) 3.53E+05 6.2E+04 6.1E+06 99.0 27.0 27.6 
 (223) 1.03E+05 4.2E+04 2.5E+05 100.0 31.4 26.6 
 (234) 1.90E+05 1.5E+04 1.5E+06 90.7 32.6 32.9 
 (236) 1.14E+05 5.3E+04 3.6E+05 99.0 20.6 18.6 
4-Methylbenzaldehyde 6.45E+05 1.6E+05 1.9E+06 100.0 15.6 14.2 
 (253) 1.42E+05 4.0E+04 6.7E+05 88.7 16.8 15.6 
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Table S2 continued.       
 (254) 2.27E+05 5.9E+04 5.0E+06 100.0 27.6 26.9 
 (258) 1.38E+07 6.3E+05 8.6E+07 97.9 5.6 6.9 
1-Dodecanol 2.92E+06 1.3E+06 8.2E+06 100.0 20.8 20.5 
2(3H)-Furanone, dihydro-5-
methyl-5-(2-methylpropyl)- 4.40E+05 9.8E+04 1.4E+06 100.0 11.5 11.8 
2-Pentylfuran 2.01E+05 3.9E+04 1.1E+06 100.0 19.7 18.8 
 (36) 6.52E+05 1.9E+05 1.3E+06 100.0 23.5 26.2 
 (52) 2.80E+05 4.1E+04 1.4E+06 100.0 23.9 20.0 
 (268) 2.06E+05 4.5E+04 1.6E+06 97.9 28.9 28.5 
 (277) 9.09E+04 3.0E+04 3.0E+05 100.0 26.6 24.8 
 (278) 2.62E+05 4.8E+04 9.3E+05 100.0 22.8 25.7 
1(3H)-isobenzofuranone 
(phthalide) 3.77E+06 1.8E+06 5.2E+06 100.0 17.1 14.8 
1,2,3-Trimethylbenzene 3.05E+05 8.8E+04 1.0E+06 99.0 16.8 14.5 
2-Ethyl-1-hexanol 9.26E+05 6.7E+05 4.0E+06 99.0 9.2 7.8 
1-Terpineol 4.36E+05 3.6E+04 1.6E+07 99.0 14.9 12.7 
1H-Indole 3.89E+05 3.7E+04 1.4E+06 100.0 30.1 30.2 
2(3H)-Furanone, 5-
ethenyldihydro-5-methyl- 
5.41E+05 2.3E+05 1.9E+06 99.0 15.5 13.0 
2(3H)-Furanone, 5-
ethyldihydro-5-methyl-  
7.19E+05 3.5E+04 1.0E+07 95.9 26.6 31.9 
2,3-dehydro-α-ionone 1.63E+06 6.4E+05 1.0E+07 100.0 31.2 31.1 
3,4-Dimethyl-2,5-furandione 9.62E+04 1.2E+04 4.8E+05 76.3 21.1 18.7 
2-Acetylfuran 7.17E+05 2.1E+05 1.6E+06 100.0 17.1 15.0 
2-Butanone 3.23E+05 7.9E+04 1.4E+06 100.0 31.1 31.1 
3-Methyl-2-pentanone 9.34E+04 2.2E+04 8.6E+05 97.9 33.3 29.8 
2-Thiophenecarboxaldehyde 8.49E+04 2.7E+04 4.2E+05 99.0 22.0 18.5 
3-Furfural 4.79E+05 1.1E+05 4.1E+06 99.0 18.1 17.8 
3-Hexanone 2.17E+05 6.0E+04 1.0E+06 100.0 32.7 30.3 
4-Heptanone 9.17E+06 8.4E+05 5.1E+07 100.0 27.2 26.5 
4-Vinylguaiacol 3.63E+05 7.6E+04 3.3E+06 94.8 33.7 30.1 
5-Methylfurfural 1.05E+06 1.8E+05 4.1E+06 100.0 20.4 18.8 
Benzaldehyde 1.16E+06 6.6E+04 3.5E+06 100.0 25.5 23.1 
Benzene derivative 4.40E+05 1.1E+05 6.4E+06 99.0 19.6 16.1 
Benzeneethanol 7.35E+04 4.0E+04 2.3E+05 87.6 15.6 13.3 
Butylbenzoate 9.63E+06 4.0E+06 2.2E+07 100.0 17.9 21.7 
cis-Theaspirane 3.82E+05 1.0E+05 8.0E+06 97.9 17.1 17.4 
α-Pentylcinnamaldehyde 3.67E+05 5.6E+04 1.5E+06 100.0 31.9 32.2 
Carvone 4.54E+05 2.7E+04 1.3E+07 88.7 39.3 33.0 
Decanoic acid 1.84E+06 2.8E+04 4.3E+06 100.0 19.1 24.1 
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Table S2 continued.       
Diethyl Phthalate 5.61E+05 2.8E+05 2.3E+06 100.0 34.6 33.9 
Dihydromyrcenol 8.50E+05 8.8E+04 2.2E+07 95.9 17.7 15.8 
Dimethyldisulfide 5.09E+06 1.4E+06 1.4E+07 100.0 24.6 26.1 
2-Phenoxyethanol 1.78E+05 4.4E+04 4.0E+05 100.0 34.8 32.7 
Furan 1.56E+05 4.3E+04 5.5E+05 100.0 28.8 25.5 
2-Methylfuran 4.11E+05 9.0E+04 1.5E+06 100.0 34.5 30.6 
Furan, tetrahydro-2,2-
dimethyl-5-(1-methyl-1-
propenyl)- 
1.68E+06 1.3E+05 9.0E+06 82.5 29.5 29.4 
γ-Terpinene 6.81E+05 5.8E+04 1.5E+07 81.4 16.9 16.3 
Guaiacol 2.50E+06 5.1E+05 1.4E+07 100.0 10.5 10.0 
2-Ethylhexanal 1.84E+05 4.9E+04 4.5E+05 96.9 21.9 21.2 
Hexanoic acid 2.07E+05 1.1E+05 4.8E+05 99.0 14.8 13.8 
Limonene 2.11E+05 4.6E+04 2.4E+06 100.0 28.7 27.5 
Methanethiol 1.43E+06 5.5E+05 3.8E+06 100.0 29.9 26.0 
Methylsalicylate 7.60E+05 1.1E+05 9.1E+06 100.0 28.2 29.6 
Neoisomenthol 1.27E+05 2.9E+04 1.4E+07 81.4 14.4 16.4 
Nonanoic acid 1.56E+06 4.5E+05 4.2E+06 100.0 24.8 21.8 
Octanoic acid 3.50E+06 5.9E+05 1.2E+07 100.0 16.8 16.3 
Phenol 3.88E+06 4.7E+04 3.0E+07 100.0 10.1 10.3 
Piperitone 1.09E+06 4.7E+04 5.2E+07 93.8 23.7 28.1 
trans-Linalool oxide 5.74E+05 8.8E+04 2.9E+06 94.8 23.8 20.6 
trans-Theaspirane 3.28E+05 5.9E+04 2.9E+06 100.0 21.8 19.4 
Thymol 1.04E+06 1.8E+05 1.5E+07 97.9 14.6 16.1 
Dimethy-trisulfide 1.75E+06 1.6E+05 4.5E+06 100.0 24.1 25.4 
beta-Damascenone 9.81E+05 2.0E+05 3.8E+06 100.0 31.2 25.3 
2-/3-Methylbutanoic acid 5.97E+04 1.8E+04 2.8E+05 86.6 24.5 22.1 
cis-Linalool oxide 2.85E+06 1.4E+05 1.1E+07 90.7 16.8 15.6 
m-Cymen-8-ol 1.36E+06 1.3E+05 8.4E+06 97.9 22.7 20.1 
p-Cymene 1.03E+07 1.1E+05 1.2E+08 99.0 21.0 23.3 
p-Cymenene 1.97E+07 7.8E+05 8.9E+07 100.0 14.0 13.8 
p-Methylguaiacol 2.83E+05 7.1E+04 3.6E+06 96.9 10.8 10.4 
trans-Ocimenol 1.39E+05 3.5E+04 1.3E+06 69.1 40.5 33.6 
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2.2. Potential markers for coffee consumption 
Table S3. List of volatile compounds testing as significantly higher in non-consumers than 
in coffee consumers after the post hoc test and their median fold changes. No value for the 
median fold change is included, if the volatile compound was not tested as significant for 
the respective normalization method. 
Volatile 
compounds a) 
No 
normalizatio
n 
Creatinin
e 
Osmolality 
Urine 
volume 
div 
Urine 
volume 
mult 
MSTUS PQN 
(26) - -1.93 -1.92 - - - - 
(118) - -1.72 -1.90 - - - - 
4-Methylbenzalde-
hyde -1.71 -2.05 -1.89 - 
- 
-1.75 - 
Benzaldehyde -1.55 -2.22 -1.81 - - -1.65 - 
(141) -1.38 -1.58 -1.74 - -1.40 -1.40 -1.47 
trans-Linalooloxide - - -1.70 - - - - 
(43) - -1.66 -1.66 - - - - 
Piperitone - - -1.64 - - - - 
(277) - -1.30 -1.62 - - - - 
(35) - -1.63 -1.51 - - - - 
(86) - -1.57 -1.51 - - - - 
(52) - -1.50 -1.47 - - - - 
Methylsalicylate - -1.50 -1.35 - - - - 
(40) - -1.55 -1.34 - - - - 
a) Steel-Dwass as post hoc test for all volatiles listed here.  
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Figure S3. Separate isomers of methylbutanoic acid based on masses 57 and 60. Panel 
A: Boxplots of 2-methyl- and 3-methylbutanoic acid for coffee consumers and non-
consumers for all normalization methods. *p < 0.05; **p < 0.01; ***p < 0.001; FC: median 
fold change. Panel B: Scatterplots of 2-methyl- and 3-methylbutanoic acid for coffee 
consumption (g/d) for all normalization methods. To achieve comparable axes for the 
different normalizations, signal intensities were scaled on the highest signal intensity to be 
100%. 
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Figure S4. Potential markers of coffee consumption. Panel A: Boxplots of the potential 
volatile markers for coffee consumers and non-consumers for all normalization methods. 
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The complex human urinary sugar profile: determinants revealed in the
cross-sectional KarMeN study
Carina I Mack,1 Christoph H Weinert,1 Björn Egert,1 Paola G Ferrario,2 Achim Bub,2 Ingrid Hoffmann,3 Bernhard Watzl,2
Hannelore Daniel,4 and Sabine E Kulling1
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Karlsruhe, Germany and 4Department of Food and Nutrition, Technical University of Munich, Freising-Weihenstephan, Germany
ABSTRACT
Background: Although sugars and sugar derivatives are an impor-
tant class of metabolites involved in many physiologic processes,
there is limited knowledge on their occurrence and pattern in
biofluids.
Objective: Our aim was to obtain a comprehensive urinary
sugar profile of healthy participants and to demonstrate the wide
applicability and usefulness of this sugar profiling approach for
nutritional as well as clinical studies.
Design: In the cross-sectional KarMeN study, the 24-h urine samples
of 301 healthy participants on an unrestricted diet, assessed via a
24-h recall, were analyzed by a newly developed semitargeted gas
chromatography–mass spectrometry (GC-MS) profiling method that
enables the detection of known and unknown sugar compounds.
Statistical analyses were performed with respect to associations of
sex and diet with the urinary sugar profile.
Results: In total, 40 known and 15 unknown sugar compounds were
detected in human urine, ranging from mono- and disaccharides,
polyols, and sugar acids to currently unknown sugar-like compounds.
A number of rarely analyzed sugars were found in urine samples.
Maltose was found in statistically higher concentrations in the
urine of women compared with men and was also associated with
menopausal status. Further, a number of individual sugar compounds
associated with the consumption of specific foods, such as avocado,
or food groups, such as alcoholic beverages and dairy products,
were identified.
Conclusions: We here provide data on the complex nature of the
sugar profile in human urine, of which some compounds may
have the potential to serve as dietary markers or early disease
biomarkers. Thus, comprehensive urinary sugar profiling not only
has the potential to increase our knowledge of host sugar metabolism,
but can also reveal new dietary markers after consumption of
individual food items, and may lead to the identification of early
disease biomarkers in the future. The KarMeN study was registered
at drks.de as DRKS00004890. Am J Clin Nutr 2018;108:502–
516.
Keywords: urinary sugar profile, monosaccharide, disaccharide,
polyol, sugar acid, GC-MS, dietary marker, sex, human urine,
KarMeN study
INTRODUCTION
A variety of structurally different sugar compounds is present
in the human body and even more so in our diet. We use the terms
“sugar compounds or sugars” to refer to the following substance
classes: mono- and disaccharides, as well as derived compounds
thereof like polyols and sugar acids. Currently, sugar compounds
are usually analyzed in urine samples with a focus on individual
substance classes and, to date, most studies in this area have
been performed with only a very limited number of volunteers
(summarized in Supplemental Table 1). Combining the results
from these studies revealed a quite complex urinary sugar profile
consisting of many different sugar compounds. This is surprising
because most recent studies have investigated the role of sugar
compounds in human body fluids and focusedmainly on common
and well-known sugar compounds. Sugars and sugar derivatives
in urine reflect the sugar compounds consumed within the diet as
well as from endogenous sources. Of note is that absolute sugar
concentrations in urine are very low because numerous sugars are
efficiently reabsorbed in kidney tubular cells. Nevertheless, sugar
compounds in human urine appear to be suitable dietary markers
and, in the future, may even serve as early disease biomarkers,
but knowledge on all this is highly limited.
In a few studies, specific sugar compounds were described
as dietary markers for individual food items with examples
such as chiro- and scyllo-inositol for citrus fruit in serum (1),
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threonate and threitol for fruit and vegetables in serum (2, 3), and
some C4 and C5 sugar compounds for broccoli consumption in
urine (4). Other studies suggested that a combination of urinary
fructose and sucrose may reflect total sugar intake (5–7), which
is especially relevant in view of associations between sugar
intake and negative health outcomes such as an increased risk for
cardiovascular disease mortality (8, 9).
Because sugar compounds are involved in a variety of disease
pathways, urinary sugars could also serve as biomarkers in the
health-disease trajectory. Abnormal concentrations of urinary
sugar compounds have been described for conditions such as
diabetes mellitus (10–14), uremia (12, 15), invasive candidiasis
(16), enzyme deficiencies like galactosemia (17, 18), pentosuria
(19), or other inborn errors of metabolism (20–25). It thus seems
reasonable to state that “there is more than glucose to look at”
(26, 27).
With respect to the more commonly analyzed sugars, such
as fructose and sucrose, there is a need to understand which
factors determine their urinary excretion (28). Even less is
known about the origin, metabolism, and functions of polyols
(10, 23, 25). In a recent study, a new pathway for erythritol
production from glucose was described and erythritol excretion
was demonstrated to be associated with weight gain (29). This
study highlights our current limited knowledge on sugars and
sugar derivatives in the human body beyond glucose and fructose.
To bridge this knowledge gap especially from the physiologic and
pathophysiologic point of view, new analytical methods offering
comprehensive detection of a wide range of major and many
minor sugar compounds for nutritional and clinical research are
thus urgently needed.
Here, we present a semitargeted gas chromatography–mass
spectrometry (GC-MS) profiling method for the detection of>50
known and unknown sugar compounds in human urine and its
application to 24-h urine samples derived from the observational
KarMeN (KarlsruheMetabolomics and Nutrition) study with 301
healthy participants (30).
METHODS
Study design and subjects
The cross-sectional KarMeN study was performed at the Max
Rubner-Institut in Karlsruhe, Germany, between 2011 and 2013.
Details on the study design and examination procedures were
previously described by Bub et al. (30). Briefly, a total of 312
healthy participants aged between 18 and 80 y, who gave their
written informed consent and were willing and able to perform all
examinations, were recruited. Participants were excluded if they
had a history of prevalent or chronic disease, were smokers, or
took any medication, hormones, or dietary supplements. Women
who were pregnant or breastfeeding were also excluded. Eleven
participants who completed the study had to be excluded for
other reasons, such as diseases requiring treatment, cardiac
complications, voluntary dropout, cancer history, and acute cold
with medication (30). Thus, a total of 301 participants remained
for statistical analysis, 172 of whom were men and 129 were
women. The local ethics committee approved the study and it
was in accordance with the 1964 Helsinki declaration and its later
amendments. The study was registered at the German Clinical
Study Register (DRKS00004890) and has the WHO universal
trial number U1111-1141-7051.
Participants were asked for a 24-h urine collection. Throughout
the collection, bottles were kept in cool bags with cooling units.
At the study center, the volume of the received 24-h urine samples
was recorded, 2× 14 mLwere centrifuged at 1850× g at 4°C for
10 min and then separated into aliquots. Samples were initially
frozen at −20°C for 1 d and then cryopreserved at −196°C until
analysis. A quality control (QC) sample was prepared by pooling
24-h urine samples from KarMeN participants. Osmolality was
assessed via freezing-point depression of 24-h urine samples
with the use of a micro-osmometer (Advanced Miro-Osmometer
model 3MO, Advanced Instruments, Norwood, MA).
For the day of the 24-h urine sample collection, trained study
personnel assessed the food consumption of each participant (in
grams per day) in a personal interview through the use of a 24-
h dietary recall with the software EPIC-Soft (developed by the
International Agency for Research on Cancer (IARC) in Lyon)
(31, 32), now renamed as GloboDiet. The amount of different
foods consumed per day was assessed with the use of a picture
booklet providing photographs of portion sizes for various foods
as well as household measures and standard portions. For further
analysis, the reported foods were summarized into food group
variables (see Supplemental Table 2). Additionally, based on the
GermanNutrient Database “Bundeslebensmittelschlüssel” (BLS,
version 3.02) (33), the total energy intake (in kcal per day) and
intake of nutrients were calculated.
Semitargeted GC-MS sugar profiling
A Shimadzu GCMS QP2010 Ultra instrument was used
in Scan-/SIM (selected ion monitoring)-mode to achieve high
selectivity and sufficient sensitivity while at the same time being
able to detect a priori unknown sugar compounds. Additionally,
some abundant nonsugar compounds could be analyzed via this
method. Table 1 and Supplemental Table 3 list all compounds
that were detectable via this method, including the target and
reference ions used for integration. The structural similarity of
sugar compounds enables the usage of only a few selected masses
for selective relative quantitation in the urine matrix (see Supple-
mental Table 3 and Supplemental Figure 1). Analytical details
regarding chemicals, sample preparation, instrument, method,
and data processing parameters were described by Rist et al. (34).
Briefly, 24-h urine samples were diluted according to osmolality
(60 mosmol/kg), 40 µL were evaporated and then derivatized
via a 2-step procedure with 15 µL methoxylaminhydrochloride
solution (20 mg/mL in pyridine; 30 min, 70°C, 1000 rpm)
and 50 µL N-methyl-N-(trimethylsilyl)trifluoroacetamide + 1%
trimethylchlorosilane reagent (1 h, 75°C) before analysis. To
remove slight drift and offset effects, the raw signal intensities
were corrected through the use of QC sample-based local linear
regression functions (35).
Statistics
For all statistical analyses, the software JMP (version 13, SAS
Institute Inc., Cary, NC, 1989–2007) was used.
Association of the urinary sugar profile with sex
A matrix with all known and unknown sugar compounds and
the information on sex and age of the KarMeN participants
was used to build a decision tree with the CART (classification
and regression tree) algorithm. This approach was used to
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uncover associations between the urinary sugar profile and sex.
Advantages of the CART algorithm are its ability to cope with
missing (not detected) values and its ability to handle categoric
and numeric values in parallel. Not detected values (usually
the results of signals below detection limits) were treated by
the algorithm as a separate level of the variable. Concerning
differences in the sugar profiles between men and women, the
focus in this work was primarily on sugar compounds that
were detected in <75% of the KarMeN participants, and thus,
are potentially more sex-specific (in a qualitative sense). Age
was included as an additional continuous variable after the first
split, thus allowing the observation of associations between age
and sugar compounds. Splitting was only allowed when -log10
(P values) (calculated by JMP) were significant after Bonferroni
correction, meaning a -log10 (P value) >3.1206.
After CART analysis, the nonparametric Wilcoxon test was
generally used to test for significant differences between men
and women for the 2 most important metabolites as well
as to distinguish between the maltose excretion of pre- and
postmenopausal women.
Association of the urinary sugar profile with diet
To assess associations of diet with the human urinary sugar
profile, an exploratory correlation analysis was performed with
the use of the variables derived from the 24-h dietary recall
(food and nutrient intake) with detected urinary sugar compounds
(listed in Supplemental Tables 2 and 3, respectively). In a
first step (selection of interesting correlations), Spearman rank
correlation coefficients were determined by the pairwise method
(threshold ρ < −0.30 or ρ > 0.30) and evaluated in conjunction
with scatter plots. In a second step, participants were divided
into groups based on consumption of certain food items for
promising correlations. A Wilcoxon test was performed to
ascertain significance for these groups. If <100 participants
consumed a particular food or nutrient, an equally large group of
nonconsumers was randomly selected. If>100 participants were
consumers, tertiles were built and a Wilcoxon test for the first
against the third tertile performed.
Sugar screening in plant materials from fruit and vegetables
To assess the plausibility and specificity of some of the
potential dietary markers for food consumption, a screening of
sugar compounds in a range of fruit and vegetable varieties was
performed with the use of the same GC-MS profiling as for the
urine samples. The aimwas to screen asmany fruit and vegetables
as possible, but not to perform a comprehensive evaluation. Thus,
only 1 pooled sample for each fruit and vegetable variety was
measured.
Sample preparation for fruit and vegetables
Fruit and vegetables were bought from regional producers
directly, weekly markets, or supermarkets. Overall, a total of
75 fruit and vegetable varieties (see Table 2) were purchased
and, if possible, they were seasonally and regionally produced.
The edible plant material of 5–20 fruits or vegetables (depending
on fruit or vegetable size) was pooled into 1 sample, frozen in
liquid nitrogen, and then coarsely ground and freeze dried for
≥3 d. The dried material was ground to a fine powder with a ball
mill (Retsch MM400, Haan, Germany) for 20–60 s (depending
on the consistence of the plant material) at 30 Hz and then
stored at −80°C until analysis. For each sample, 20 ± 0.1 mg
of freeze-dried powder was weighed out and then after addition
of 20 µL of internal standard solution (pinitol and phenyl-β-
glucopyranoside in water, each 2 mmol/L) extracted twice with
750 µLmethanol for 10 min at 35°C and 1400 rpm. The collected
supernatant was mixed and then centrifuged for 5 min at 4°C and
16,100 × g. After which, 20 µL of supernatant was evaporated
and then derivatized with the use of the same 2-step procedure
as for the urine samples, except that 40 µL of methoxyl-
aminhydrochloride solution in pyridine (25 mg/mL) and 96
µL of N-methyl-N-(trimethylsilyl)trifluoroacetamide + 1%
trimethylchlorosilane were used.
Semitargeted GCMS sugar profiling and data processing
The method for the measurement of the fruit and vegetable
samples was the same as for the urine samples, except that
the Rxi-5Sil-MS column was slightly shorter (54 m + 4 m
precolumn), and as a result, time frames for SIM had to be
adjusted (34). Each day, 30 fruit and vegetable samples, six
24-h urine QC samples, and a solvent blank were prepared and
analyzed. Data processing was performed in the same way as for
the 24-h urine samples (34).
RESULTS
Analytical performance of the semitargeted GC-MS sugar
profiling method
Our newly developed and validated semitargeted GC-MS
sugar profiling method (see Supplemental Tables 3 and 4
and Supplemental Figures 1 and 2) enables the sensitive
detection and relative quantification of 55 major and minor sugar
compounds (see Figure 1 and Table 1) encompassing mono- and
disaccharides, polyols, sugar acids, and as yet not identified sugar
compounds (see Supplemental Figure 1).
The assignment of the analyzed known and unknown sugar
compounds into the different substance classes is shown in
Figure 1. If desired, some amino and organic acids can also be
analyzed with the method described here and this leads to a total
number of 68 integrated analytes (see Table 1 and Supplemental
Table 3). All sugar compounds detected via the semitargeted
GC-MS method and their signal intensity ranges are listed in
Figure 2.
Our method is also characterized by very good long-term
repeatability and intermediate precision (see Supplemental
Table 4 and Supplemental Figure 2) as proven by measurement
series comprising overall 456 runs (312 study samples plus
144 QC samples). Thus, the method is suitable for long-term
measurement series of human biofluids in large study cohorts.
Sugar profiling in participants of the KarMeN study
Sugar profile of human urine and biological variability
To determine metabolite-specific differences in the interindi-
vidual, i.e., biological variability, the CVs of the measured
sugar compounds across all 301 KarMeN participants were
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TABLE 2
Summary of a sugar screening in 75 fruit and vegetable varieties1
Psicose Mannoheptulose2 Perseitol2 Mannitol3 Galactose Threitol Xylose Polyol U02
Eggplant — 5 — tr Middle — Low tr
Avocado — 100 100 tr tr — tr tr
Leaf spinach tr 13 — tr Low — tr tr
Cauliflower — 1 — tr High — Middle tr
Common bean tr 6 — <0.1 Low — Low Low
Broccoli — 5 — tr Low — Low Low
Iceberg lettuce — 3 — <0.1 Low — Low Low
Peas tr 2 — <0.1 Low — tr Low
Lamb’s lettuce Low 27 — tr Middle — Low High
Cucumber — 4 — <0.1 Middle — tr Low
Carrot — 29 — 2.6 Low — tr Low
Potato — 5 — <0.1 Low — — —
Garlic — — — tr tr — — tr
Kohlrabi — tr — tr Low — tr tr
Garden lettuce — 11 — tr Low — Low Middle
Red cabbage — tr — — Middle — tr tr
Pointed cabbage — tr — — Low — tr tr
White cabbage — tr — — Low — tr tr
Pumpkin — tr — <0.1 Middle tr tr Low
Leek — tr — — Low — tr tr
Striped lentil — — — tr tr — — tr
Black lentil — — — tr tr — — —
Lentil, “Perla” — — — tr tr — — —
Corn — — — tr Low tr tr —
Green bell pepper — 6 — <0.1 High — Low tr
Red bell pepper — 7 — <0.1 High — Low tr
Hot pepper — 22 — <0.1 High — Low tr
Button mushroom — 1 <1 100 tr — — tr
Shiitake — — <1 77.4 tr tr — —
Small radish — 2 — <0.1 Low — Low tr
Radish — — — tr Low — tr tr
Beetroot — — — — Middle — tr tr
Pointed pepper — 12 — <0.1 Middle — tr —
Soy — — — <0.1 Low — tr tr
Green asparagus — — — <0.1 Low — Low tr
White asparagus — — — <0.1 Low — Low tr
Grape tomato — 6 — <0.1 Low — Low —
Tomato, “Matina” — 11 — <0.1 High — Low tr
Tomato, “Resi” — 7 — <0.1 High — tr tr
Zucchini — — — <0.1 High — Low Low
Onion — tr — tr Low — tr —
Pineapple — — — — Middle — tr —
Apple — 6 — 0.1 Low — High tr
Apricot — 4 — <0.1 Low — Low tr
Banana — — — tr Low — — —
Pear — 5 — <0.1 Low tr Low tr
Blackberry — 4 — <0.1 Low — Low —
Clementine — — — tr Low — Low —
Strawberry, “Asia” — 4 — — Low — High tr
Strawberry, “Elsanta” — 2 — tr Low — High tr
Pomegranate — 7 — 18.1 Low tr tr tr
Grapefruit — tr — tr Low — tr —
Blueberry — 10 — tr Low — Low —
Raspberry — 4 — tr Low — Middle —
Honeydew melon — tr — <0.1 High tr tr Low
Red currants — 6 — tr Low — Low —
Black currants — 14 — <0.1 Low — Low —
Sour cherry — 7 — <0.1 Low tr Low tr
Sweet cherry — 1 — <0.1 Low — Low tr
Kiwi fruit — 5 — <0.1 Middle — tr —
Mango — 4 — tr Low — tr —
Small yellow plums — 6 — <0.1 Low — Low —
(Continued)
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TABLE 2 (Continued)
Psicose Mannoheptulose2 Perseitol2 Mannitol3 Galactose Threitol Xylose Polyol U02
Nectarine — 4 — <0.1 Low — Low —
Orange — tr — — Low — Low —
Papaya — tr — <0.1 Low tr Low tr
Passion fruit — 2 — tr Low tr tr —
Yellow peach — 5 — <0.1 Low — Middle tr
White peach — 4 — <0.1 Low — Low tr
Physalis — 7 — <0.1 Low — tr —
Gooseberry — 3 — — Low — Low —
Red table grapes — 4 — — Low — tr tr
White table grapes — 5 — — Low tr tr tr
Lemon — — — tr Low — tr —
Plum — 5 — <0.1 Low — Low tr
Fig — 4 — tr Middle — tr tr
1High, fruit or vegetables with signal intensities in the highest tertile of the signal intensities for this analyte; Low, fruit or vegetables with signal intensities
in the lowest tertile of the signal intensities for this analyte; Middle, fruit or vegetables with signal intensities in the middle tertile of the signal intensities for
this analyte; tr, trace analytes (analytes below a signal intensity of 8000).
2Ratios of mannoheptulose and perseitol signal intensities for the fruit and vegetables compared with avocado signal intensity.
3Ratios of mannitol signal intensities for the fruit and vegetables compared with button mushroom signal intensity.
determined. Some sugar compounds were excreted with a narrow
concentration range, for example glucuronic acid with a CV of
29.8%, whereas others showed a huge biological variability, such
as lactose with a CV of 294.5% (see Figure 2). In addition, the
relative frequency of occurrence of individual sugar compounds
in the 24-h urine samples of KarMeN participants is listed
in Supplemental Table 3. To further assess factors underlying
the huge biological variability, analyses focused on sex as a
determinant and on dietary intake reconstructed from dietary
intake measures.
Association of the urinary sugar profile with sex
To identify sugar compounds associated with sex, a decision
tree using the CART algorithm was built (see Figure 3). In
FIGURE 1 Classification assignment of sugar compounds into different
substance classes.
Table 3, possible candidates for a split are given for the first
3 nodes and for leaves. Evidently, the most relevant sugar
compound separating men and women was maltose, which was
detected in 78.3% of women but only in 35.5% of men. In
addition, the urinary maltose concentration was significantly
higher in women (P < 0.0001, see Figure 3). Other important
metabolites were gluconic acid, fructose, and an unknown sugar
compound, which were found in>75% of the study samples and
recently discussed by Rist et al. (34). In the second node, where
age was included as an additional potential splitting candidate,
the 3 top determinants for separating men and women were
age, gluconic acid, and sedoheptulose. Interestingly, splitting on
the basis of sedoheptulose would have been similar to splitting
on age as a result of the close association between age and
sedoheptulose concentration in 24-h urine samples (34). The
second split was done based on age as a top determinant, thereby
indicating a close association between urinary maltose, sex,
and age. The cut point for age was 45 y, thus suggesting that
sugar excretion patterns change with menopause in women (see
Figure 3). Gluconic acid was the only possible candidate
metabolite for the third and last split (see Figure 3 and Table 3);
however, to prevent overfitting, no further splitting was done.
Boxplots of the 2 most important sugar compounds that separate
men and women and the interaction between maltose excretion,
sex, and age (menopausal status) are shown in Figure 3.
Association of the urinary sugar profile with diet
A correlation analysis was performed based on 24-h urinary
sugar profiles with the food consumption and nutrient intake
data and a heat map generated on the basis of the Spearman
rank correlation coefficients (Figure 4). The Spearman rank
correlation coefficients with ρ > 0.30 are listed in Table 4;
no correlations with ρ < –0.30 were observed. Significant
correlations were observed for 1) avocado consumption with
perseitol, 2) dairy product consumption with galactose and
lactose, 3) alcoholic beverage consumption with xylitol and
ethyl-β-glucuronide, 4) mushroom consumption with mannitol,
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FIGURE 2 Interindividual/biological variability of the sugar profile in human urine from 301 participants of the KarMeN study. Sugar compound intensities
were median-centered and unit variance scaled to allow for a comparison of the biological variance. Whiskers of box plots indicate ± 1.5 IQR. Median,
minimum, maximum, and CV refer to peak area and enable a relative comparison of signal intensity. For reasons of simplicity, only the first of 2 derivatives
was listed.
5) fruit consumption with threitol, xylose, and an unknown
polyol, 6) citrus fruit juice and fruit drink consumption with
chiro-inositol and galactonic acid, and 7) sucrose intake with
fructose and sucrose (see Table 4 and Figure 4). In the case of
avocado, in addition to perseitol, mannoheptulose presented itself
as a potential dietary marker although the correlation coefficient
was slightly below our threshold of 0.30 (ρ = 0.2704; see
Figure 4). To verify this observation despite the low number
of avocado consumers (n = 9), Spearman rank correlation
coefficients were calculated for the avocado consumers and
18 randomly chosen nonconsumers (n = 27) (mannoheptulose:
ρ = 0.7748, perseitol: ρ = 0.8713; see Figure 5). For some
of these potential dietary markers box and scatter plots as well
as their origin and potential confounders or other interferences
are shown in Figure 5. A second line of evidence that
those metabolites may be potential dietary markers for distinct
foods/products was provided by analyzing the sugar profiles of
75 selected fruit and vegetable varieties (see Table 2).
DISCUSSION
Sugar profiling in participants of the KarMeN study
Sugar profile of human urine and biological variability
With the analytical method described here, we provide a
straightforward and reliable tool to obtain sugar profiles and
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FIGURE 3 Identification of urinary markers discriminating sex via the CART approach. (A) Decision tree with splitting rules, the number of men or
women, and the ratio between men and women for each branch; (B) box plots for the 2 top sugar compound candidates to differentiate sex; (C) association of
age with maltose excretion in women (pre- and postmenopausal). Significance was established with the use of the Wilcoxon test, with participants excluded
where the sugar compound was not detected. CART, classification and regression tree.
TABLE 3
Results of building a decision tree (CART) for the identification of possible
markers to differentiate sex. Possible candidate sugar compounds for split-
ting are listed only if significant P values were achieved after Bonferroni
correction1
Sugar compound Candidate G² −log10 (P value) Cut point2
First node: split candidates
Maltose 152.6 55.8316 6.50E + 03
Gluconic acid 56.6 17.0557 1.05E + 05
Unknown U05 37.8 9.1285 6.66E + 05
Fructose3 27.1 5.0777 2.25E + 05
Second node: split candidates
Age 34.7 8.6471 45.363
Gluconic acid 27.1 5.8762 1.38E + 05
Sedoheptulose3 25.3 5.2497 1.32E + 05
Unknown U05 19.8 3.4428 7.07E + 05
Third node: split candidates
Gluconic acid 20.0 4.0476 1.38E + 05
First leaf: split candidates4
Second leaf: split candidates4
Third leaf: split candidates
Mannonic acid 21.6 4.6179 5.62E + 04
Unknown U03 17.5 3.3893 4.73E + 04
Fourth leaf: split candidates4
1G2, likelihood ratio chi-square; highest values indicate best split.
2Best value for splitting the variables (cut point).
3For reasons of readability, only the higher-ranking derivative was listed.
4Candidate P values were below the significance level.
semiquantitative data in biofluids like urine. We observed a
considerably wider range of sugar compounds than commonly
known or expected in human urine (see Figure 2, Table 1, and
Supplemental Table 1). There are many less known urinary sugar
compounds with unclear origin such as psicose, perseitol, or
mannoheptulose; their origin could be exogenous or endogenous.
However, urinary sugar profiles partly showed a remarkable
variability (see Figure 2), and thus, we believe that many
individual sugars are dependent on sex, health status, or are a
surrogate of a dietary pattern or the consumption of distinct food
items.
Association of the urinary sugar profile with sex
The most important metabolites to differentiate between
male and female sugar profiles were maltose and gluconic
acid. Maltose has been reported to be present in very low
concentrations in human urine, but no differences with respect
to sex have been described so far (10, 12, 23, 36–39). We
hypothesize that the maltose excretion seen in women may be
associated with the vaginal microbiota (dominated by lactic acid–
producing Lactobacillus species). Spear et al. (40) demonstrated
that vaginal fluid possesses α-amylase activity, and thus is able to
degrade free glycogen to maltose, maltotriose, and maltotetraose,
which can then be utilized by Lactobacillus species (41, 42). This
degradation pathway of free glycogen released from the vaginal
epithelium might be responsible for the higher excretion rate of
maltose in female urine.
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FIGURE 4 Heat map of Spearman rank correlation coefficients for the correlations of sugar compound excretion with food consumption and sugar intake
(for an explanation of variables, see Supplemental Table 2) during the 24-h collection of urine. Correlations were estimated by a pairwise method. Boxes
indicate the highest (most significant) correlations. The amount of consumed food is always given in g/d.
We observed a significantly lower maltose content in the urine
of postmenopausal women in comparison with premenopausal
women (see Figure 3). Postmenopausal women have significantly
lower amounts of glycogen and Lactobacilli counts in the vaginal
fluid as a result of reduced estrogen concentrations (41, 43,
44). Collectively, these observations concur with our finding of
reduced maltose concentrations in postmenopausal women and
add plausibility to a link between maltose excretion and the
vaginal microbiota.
For gluconic acid and fructose we could not find a plausible bi-
ological explanation for the observed sex-dependent differences
in urine.
Association of the urinary sugar profile with diet
Based on the correlation analysis, potential dietary markers for
the consumption of various food items as well as food groups
were identified (Figure 5 and Table 4). This analysis suggests the
following sugar compounds to serve as specific dietary markers:
mannoheptulose and perseitol for avocado and galactose and
lactose for dairy products. These sugars are known constituents
of these respective foods (45–50). Although an increase of
mannoheptulose and perseitol excretion in urine after avocado
consumption (25) has been described in an intervention with 3
volunteers, it was not specifically defined as a dietary marker. An
increase of galactose and lactose after pure lactose ingestion has
been observed (49, 51–53). Moreover, in a recent intervention
study with milk, both galactose and lactose were suggested as
specific dietary markers for milk consumption (54).
Although mannitol appears to be a plausible dietary marker
for mushroom consumption (55), its specificity is questioned
because there are many other sources of mannitol in the human
diet (48) (see also Table 2) — a fact that confounds the
aforementioned identified association (see Figure 5).
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TABLE 4
Correlations between analytes and the consumed amounts of certain foods, food groups, or nutrients as determined by a 24-h recall (see Supplemental
Table 2)1
Participants
Spearman2
Sugar compounds Dietary intake nexcr. ning. ρ
Perseitol Avocado 219 9 0.3388
Galactose3 Milk sum 301 234 0.6644
Galactose3 Dairy products sum 301 279 0.6082
Galactose3 Milk 301 174 0.4779
Galactose3 Yoghurt 301 84 0.3017
Lactose3 Milk sum 300 234 0.4204
Lactose3 Dairy products sum 300 279 0.3364
Lactose3 Milk 300 174 0.3180
Galactonic acid Milk sum 296 234 0.3403
Galactonic acid Dairy products sum 296 279 0.3005
Xylitol Alcoholic beverages 301 96 0.6379
Xylitol Beer 301 47 0.4667
Xylitol Wine and sparkling wine 301 55 0.4531
Ethyl-β-glucuronide Alcoholic beverages 144 96 0.5885
Ethyl-β-glucuronide Wine and sparkling wine 144 55 0.4446
Ethyl-β-glucuronide Beer 144 47 0.3457
Sorbitol Alcoholic beverages 299 96 0.4948
Sorbitol Wine and sparkling wine 299 55 0.4496
Allose Alcoholic beverages 301 96 0.3425
Allose Wine and sparkling wine 301 55 0.3128
Arabitol Alcoholic beverages 301 96 0.3340
Mannitol Mushrooms 301 35 0.3633
Mannitol Button mushroom 301 32 0.3489
chiro-Inositol Citrus fruit juices and drinks 260 65 0.4941
chiro-Inositol Citrus fruit 260 37 0.3000
Galactonic acid Citrus fruit juices and drinks 296 65 0.3825
Threitol Fruit sum 301 228 0.4904
Threitol Apple 301 106 0.4359
Xylose3 Fruit sum 301 228 0.4768
Xylose3 Apple 301 106 0.4736
1-Deoxy-sorbitol Apple 299 106 0.4653
1-Deoxy-sorbitol Fruit sum 299 228 0.3504
1-Deoxy-sorbitol Fruit juice and juice drink 299 131 0.3130
1-Deoxy-sorbitol Fruit juices 299 123 0.3097
Sugar acid U09 Fruit juice and juice drink 301 131 0.3649
Sugar acid U09 Fruit juices 301 123 0.3395
Polyol U02 Fruit sum 301 228 0.3516
Galactonic acid Fruit juices 296 123 0.3498
Galactonic acid Fruit juice and juice drink 296 131 0.3320
Xylonic acid Fruit juice and juice drink 301 131 0.3408
Xylonic acid Fruit juices 301 123 0.3107
Xylonic acid Fruit sum 301 228 0.3091
chiro-Inositol Fruit juices 260 123 0.3350
chiro-Inositol Fruit juice and juice drink 260 131 0.3119
1-Deoxy-sorbitol Monosaccharides 299 301 0.4676
Unknown U24 Polysaccharides 301 301 0.4477
Unknown U24 Bread sum 301 293 0.4463
Unknown U24 Carbohydrates 301 301 0.3949
Fructose3 Monosaccharides 301 301 0.3966
Fructose3 Sucrose 301 301 0.3581
Fructose3 Disaccharides 301 301 0.3192
Threitol Monosaccharides 301 301 0.3955
Xylonic acid Monosaccharides 301 301 0.3919
Xylose3 Monosaccharides 301 301 0.3785
Sucrose Sucrose 301 301 0.3620
Sucrose Disaccharides 301 301 0.3243
Sucrose Candy 301 104 0.3132
Mannoheptulose Monosaccharides 300 301 0.3135
1nexcr., number of participants who excreted a certain sugar compound; ning., number of participants who ingested individual foods or food groups.
2Spearman rank correlation coefficients < –0.30 or >0.30. All listed correlations had significant P values < 0.0001.
3For reasons of readability, only the higher-ranking derivative was listed.
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FIGURE 5 (Continued)
We also identified xylitol as a potential dietary marker for
alcoholic beverage consumption. An increase of xylitol in
urine after administration of ethanol (56) has been described
before, but the causality underlying the relation between alcohol
consumption and urinary xylitol output (56, 57) warrants further
research. Ethyl-β-glucuronide has already been described as a
dietary marker for alcoholic beverage consumption (58–60); we
observed a moderate association (see Figure 5 and Table 4). In
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FIGURE 5 Overview of potential dietary markers (includes results of the KarMeN study and sugar screening of fruit and vegetables as well as literature
data). Potential dietary markers of food consumption with the strongest associations in the correlation analysis, their plausibility in terms of origin, and their
specificity in terms of potential confounders or other interferences. Shaded violet: food/nutrient level; shaded light blue: interfering sources for potential dietary
markers (foods, drugs, results from sugar screening of fruit and vegetables); shaded red: metabolization in human; shaded yellow: results in 24-h urine samples.
Colors of boxes and arrows as follows: green (part 1): consumption of avocado; grey (part 1): consumption of dairy products; dark blue (part 2): consumption of
alcoholic beverages; brown (part 2): consumption of mushrooms; light blue: interfering sources for potential dietary markers (foods, drugs, results from sugar
screening of fruit and vegetables). Check: compound occurs in specific food; cross: compound does not occur in specific food. The amount of consumed food is
given in g per day. Significance was established by use of the Wilcoxon test. Spearman rank correlation coefficients were calculated using all 301 participants,
except for avocado, where the 9 avocado consumers plus 18 randomly selected participants were used.
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light of the many other potential confounders and interferences
for ethyl-β-glucuronide detection (61–64) (see Figure 5), we
recommend to use measurements of additional metabolites such
as ethylsulfate (65) or in combination with xylitol.
It would be highly desirable to use some of these dietary
markers in future as an objective measure of food consumption
in comparison with self-reported consumption, where biases
such as under- or over-reporting in cases of perceived unhealthy
or healthy foods often occur (64). Objective dietary markers
would allow more reliable insights into health aspects, and thus,
relations between diet and health could be more accurately
ascertained.
In more general terms, a dietary marker should fulfil a number
of criteria such as its specificity, the dose-response relation,
plausibility of origin, and suitability in free-living populations,
and, importantly, analytical robustness (66). Questions around
the quality of dietary markers also cover issues on whether a
metabolite is a short-term marker of intake over a 24–36 h period
or whether it can also serve as a long-term reporter molecule
especially in epidemiologic studies (67). Moreover, whether
there are saturation effects and whether the dietary marker can
quantitatively assess consumption are also important issues (66).
Specificity and dose-response effect, plausibility, and suitabil-
ity in a free-living population as in our KarMeN population
on an unrestricted diet as well as methodological validity were
all addressed in the present study. The main limitations in our
approach were 1) the low number of participants consuming
some specific food items such as avocado, 2) the potential bias
through the use of self-reported food consumption data for the
correlation analysis, and 3) owing to our study design so far only
a conclusion about metabolites’ usefulness as short-term markers
can be drawn. Other limitations might be that only a single
urine collection was measured potentially leading to exaggerated
interindividual variation and that only fruit and vegetables, but
not processed food and beverages, were screened during the
sugar profiling of food. However, our aim is that the developed
analytical method and the approaches used to identify some
crucial sugar compound determinants will be taken into larger
and more diverse cohorts as the next step to deriving quantitative
dietary markers and to shedding light on the diet-health relation
for one of the most important food substrates in the human diet
and metabolism, namely the sugars.
In conclusion, we have demonstrated that the human urinary
sugar profile is complex and comprises many more compounds
than previously anticipated. With the large number of sugar
compounds detected, we identified also a huge gap in knowledge
regarding the metabolism of most of these sugar compounds, in
particular along the diet-health-disease trajectory. We therefore
suggest that future research should not only encompass analyzing
common and well-known sugar compounds, but rather strive for
a more comprehensive view on sugar compounds. However, the
data from our study can be used as a reference for normal sugar
profiles of healthy humans with respect to the occurrence of
individual sugar compounds along with variances in excretion.
For some sugars, we identified crucial determinants such as sex
and pre- compared with postmenopausal women. However, these
determinants need further study.We also identified a considerable
number of sugar compounds as potential dietary markers for
individual food items and groups (see Figures 4 and 5), for which
confirmation and assessment of their quantitative dimension and
their usability as long-term markers in epidemiologic studies
are required in future studies. Although our newly developed
semitargeted GC-MS method is only semiquantitative, it clearly
offers a rapid and cost-effective strategy to obtain comprehensive
insights into the sugar profile by detecting not only numerous
known, but also some unknown sugar-like compounds that
also deserve identification. Our analytical method may also
be useful in identifying the underlying physiologic processes
that allow assessing determinants for absorption/permeation
from the intestine into blood circulation as well as for renal
secretion/reabsorption. Ultimately, this analytical method may
not only help to identify dietary markers, but also to identify
disease biomarkers in the future.
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Supplemental Table 1. Sugar compounds present in human urine as reported in the current literature. 
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1968: Bhatti et al. (1) X X X X X X X X X X X X 
1968: Jolley et al. (2) X X X X X X X X X X X X 
1970: Butts et al. (3) X X X X X X X X X X 
1972: Nakamura et al. (4) X X X 
1972: Pitkänen et al. (5) X X X X X 
1975: Pfaffenberger et al. (6) X X X X X X X X X X X X 
1976: Lawson et al. (7) 
1981: Mount et al. (8) X 
1983/4: Niwa et al. (9, 10) X X X X X X X X X X X X X X 
1984: McIntosh  (11) X X X X X 
1986: Jansen et al. (12) X X X X X X X X X X X X 
1987: Burke et al. (13) X X X X 
1989: Haga et al. (14) X X X X X 
1991: Shoemaker et al. (15) X X X X X X X X X X 
2001: Yoshii et al. (16) X X 
2004: Huck et al. (17) X X X X X X X X X X 
2005/7: Wamelink et al. (18, 19) X X X X X X X 
2006: Lee et al. (20) X X X X 
2009: Koy et al. (21) X X X X 
2010: Fei et al. (22) X X X X X 
2012: Zhang et al. (23) X X X X X X X X X X 
2013: Ge et al. (24) X X X X 
2013: Bouatra et al. (25) X X X X X X X X X X X X X X X 
2015: Vasquez et al. (26) X 
2017: Bawazeer et al. (27) X X X X X X 
Semi-targeted sugar profiling X X X X X X X X X X X X X X X X X X X X 
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1968: Bhatti et al. (1) X X 14 
1968: Jolley et al. (2) X 13 
1970: Butts et al. (3) 10 
1972: Nakamura et al. (4) 3 
1972: Pitkänen et al. (5) X X X 8 
1975: Pfaffenberger et al. (6) X X X X X 17 
1976: Lawson et al. (7) X X X X X X X X 8 
1981: Mount et al. (8) X X X 4 
1983/4: Niwa et al. (9, 10) X X X X X X X X X X X 25 
1984: McIntosh  (11) X X X X X X X 12 
1986: Jansen et al. (12) X X X X 16 
1987: Burke et al. (13) 4 
1989: Haga et al. (14) X X X X X X X 12 
1991: Shoemaker et al. (15) X X X X X X X 17 
2001: Yoshii et al. (16) X X 4 
2004: Huck et al. (17) X 11 
2005/7: Wamelink et al. (18, 19) X X X X X 12 
2006: Lee et al. (20) X X X X 8 
2009: Koy et al. (21) X 5 
2010: Fei et al. (22) X X X 8 
2012: Zhang et al. (23) X X X X X 15 
2013: Ge et al. (24) X X X 7 
2013: Bouatra et al. (25) X X X X X X X X X X X 26 
2015: Vasquez et al. (26) X X 3 
2017: Bawazeer et al. (27) 4 
Semi-targeted sugar profiling X X X X X X X X X X X X X X X X X X X X 40 
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 Online Supporting Material 
Supplemental Table 2. Description of food groups and nutrient variables derived from 24 h 
dietary recall and nutrient intake data. These variables were used as such for the correlation 
analysis. 
Food/nutrient variable Food/nutrient variable 
Carbohydrates  
Monosaccharides  
Disaccharides  
Polysaccharides  
Sucrose  
Bread sum  
   Bread and buns (whole meal and white, brown or    
   multigrain) 
   Cereal and cereal products 
   Baked goods (pastries) 
Vegetables sum 
   Vegetables 
   Mushrooms 
   Legumes 
   Avocado 
Potato sum 
Fruit sum 
   Banana 
   Apple 
   Citrus fruit 
   Other fruit 
   Fig 
Nuts sum 
Fat and oil sum 
   Animal fat (including butter, lard, fish oil) 
   Vegetable fat (including margarine) 
Dairy products sum 
   Milk sum 
     Milk 
     Milk lactose free 
     Mixed milk beverages 
     Yoghurt 
     Kefir and buttermilk and set milk 
     Cream and sour cream 
     Condensed milk 
   Cheese and curd 
     Curd 
     Cream cheese 
     Hard cheese 
     Blue cheese 
     Other cheese  
Eggs sum 
Meat sum 
   Meat 
   Sausage products 
Fish sum 
Soup 
Sauce (including warm and cold sauces; exceptions: 
fruit-, vegetable-, ground meat sauce) 
Candy sum 
   Candy 
   Ice cream 
   Sugary spreads (jam, jellies, honey and chocolate  
   spreads) 
   Dessert (including pudding, semolina, tiramisu) 
Non-alcoholic beverages sum 
   Water 
   Coffee and green/black tea 
     Coffee 
     Herbal and fruit tea 
   Fruit juice and juice drink 
     Fruit juices 
     Juice drinks 
     Citrus fruit juices and drinks 
   Sugar sweetened beverages 
     Cola 
   Other non-alcoholic beverages 
Alcoholic beverages 
   Beer 
   Wine and sparkling wine 
   Spirituous beverages 
   Other alcoholic beverages (e.g. alcopops, cocktails) 
Other sum (milk substitutes, meat substitutes, cereal 
substitutes, sweeteners, sugar substitutes, beverage 
powders/-granules, herbs, spices, vegetarian spreads, 
protein powder, yeast, miso) 
Italic and normally written variables are part of the above written summarized variables in bold 
or italic. 
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 Online Supporting Material 
Supplemental Table 3. Summary of all analyzed known and unknown (U) compounds detected using the semi-targeted GC-Scan-/SIM-
MS profiling method, their level of identification, occurrence of partial or total chromatographic coelution, and frequency in all KarMeN 
participants (including excluded 11 participants). The corresponding target and reference ions are also listed. All bold set analytes were 
used for the statistical analysis. 
Substances Identification Level1 Coelution
2 Frequency 
(%) Target ion Reference ions Ratios
4
 
Allowance5 
(%) 
L-Serine 1  100.0 218.00 204.10, 117.00 185.58, 14.32 30 
L-Threonine 1 partialchrom. 100.0 218.00 117.00, 292.15 110.31, 21.75 30 
meso-Erythritol 1  100.0 204.10 307.15, 117.00 71.16, 143.11 30 
D-Threitol 1  100.0 204.10 117.00, 307.15 126.91, 52.92 30 
Erythronic acid 1 partialchrom. 100.0 292.15 217.10, 117.00 37.58, 31.34 30 
Threonic acid 1  100.0 292.15 117.00, 217.10 57.03, 44.66 30 
L-Cysteine 1  100.0 220.00 218.05 70.99 306 
Creatinine-enol 1  100.0 329.00 314.00, 117.00 52.63, 18.71 30 
Tartaric-acid 1 partialchrom. 99.7 292.15 117.00, 277.20 4.04, 9.81 30 
L-Phenylalanine 1 partialmass. 99.0 218.00 147.05 23.14 306 
D-Xylose deriv. 1 1 partialchrom. 100.0 307.15 277.20, 117.00 21.65, 46.70 506 
D-Xylose deriv. 2 1 partialchrom. 100.0 160.10 277.20, 307.15 81.76, 355.50 406 
Sugar acid U01 3 partialchrom. 100.0 333.10 204.10 181.23 506 
D-Arabinose deriv. 1 1  100.0 307.15 160.10, 277.20 22.84, 21.86 30 
D-Arabinose deriv. 2 1  100.0 307.15 277.20, 160.10 21.86, 22.84 30 
D-Ribose 1 partialchrom. 100.0 307.15 277.20, 204.10 20.96, 10.53 30 
Polyol U02 3  100.0 307.15 319.20, 217.10 99.91, 107.94 30 
Unknown U03 4  100.0 307.15 217.10, 277.20 161.04, 21.32 30 
D-Xylitol 1 partialchrom. 100.0 307.15 319.20 85.51 306 
Levoglucosan 1 partialchrom. 99.4 204.10 333.10 24.78 306 
D-Arabitol 1  100.0 307.15 319.20, 204.10 88.31, 52.63 30 
D-Ribitol 1 partialchrom. 100.0 319.20 307.15, 204.10 62.41, 41.07 30 
L-Fucose
 
deriv. 1 1 partialchrom. 100.0 117.00 160.10, 277.20 13.50, 10.62 30 
Unknown U04 4 partialmass. 71.83 204.10 217.10, 117.00 50.09, 9.63 30 
L-Fucose
 
deriv. 2 1  100.0 117.00 160.10, 277.20 9.95, 11.19 30 
Unknown U05 4 partialchrom. 100.0 204.10 217.10, 117.00 476.21, 13.07 30 
Sugar acid U06 3 partialmass. 100.03 333.10   6 
Xylonic acid 1  100.0 292.15 333.10, 307.15 19.21, 14.62 30 
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Ribonic acid 1  100.0 292.15 333.10, 307.15 19.21, 14.62 30 
1-Deoxysorbitol 2  99.4 319.20 117.00, 217.10 154.70, 37.55 30 
Sugar acid U09 3  100.0 292.15 333.10 16.91 306 
Arabonic acid 1 partialmass. 100.0 292.15 333.10 14.66 306 
D-Fucitol 1 partialmass. 100.03 319.20 117.00, 307.15 284.39, 50.19 506 
Unknown U11 4  69.6 245.00 292.15, 117.00 55.78, 96.48 30 
Unknown U12 4 partialchrom. 99.4 307.15 217.10 203.03 306 
Isocitric acid 1 partialmass. 100.0 245.00   6 
Hippuric acid 1 partialmass. 100.0 206.00 105.00 117.45 30 
D-Psicose deriv. 1 1 partialchrom. 100.0 307.15 217.10 159.68 606 
D-Quinic acid 1  100.0 345.00 255.00, 204.10 53.26, 10.91 30 
D-Psicose deriv. 2 1  100.0 307.15 204.10, 217.10 7.08, 181.54 30 
D-Fructose
 
deriv. 1 1  100.0 307.15 205.10, 217.10 29.81, 181.54 30 
Allose 1 partialmass. 100.0 319.20 205.10 63.09 306 
D-Fructose
 
deriv. 2 1 partialmass. 100.0 307.15   6 
D-Galactose deriv. 1 1 partialchrom. 100.0 319.20 205.10, 217.10 48.93, 20.81 30 
D-Glucose deriv. 1 1  100.0 319.20 205.10, 217.10 70.92, 54.54 30 
D-Mannose deriv. 2 1 partialmass. 99.0 319.20 205.10 135.68 506 
D-Galactose deriv. 2 1 partialchrom. 97.1 319.20 205.10, 217.10 64.51, 120.70 30 
D-Glucose deriv. 2 1  100.0 319.20 205.10, 217.10 73.08, 23.79 30 
L-Lysine 1  100.0 156.00 318.20 9.69 306 
D-Mannitol 1  100.0 319.20 307.15, 205.10 16.01, 60.25 30 
D-Glucuronic acid deriv. 1 1 partialchrom. 100.0 333.10 160.10 59.35 306 
D-Sorbitol 1 partialchrom. 99.4 319.20 307.15, 205.10 20.98, 64.13 30 
L-Tyrosine 1 partialmass. 100.0 220.00   6 
D-Galactitol 1 partialmass. 99.0 319.20 307.15, 205.10 58.94, 63.87 30 
D-Glucuronic acid deriv. 2 1 partialmass. 100.0 333.10 160.10, 217.10 32.83, 5.56 30 
chiro-Inositol 1 partialmass. 86.5 318.20 204.10, 307.15 3.76, 8.21 30 
Unknown U16 4  99.7 202.10 319.20, 333.10 32.18, 15.53 30 
D-Mannonic acid 1 partialmass. 100.0 333.10 319.20 17.21 306 
Ethyl-β-D-glucuronide 1  47.43 204.10 217.10, 117.00 117.01, 7.40 30 
D-Galactonic acid 1  98.1 319.20 333.10, 205.10 52.62, 93.65 30 
D-Gluconic acid 1  99.4 333.10 319.20, 205.10 48.75, 40.59 30 
scyllo-Inositol 1  100.0 318.20 204.10, 307.15 25.73, 10.18 30 
myo-Inositol 1 partialmass. 100.0 318.20 307.15, 204.10 26.29, 35.63 30 
Mannoheptulose 1  99.7 319.20 205.10, 217.10 58.97, 31.71 30 
Monosaccharide U21 3  100.0 319.20 205.10, 217.10 50.78, 22.92 30 
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Sedoheptulose
 
deriv. 1 1  100.0 319.20 205.10, 217.10 49.13, 33.01 30 
Sedoheptulose
 
deriv. 2 1  99.7 319.20 205.10, 217.10 51.83, 33.27 30 
Perseitol
 
1  72.13 319.20 307.15, 205.10 35.09, 57.19 30 
Unknown U24 4 partialchrom. 100.0 204.10   6 
Unknown U25 4 partialchrom. 94.9 204.10 217.10, 307.15 348.29, 9.50 30 
Disaccharide U26 3 partialchrom. 88.1 204.10 217.10, 319.20 37.30, 23.24 30 
D-Sucrose 1  100.0 361.15 319.20, 217.10 3.46, 30.72 30 
D-Lactose deriv. 1 1 partialchrom. 99.7 361.15 204.10, 319.20 112.49, 41.05 30 
D-Lactose deriv. 2 1 partialchrom. 99.7 361.15 319.20 19.61 306 
D-Maltose deriv. 1 1 partialchrom. 56.13 361.15 204.10, 319.20 48.63, 3.12 30 
Unknown disaccharide 29 3 partialchrom. 90.43 361.15 204.10 66.65 306 
Unknown disaccharide 27 3 partialchrom. 100.0 204.10 217.10, 319.20 18.39, 4.10 30 
Unknown disaccharide 28 deriv. 1 3 partialchrom. 39.13 361.15 204.10, 319.20 143.93, 91.71 30 
Unknown disaccharide 28 deriv. 2 3 partialchrom. 54.23 361.15 319.20, 204.10 86.44, 175.07 30 
11: Identified using standard substance or in-house spectral database; 2: Identified using external spectral database; 3: Assigned substance class 
according to mass spectra; 4: Unknown compound. 2partialmass.: total chromatographic coelution, separation through masses possible; partialchrom.: 
partial chromatographic coelution and separation through masses possible. 3Trace analytes. 4Ratios of reference ions to target ion. 5Values allowing 
the ratio between target ion and reference ions to deviate from the original ratio.  6In some cases, it became necessary to use a higher allowance and/or, 
to use only one or no reference ion because of overlapping peaks with similar mass spectra. 
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Supplemental Table 4. Intra-day (n = 8) and inter-day (n = 140) repeatability and intermediate precision of internal standards and sugar 
compounds in QC samples before signal intensity drift/batch correction. 
Analytes Intra-day Inter-
day 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 mean 
Xylose
 
Arabinose
 
Ribose
 
Fucose
 
Psicose
 
Fructose
 
Allose 
Galactose
 
Glucose
 
Mannose
 
Mannoheptulose
 
Sedoheptulose 
Unknown monosaccharide U03 
Unknown monosaccharide U21
 
Sucrose
 
Lactose
 
Maltose †
 
Unknown disaccharide U26 
Unknown disaccharide U27 
Unknown disaccharide U28† 
Unknown disaccharide U29† 
Threitol
 
meso-Erythritol
 
Xylitol
 
Arabitol
 
Ribitol 
1-Deoxy-sorbitol
 
Fucitol †
 
Mannitol
 
3.9 
3.1 
2.7 
2.4 
3.1 
2.9 
4.4 
2.6 
1.8 
2.0 
3.2 
3.2 
3.5 
4.3 
1.7 
2.6 
1.7 
3.0 
23.2 
5.1 
7.2 
1.7 
2.5 
2.0 
2.5 
2.2 
2.0 
4.5 
1.6 
9.6 
9.2 
9.1 
9.4 
9.2 
9.4 
10.5 
10.7 
9.9 
9.7 
11.4 
10.4 
7.9 
10.9 
12.3 
14.3 
9.8 
10.7 
12.5 
11.8 
25.4 
9.0 
9.1 
9.5 
9.2 
9.9 
9.3 
10.3 
9.9 
4.2 
2.2 
2.1 
4.2 
3.4 
2.4 
5.8 
5.6 
7.1 
5.7 
6.3 
5.8 
3.1 
6.8 
2.8 
6.1 
5.5 
3.1 
5.2 
4.6 
6.5 
3.4 
2.7 
5.2 
4.3 
5.9 
9.4 
9.9 
7.5 
11.3 
10.5 
8.9 
5.9 
7.7 
8.3 
8.0 
9.1 
6.9 
7.2 
6.6 
6.9 
10.0 
6.1 
5.3 
5.9 
26.1 
5.7 
4.9 
3.8 
11.1 
5.1 
4.9 
6.9 
6.2 
6.3 
6.1 
7.0 
6.2 
5.7 
6.1 
5.4 
5.5 
6.0 
6.8 
5.1 
5.7 
6.3 
3.9 
5.6 
7.1 
7.2 
5.5 
9.2 
7.7 
5.4 
5.2 
59.0 
9.7 
18.0 
5.1 
4.4 
6.0 
6.7 
6.8 
6.1 
6.8 
7.0 
5.3 
6.1 
5.7 
5.5 
6.1 
5.9 
6.8 
6.6 
6.5 
6.3 
5.8 
5.6 
5.1 
5.2 
8.5 
13.6 
10.5 
8.2 
13.1 
6.8 
16.0 
4.9 
4.5 
5.8 
6.1 
6.2 
7.1 
6.4 
6.7 
5.1 
5.4 
5.1 
5.3 
5.9 
6.5 
5.0 
5.1 
5.6 
5.2 
5.5 
4.8 
6.9 
4.5 
5.4 
8.0 
23.5 
4.7 
5.2 
4.0 
9.7 
5.3 
5.5 
6.1 
5.8 
8.3 
6.1 
6.7 
5.4 
2.8 
2.6 
2.5 
2.7 
3.3 
3.5 
3.7 
3.8 
3.3 
4.8 
5.5 
2.3 
3.4 
2.7 
6.7 
10.9 
39.4 
5.4 
8.3 
4.9 
43.4 
2.2 
2.6 
2.6 
2.7 
3.1 
3.8 
3.5 
4.2 
6.4 
8.8 
8.9 
8.1 
7.7 
6.7 
7.4 
7.8 
8.0 
7.2 
8.2 
6.9 
8.7 
10.0 
13.4 
12.5 
16.1 
9.5 
16.0 
14.1 
34.4 
9.2 
9.1 
10.5 
10.3 
8.9 
9.3 
9.1 
10.5 
3.5 
4.3 
2.9 
3.8 
2.6 
2.0 
4.0 
4.2 
3.7 
3.4 
4.1 
2.9 
5.1 
2.0 
4.9 
9.6 
9.5 
4.9 
9.7 
3.7 
13.5 
4.5 
4.3 
3.9 
4.3 
4.1 
4.3 
4.5 
4.0 
2.6 
3.1 
2.7 
2.8 
2.9 
3.7 
2.8 
2.8 
2.7 
2.3 
4.9 
2.2 
5.4 
2.4 
6.4 
7.6 
10.6 
2.6 
7.3 
2.4 
22.2 
2.6 
3.4 
2.7 
2.8 
3.1 
2.5 
2.0 
2.4 
5.4 
6.2 
6.2 
4.5 
3.4 
3.5 
4.4 
3.8 
4.1 
6.6 
8.5 
3.7 
5.3 
2.8 
10.7 
42.0 
43.2 
19.7 
10.6 
13.2 
57.7 
5.9 
6.1 
5.9 
5.7 
6.1 
6.1 
4.7 
4.5 
3.1 
3.2 
2.9 
3.4 
3.3 
2.8 
2.7 
2.9 
2.8 
3.0 
5.8 
3.5 
3.0 
2.9 
4.8 
3.9 
23.0 
2.8 
15.0 
5.5 
8.3 
3.7 
3.4 
3.2 
3.1 
3.1 
3.0 
2.7 
3.0 
3.0 
2.4 
2.5 
2.9 
2.7 
3.1 
1.7 
2.0 
2.7 
2.9 
4.9 
2.4 
2.7 
2.4 
6.2 
4.7 
7.5 
2.4 
7.0 
2.5 
13.8 
2.4 
2.4 
2.6 
2.4 
2.5 
2.4 
2.7 
2.5 
5.1 
5.2 
4.8 
4.7 
4.8 
4.8 
5.2 
5.2 
5.1 
5.0 
6.2 
4.8 
5.5 
4.9 
7.0 
10.7 
16.5 
6.3 
14.1 
6.6 
20.5 
4.6 
4.6 
5.2 
5.1 
5.5 
5.5 
5.8 
5.4 
11.6 
12.8 
12.6 
8.6 
13.7 
13.7 
15.7 
16.3 
15.8 
13.8 
16.5 
15.8 
13.0 
20.1 
15.7 
29.3 
29.1 
19.3 
33.8 
16.5 
32.1 
13.4 
12.9 
14.1 
13.1 
14.7 
15.9 
15.9 
14.9 
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Sorbitol
 
Galactitol
 
Perseitol †
 
chiro-Inositol †
 
scyllo-Inositol
 
myo-Inositol
 
Unknown polyol U02 
Erythronic acid
 
Threonic acid
 
Xylonic acid
 
Ribonic acid
 
Arabonic acid
 
Glucuronic acid
 
Mannonic acid
 
Galactonic acid
 
Gluconic acid
 
Unknown sugar acid U01 
Unknown sugar acid U06† 
Unknown sugar acid U09 
Levoglucosan
 
Ethyl-β-D-glucuronide
 
Unknown U05 
Unknown U12 
Unknown U24 
Unknown U25† 
1-O-Methyl-2-deoxyribose
 
D-Pinitol 
Phenyl-β-D-glucopyranosid
 
2.3 
5.2 
5.8 
3.8 
2.4 
2.5 
5.7 
2.1 
2.0 
2.7 
2.2 
2.4 
1.7 
7.9 
8.2 
2.9 
4.9 
5.7 
2.4 
2.8 
2.6 
11.7 
6.6 
2.2 
9.5 
2.6 
3.7 
2.3 
8.7 
12.4 
16.4 
9.4 
10.1 
10.1 
10.3 
9.3 
9.0 
8.7 
9.9 
9.8 
9.8 
9.0 
11.9 
9.8 
10.8 
12.2 
9.6 
11.4 
9.8 
8.8 
11.2 
10.4 
15.0 
3.3 
2.0 
3.8 
10.0 
4.7 
24.1 
3.0 
3.9 
3.6 
5.8 
2.4 
2.8 
5.0 
6.0 
2.4 
7.0 
4.9 
7.6 
3.7 
3.0 
12.8 
3.6 
4.5 
2.9 
6.2 
4.5 
3.1 
5.8 
2.3 
2.5 
3.1 
7.0 
8.7 
13.1 
7.8 
5.9 
5.7 
8.9 
5.6 
5.7 
5.2 
6.3 
5.3 
10.0 
9.1 
5.4 
7.8 
7.2 
10.7 
5.7 
4.7 
3.6 
8.4 
7.0 
4.2 
4.8 
4.5 
5.6 
3.7 
7.6 
11.3 
14.6 
8.0 
10.1 
10.2 
6.5 
6.3 
6.2 
7.2 
8.2 
6.0 
8.2 
7.6 
6.7 
6.4 
7.9 
9.9 
7.3 
5.9 
3.5 
24.1 
5.6 
6.3 
5.3 
4.0 
4.8 
5.3 
6.3 
10.8 
11.3 
8.6 
6.0 
5.9 
7.2 
5.6 
5.6 
7.8 
5.0 
6.1 
6.9 
5.6 
7.9 
10.5 
6.8 
7.5 
6.0 
4.6 
8.6 
9.5 
5.5 
6.4 
14.8 
4.8 
6.8 
7.4 
6.8 
8.1 
11.6 
4.9 
4.4 
4.6 
5.5 
5.6 
5.0 
5.2 
6.3 
5.2 
5.8 
5.5 
6.5 
8.5 
7.8 
8.4 
5.7 
4.7 
3.7 
5.9 
4.9 
4.2 
6.3 
2.9 
2.7 
2.7 
4.2 
9.6 
13.2 
4.1 
4.6 
4.5 
3.3 
2.3 
2.4 
3.7 
2.8 
2.6 
3.4 
5.7 
5.2 
8.5 
5.1 
4.6 
2.4 
4.6 
4.6 
4.7 
3.0 
3.1 
20.4 
3.9 
3.5 
2.9 
10.6 
11.8 
19.4 
10.9 
14.1 
14.0 
10.4 
10.1 
10.3 
10.1 
9.8 
8.6 
8.3 
6.1 
9.0 
10.2 
8.9 
10.2 
8.8 
7.7 
6.7 
23.5 
8.9 
11.3 
7.8 
5.8 
6.7 
5.9 
4.5 
5.0 
12.9 
4.4 
3.7 
4.1 
4.4 
4.9 
4.1 
4.7 
6.5 
6.0 
3.4 
7.5 
8.6 
13.3 
9.1 
7.9 
4.8 
7.1 
5.9 
8.2 
5.0 
4.1 
6.0 
7.7 
4.9 
4.1 
2.4 
4.2 
16.1 
5.2 
2.7 
2.7 
2.3 
3.3 
2.9 
3.4 
5.6 
4.3 
3.1 
6.9 
8.1 
8.7 
7.0 
6.5 
3.4 
4.1 
3.7 
5.7 
3.7 
2.2 
8.9 
3.5 
4.1 
3.3 
7.3 
8.1 
7.0 
8.2 
3.7 
3.0 
5.7 
5.5 
6.1 
4.4 
5.6 
4.1 
4.8 
5.2 
10.9 
10.2 
7.8 
13.5 
3.6 
5.1 
8.6 
26.5 
5.3 
6.6 
21.5 
4.4 
4.7 
2.7 
4.1 
6.1 
25.4 
3.4 
3.1 
3.4 
3.7 
3.7 
3.5 
3.0 
3.1 
3.7 
2.8 
6.5 
5.3 
6.1 
5.4 
7.2 
2.9 
4.9 
3.2 
9.5 
3.6 
4.1 
3.8 
3.9 
1.3 
1.6 
4.0 
9.3 
30.1 
3.2 
2.6 
2.6 
4.1 
2.6 
2.6 
2.6 
3.5 
2.6 
3.9 
4.2 
5.0 
8.0 
3.3 
6.7 
2.0 
5.1 
3.7 
8.5 
2.6 
2.9 
4.9 
2.7 
2.5 
2.5 
6.1 
8.2 
15.8 
6.1 
5.5 
5.5 
6.0 
5.0 
4.9 
5.3 
5.8 
4.9 
5.7 
6.5 
7.6 
8.2 
6.8 
8.8 
4.9 
5.5 
5.1 
11.5 
5.5 
5.1 
9.6 
4.0 
4.0 
3.7 
13.7 
15.7 
29.2 
14.9 
14.7 
13.1 
13.3 
12.8 
12.4 
13.5 
12.9 
12.3 
12.4 
9.2 
20.1 
14.3 
11.8 
14.5 
13.6 
11.7 
16.1 
20.9 
14.4 
15.8 
26.3 
12.9 
10.4 
12.4 
Mean  
Median 
3.9 
2.7 
10.2 
9.8 
5.2 
4.6 
7.2 
6.3 
8.2 
6.4 
7.2 
6.4 
6.1 
5.5 
5.9 
3.7 
10.3 
9.1 
5.4 
4.5 
4.6 
3.3 
9.1 
5.9 
4.8 
3.4 
4.2 
2.7 
6.6 
5.5 
15.9 
14.3 
†
 Trace analytes 
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In total, 55 known and unknown sugar compounds were detected in 24 h urine samples including 
analytes that were not consistently detected in all participants (see Section 3.2/3.2.1). 
Identification levels, frequency in study samples, and partial coelution are shown in 
Supplemental Table 3. To evaluate the long-term repeatability and intermediate precision during 
a large-scale analysis with overall 312 study samples (including the excluded 11 participants) and 
140 QC samples, coefficients of variation (CV) of (uncorrected) peak areas of all sugar 
compounds in the QC samples were calculated (see Supplemental Table 4). In Supplemental 
Figure 2, the distribution of the average intra-day and inter-day repeatability is depicted. The 
internal standards in study and QC samples had average intra- and inter-day repeatabilities of 
between 2.6 and 8.2% and 10.5 and 13.4%, respectively. Despite this fact, a QC sample based 
drift correction was performed to remove the shallow, but steady, long-term trends in signal 
intensity leading to the slightly worsened inter-day repeatability (see Figure 2 and section 2.2). 
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Supplemental Figure 1. Spectra of unknown sugar-like compounds (A-O) and their assignments 
to substance classes. 
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Supplemental Figure 2. Distributions of the calculated average intra-day (A) and inter-day (B) 
CVs for all sugar metabolites measured in the QC samples (before drift correction). Broken lines 
indicate level for excellent repeatability (10%) and good repeatability (15%) for intra- (A) and 
inter-day (B), respectively. 
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Supplemental Figure 3. Scatter plots of fig consumption (g/d) with mannoheptulose (A) and 
perseitol (B) excretion in urine of all 301 participants, including 7 fig consumers. 
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Exploring the Diversity of Sugar Compounds in Healthy,
Prediabetic, and Diabetic Volunteers
Carina I. Mack,* Paola G. Ferrario, Christoph H. Weinert, Björn Egert, Anja S. Hoefle,
Yu-Mi Lee, Thomas Skurk, Sabine E. Kulling, and Hannelore Daniel
Scope: Diabetes is thought to primarily represent a disturbance of
carbohydrate metabolism; however, population studies employing
metabolomics have mainly identified plasma amino acids and lipids, or their
products, as biomarkers. In this pilot study, the aim is to analyze a wide
spectrum of sugar compounds in the fasting state and during an oral glucose
tolerance test (OGTT) in healthy, prediabetic, and type 2 diabetic volunteers.
Methods and results: The three volunteer groups underwent a standard
OGTT. Plasma samples obtained in the fasting state, 30 and 90 min after the
OGTT, are subjected to a semitargeted GC–MS (gas chromatography–mass
spectrometry) sugar profiling. Overall, 40 sugars are detected in plasma, of
which some are yet unknown to change during an OGTT. Several sugars (e.g.,
trehalose) reveal significant differences between the volunteer groups both in
fasting plasma and in distinct time courses after the OGTT. This suggests an
endogenous production from orally absorbed glucose and/or an
insulin-dependent production/removal from plasma.
Conclusion: It is demonstrated that more sugars than expected can be found
in human plasma. Since some of these show characteristic differences
depending on health status, it may be worthwhile to assess their usability as
biomarkers for diagnosing early-stage insulin resistance and type 2 diabetes.
1. Introduction
Although glucose and insulin, or HbA1c levels are routinely de-
termined for type 2 diabetes management, they do not reveal
which metabolic perturbations occur during glucose consump-
tion, as simulated by an oral glucose tolerance test (OGTT).[1–5]
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Therefore, metabolomics has become
popular as a more comprehensive pro-
filing approach and biomarker discov-
ery tool. This approach has revealed nu-
merous differences in plasma or urine
metabolites between healthy subjects and
subjects with impaired glucose tolerance
and/or type 2 diabetes.[4,6–12] Some stud-
ies have not only searched for differ-
ences in metabolite profiles during fast-
ing, but also in time courses during an
OGTT.[1,3,13–18] Remarkably, these studies
mainly identified plasma amino acids,
various lipid species, or bile acids as dis-
criminatingmarkers related to insulin re-
sistance (IR) and type 2 diabetes. Consid-
ering diabetes is associated with marked
alterations in carbohydrate metabolism,
it is thus surprising that other sugars or
sugar-derived intermediates have rarely
been identified as associated with the
metabolic impairments.
We recently established a semitargeted
sugar profiling method and demon-
strated a rather complex mixture com-
prising 55 different sugar compounds
in urine samples of healthy human volunteers.[19] This find-
ing suggested that the plasma sugar profile is equally complex.
Metabolite profiling studies of human biofluids typically analyze
only a few sugar compounds; this is mainly due to analytical limi-
tations such as insufficient separation and identification of struc-
tural isomers.[19–22] Therefore, sugars or sugar-like candidates are
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Table 1. Basic characteristics of the three volunteer groups.
Healthy Prediabetic Diabetic
All Male Female All Male Female All Male Female
n — 15 — 15 10 5 11 3 8
Age [years]
a)
— 26.3 ± 2.5 — 62.1 ± 6.5 60.0 ± 5.9 66.2 ± 6.1 63.0 ± 6.2 65.3 ± 4.7 61.9 ± 6.6
BMI [kg cm−²]
a)
— 24.0 ± 2.0 — 29.0 ± 5.9 28.5± 6.2 30.1 ± 5.6 29.4 ± 2.6 28.9 ± 1.8 29.5 ± 2.9
a)For age and BMI mean values ± standard deviations are reported.
often reported as unknowns,[8,14] or are represented as a group,
for example “hexoses”[7,9,14] or “fructose/glucose/galactose,”[13,18]
which clearly limits interpretability. In addition to glucose, sugar
compounds identified as changing during the time course of
an OGTT or that display altered levels in type 2 diabetes pa-
tients are 1,5-anhydroglucitol, mannose,maltose, and glucuronic
acid.[11,12,14,15,20,23] These findings suggest that additional sug-
ars, and intermediates of the metabolic conversion of glucose,
may be found in plasma and urine when specific methods are
employed.
We therefore applied our semitargeted sugar profiling
method, previously used for urine analysis,[19] to assess whether
novel sugar compounds can be identified in plasma of healthy,
prediabetic, and diabetic subjects in a fasted state and after an
OGTT.
2. Experimental Section
2.1. Study Design and Subjects
This pilot study was part of the MIPROMET cohort, which was
performed at the Human Study Center of the Technical Uni-
versity of Munich at the Weihenstephan campus.[24] Study de-
sign, participant recruitment, and examination procedures for
healthy and prediabetic participants were previously described by
Hoefle et al.[24] Type 2 diabetic participants were additionally re-
cruited with study design and research parameters identical to
those of the healthy and prediabetic volunteers.[24] For patients
with type 2 diabetes, oral medication (metformin alone) and/or
insulin therapy was an additional inclusion criterion. Prediabetic
and diabetic states were defined according to WHO criteria.[25]
Altogether, 15 male healthy controls, 15 male and female predia-
betic cases, and 11 male and female diabetic cases were recruited
for this pilot study. However, distribution of males and females,
as well as age class was unbalanced between volunteer groups
(see Table 1 for volunteer characteristics) because of difficulties
with recruitment due to strict inclusion criteria (see flow chart in
Figure S1, Supporting Information File 1).
Volunteers received a test drink containing 50 g of maltodex-
trin19 (starch hydrolysate; Berco Arzneimittel, Kleve, Germany),
10 g of lactulose (Hemopharm, Bad Vilbel, Germany), 2 g of
4-hydroxyproline (Sigma-Aldrich, Munich, Germany), or 1 g of
acetaminophen (Paracetamol; Ratiopharm, Ulm, Germany) in
the case of prediabetic and diabetic volunteers, and ten drops of
lemon or vanilla flavor (Dr. Oetker, Bielefeld, Germany). Inclu-
sion of non-digestible lactulose enabled the assessment of the
oro-cecal transit time by detecting hydrogen exhalation in the
breath as a result of fermentative production of hydrogen by the
intestinal flora. The appearance of acetaminophen in plasma de-
pended on the velocity of gastric emptying as the limiting step, al-
lowing the rate of appearance of paracetamol in the blood to serve
asmarker for gastric emptying[26]; similarly 4-hydroxyproline can
be applied. Maltodextrin19 rather than d-glucose was used since
this prevents secondary effects of high osmolarity on gastric emp-
tying. Maltodextrin19 could be considered equivalent to glucose
due to its fast hydrolysis in the gut. With a dextrose equivalent of
19, maltodextrin19 was close to the typically used glucose syrup
in commercial OGTT solutions.
Plasma samples were taken in fasted state, as well as 30 and
90 min after ingestion of the test drink. Blood was collected in
monovettes coatedwith EDTA, then inverted gently ten times and
centrifuged at 20 °C at 1000 × g for 10 min. Thereafter, plasma
was aliquoted on ice, frozen on dry ice, and stored at−80 °C until
analysis.
All procedures performed in the study were in accordance
with the 1964 Helsinki declaration and its later amendments.
The study was approved by the Ethics Committee of the Tech-
nical University of Munich (#2436/09) and was registered at the
GermanClinical StudyRegister (DRKS00005682). Informed con-
sent was obtained from all individual volunteers included in the
study.
2.2. Semitargeted GC-MS Sugar Profiling
For plasma sample preparation, 20 µL of the internal standard so-
lution (see Table S1, Supporting Information File 1) were pipet-
ted into a 1.5 mL Eppendorf reaction tube before adding 40 µL
plasma sample. Then, 150 µL of ice-cold methanol were added
and the tubemixed for protein precipitation. After centrifugation
for 10 min at 16 100 × g and 4 °C, 120 µL of the supernatant were
transferred to a second 1.5 mL Eppendorf reaction tube. For lipid
extraction, 700 µL tert-butylmethyl ether (TBME)were added and
samples vigorously mixed for 2 min. After the addition of 70 µL
of water, samples were again vigorously mixed for 2 min and
then shortly centrifuged for phase separation. The upper TBME-
containing phase was discarded and the aqueous phase trans-
ferred to a GC screw-top vial with a 300 µL insert. After rinsing
the reaction tube with 30 µL methanol, the wash solution was
added to the aqueous phase in the GC vial. Samples were then
evaporated for 90min at 40 °C and<1mbar. For removal of traces
of water, 20 µL of methanol were added and samples evaporated
again under the same conditions for 30 min. Afterward, sam-
ples were methoximated using 20 µL methoxylaminhydrochlo-
ride in pyridine (20 mg mL−1), the reaction was carried out for
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6 h at 60 °C and 1000 rpm. Trimethylsilylation was carried out
by adding 40 µL N-(trimethylsilyl)-N-methyltrifluoroacetamide
(MSTFA) with 1% trimethyl chlorosilane (TMCS) and incuba-
tion for 1 h at 75 °C without shaking. Analyses were performed
on a Shimadzu GCMS QP2010 Ultra instrument (see Table S2,
Supporting Information File 1) in scheduled Scan-/SIM (selected
ion monitoring)-mode allowing the selective and sensitive detec-
tion of sugar compounds. Measurements were performed with
helium as carrier gas in constant pressure mode on a 60 m Rxi-
5SilMS columnwith 10m integrated pre-column, 0.25mm inter-
nal diameter, and 0.25 µm film thickness. 1.2 µL sample were in-
jected in cold split mode and a split ratio of 1:5. For further details
about instrument parameters, see Table S3, Supporting Infor-
mation File 1. The GCMSsolution (version 4.1.4, Postrun Anal-
ysis) software was used to pre-process the data (details see Table
S4, Supporting Information File 1). For each measurement day,
along with the study samples, quality control (QC) samples (mix-
ture of all study samples) were regularly measured to enable cor-
rection of drift and offset effects and a solvent blank was created
using water instead of the sample.[27] A retention index marker
solution was added to the solvent blank.[27] Each day, 24 study
samples, seven QC samples, and a solvent blank were prepared
and analyzed, beginning with the daily blank, followed by four
blocks of six study samples surrounded byQC samples, and at the
beginning and end of the day two QC samples were always mea-
sured. Each measurement week, the liner was changed and the
MS was tuned. The injector septum was replaced every 100 runs.
2.3. Analysis of the Ingested Test Drink for the OGTT and Further
Commercial OGTT Solutions
A 2mL sample of the ingested test drink for the OGTT was evap-
orated and then 10 mg of the dried powder were solved in 500 µL
of deionized water. Afterward, 50, 100, and 200 µL of the solution
were evaporated for GC-MS analysis. Derivatization and GC-MS
analysis were the same as described earlier for plasma sam-
ples (see also Methods Section 1.2.1, Supporting Information
File 1).
An additional GC × GC-MS measurement was performed to
explore the sugar profile of the ingested test drink and two com-
mercial OGTT solutions (Accu-Chek Dextrose O.G-T., Roche and
Rapilose OGTT solution, Galen) in more detail. For the ingested
test drink 25 µL of the solution described earlier were evaporated,
while in the case of both commercial OGTT solutions 50 µL of
a 1:20 dilution were evaporated. Derivatization was as described
earlier for plasma samples (see also Methods Section 1.2.1, Sup-
porting Information File 1). The GC ×GC-MS parameters can be
found in Table S6, Supporting Information File 1.
2.4. Statistics
2.4.1. Test for Group and Time Differences After an OGTT
The pilot study consisted of repeated measurements of sugar
compounds at non-equidistant time points (0, 30, and 90 min)
in three independent groups (15 healthy, 15 prediabetic, and
11 diabetic participants). Due to the participant recruitment,
the pilot study had unbalanced participant characteristics. Par-
ticipant recruitment reflected the fact that older people were
more prone to develop type 2 diabetes mellitus; the average age
of healthy participants was ≈26 years in contrast to 63 years
in diabetic participants (Table 1). Moreover, the distribution of
sex in the three groups was uneven (Table 1). A general model
accounting for the characteristics leading to the unbalanced
design would describe each sugar compound dependent on:
i) group, time, and interaction between both, ii) age, BMI,
and sex (as competing covariates), and iii) with random slope
and random intercept to account for correlations across time
(longitudinal data). An example of such possible models can be
found in File 2, Supporting Information.
However, according to the one-in-ten rule, it is not reasonable
to fit such a general model with the limited sample size in this
pilot study. To find a compromise between model complexity
and feasibility, a simpler model (mixed linear model) was fitted
where each sugar compound was described dependent on group
and time with a random intercept (to account for correlation
between repeated measurements at different time points for
each participant). Testing was performed for group and time
differences in order to identify and focus on sugar compounds,
which change concentration differently in healthy, prediabetic,
and diabetic participants after an OGTT. Specifically, the dif-
ferences in sugar compounds were tested for i) healthy versus
diabetic group, ii) healthy versus prediabetic group, and iii)
prediabetic versus diabetic group, while keeping time constant.
Moreover, the differences in sugar compounds were tested
for i) 0 versus 30 min, ii) 0 versus 90 min, and iii) 30 versus
90 min, while keeping group constant (see File 3, Supporting
Information).
For the sake of simplicity and to ensure comparability, nor-
mality for sugar compound variables was generally assumed,
although literature has shown that this assumption is not always
justified.[28,29] For model diagnostics, QQ-plots depicting the
quantiles of the residuals against the theoretical normal were
included to ascertain normality (File 3, Supporting Informa-
tion). For those sugar compounds found to be significantly
different either dependent on health status and/or on time,
a visual analysis of these QQ-plots was performed. For the
majority of sugar compounds, the assumption of normality was
justified.
The software R (version 3.3.2 2016-10-31)[30] was used to per-
form these statistical analyses. The applied R packages can be
found in[31–37] and were added as libraries in Files 2 and 3, Sup-
porting Information. A detailed report (including the R script) of
the main statistical analyses using R can be found in File 3, Sup-
porting Information. Generally, when no value was reported due
to the signal intensity being below the limit of detection, half of
the minimal signal intensity for this sugar compound was con-
sidered.
2.4.2. Differentiation of Healthy, Prediabetic, and Diabetic Subjects
in the Fasted State
Independently of the administration of maltodextrin19, some
sugar compounds already differ between the healthy, prediabetic,
and diabetic group in the fasted state. A principal component
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analysis (PCA) and a one-way ANOVA were performed in order
to identify such sugar compounds.
First, the PCAwas performed to observewhether plasma sugar
profiles in the fasted state enable a separation of healthy, predi-
abetic, and diabetic volunteers. Both the scores and the loadings
plot were drawn. The loadings plot was evaluated to ascertain
whether glucose was the main variable driving the separation of
the three groups.
Second, to determine the sugar compounds differentiating
between the three groups, an ANOVA-based response screen-
ing workflow was applied. Briefly, a first one-way ANOVA
with correction for multiple testing was performed to screen
for significant sugar compounds, which were then tested for
normality and homogeneity of variances. A second one-way
ANOVA and post-hoc tests (each depending on the distribution
and homogeneity of variance) were performed to receive the
final selection of sugar compounds significantly differentiating
between the healthy, prediabetic, and diabetic group in the fasted
state. Specifically, the second one-way ANOVA was a normal
one-way ANOVA (in the case of normality and homogeneity
of variances), a one-way ANOVA with Welch-correction (in
the case of normality and inhomogeneity of variances), or a
one-way ANOVA with Kruskal–Wallis-correction (in the case of
non-normality). For a more detailed description of the screening
workflow, the reader is referred to the Supporting Information
by Weinert et al.[38] Box plots were plotted for the significant
sugar compounds revealed by these procedures. The software
JMP (version 13, SAS Institute Inc., Cary, NC, 1989–2007) was
used to perform these statistical analyses.
2.5. Evaluation of Potential Confounders in Fasting Plasma
Samples in an Independent Study
In the present study, the healthy group comprised solely male
volunteers, the prediabetic group was 2/3 male, and the diabetic
group was 2/3 female (Table 1). Moreover, in addition to sex, also
age and body mass may represent important baseline covariates
(Table 1). Due to the sample size limitation of this pilot study,
another independent external study was considered to generally
ascertain the influence of age, BMI, and sex on the sugar com-
pounds of interest using correlation analyses and unpaired tests.
The sugar profile of a subset of fasting plasma samples from
the cross-sectional KarMeN study was analyzed. Details about
study design, participant recruitment, and examination proce-
dures, as well as sample storage were described by Bub et al.[39]
Sample preparation, data preprocessing, and treatment were ex-
actly the same as described in Section 2.2 and in Section 1.2.1,
Supporting Information File 1. Minor changes in the instrument
parameters can be found in Table S3, Supporting Information
File 1. For participant characteristics of the randomly selected
subset of 58 fasting plasma samples (about ten participants for
every 10 years with half of the participants being male) see Table
S5, Supporting Information File 1.
In particular, to ascertain the influence of age, BMI, and sex
on sugar compounds found to differentiate between healthy, pre-
diabetic, and diabetic subjects, a correlation analysis (Spearman
correlation coefficients), t-tests (in the case of normality and ho-
mogeneity of variances), Welch’s t-tests (in the case of normal-
Figure 1. Distribution of the average intra-day coefficients of variation for
all sugar compounds measured in the QC samples before drift correction.
Dashed line indicates coefficients of variation below and above 25%.
ity and inhomogeneity of variances), or Wilcoxon t-tests (in the
case of non-normality) were performed. In the case of age, two
groups of the KarMeN volunteers were defined covering the same
age range as the healthy (21–30 years; n = 10) and prediabetic
and diabetic volunteers (50–72 years; n = 23) of the MIPROMET
study. For BMI, KarMeN participants were divided into two
groups (19–23.9 kg m−², n = 29 and 24–30 kg m−², n = 29). In
the case of sex, 28 males were compared with 30 females. The
KarMeN study was registered at the German Clinical Study Reg-
ister (DRKS00004890) and was in accordance with the 1964
Helsinki declaration and its later amendments.
The software JMP (version 13, SAS Institute Inc., Cary, NC,
1989–2007) was used to perform these statistical analyses.
3. Results
3.1. Plasma Sugar Profile
Overall, we detected 40 sugar compounds represented by mono-
and disaccharides, polyols, sugar acids, and so far unknown
sugar-like compounds with the semitargeted sugar profiling
method. Based on characteristic masses in the scan mass spec-
tra, unknown compounds were defined as sugar-like compounds
(e.g.,m/z 292 and 333 are characteristic for sugar acids,m/z 319
and 307 for aldoses, ketoses as well as polyols, m/z 305 and 318
for cyclitols, and m/z 361 is characteristic for disaccharides).
Additionally, in some cases the chromatographic elution or-
der allowed us to derive the number of C-atoms in the sugar
compound (e.g., pentose or hexose). However, future absolute
identification can only be ensured by comparing retention
indices and mass spectra of the unknown sugar-like compounds
(Figure S2, Supporting Information File 1) with those of known
standard substances. Data on the quality of measurement (e.g.,
reproducibility of quality control samples and internal standards,
identification level, median, and range from minimum to max-
imum of peak area in the study samples) and on selectivity can
be found in Table S7, Supporting Information File 1. Figure 1
Mol. Nutr. Food Res. 2020, 64, 1901190 1901190 (4 of 14) © 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
3 PUBLICATIONS  
97 
 
  
www.advancedsciencenews.com www.mnf-journal.com
Figure 2. Glucose as example for the statistical workflow to detect group and time differences after an OGTT. Panel A) Box plots grouped by health status
and time. Panel B) QQ-plots depicting the quantiles of the residuals against the theoretical normal. Panel C) Plot for the effect (dots) and confidence
interval (lines) for differences in the health status (group). Panel D) Plot for the effect (dots) and confidence interval (line) for differences during the
time points (time). Significance corresponds to the confidence interval line not crossing the vertical dotted zero-line.
depicts the distribution of the average intra-day coefficients of
variation for all sugar compounds measured in the QC samples
before drift correction. 70% of the sugar compounds had a
coefficient of variation of less than 25% and could therefore be
measured with good reproducibly. Interestingly, disaccharides
such as sucrose, lactose, maltose, trehalose, and lactulose were
detected in all plasma samples, even though carbohydrates are
generally hydrolyzed into monosaccharides before absorption.
Lactulose was only detected in the time course after ingestion of
the test drink containing lactulose for transit-time measurement
(Figure S3, Supporting Information File 1).
3.2. Results for Group and Time Differences After an OGTT
The longitudinal trend of each sugar compound was illustrated
by box plots grouped by health status and time points. Each sugar
compound was modeled by a mixed linear model on group and
time (both as factor variables) with a random intercept. Then, we
tested for all possible group and time differences. In Supporting
Information File 3, each sugar compound is presented by box
plots, the fittedmodel, test results, andQQ-plots (see e.g., glucose
in Figure 2). Table 2 summarizes the sugar compounds showing
significant group and/or time differences. Moreover, in Table 2,
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Table 2. Significant sugar compounds to evaluate health status-dependent changes in time courses during an OGTT.
Sugar compounds p-values—Group p-values—Time Direction of time-dependent
change
a)
Healthy—Diabetic Prediabetic—Diabetic Prediabetic—Healthy 0–30 min 0–90 min 30–90 min Healthy Prediabetic Diabetic
Glucose
b),d) <0.001 <0.001 <0.001 <0.001 <0.001 0.013 ↑↓ ↑ ↑
Mannose
c) <0.001 <0.001 <0.001 ↓ − ↑
1,5-Anhydroglucitol <0.001 <0.001 0.044 ↑↓ − −
U15 <0.001 0.004 <0.001 0.041 ↑↓ ↑ ↑
Sedoheptulose
b),d)
0.001 0.03 ↑↓ − −
Fructose
b),d) <0.001 <0.001 0.005 0.002 ↑↓ ↑ ↑
Trehalose
c) <0.001 <0.001 <0.001 <0.001 0.004 ↑↓ ↑ ↑
Sorbitol
b) <0.001 <0.001 ↑↓ ↑ ↑
Arabinose
b) <0.001 0.014 ↑↓ ↑ ↑
U01 0.001 0.035 − ↓ ↓
U07 0.007 <0.001 0.013 ↑↓ ↑ ↑
U16 0.004 0.018 − ↑↓ ↑
meso-Erythritol 0.038 ↑↓ − −
Glucuronic acid
d)
0.027 ↓ − −
Psicose <0.001 <0.001 <0.001 ↑ ↑ ↑
U18
b)
0.015 0.012 <0.001 <0.001 <0.001 ↑ ↑ ↑
Threitol <0.001 <0.001 ↑ ↑ −
Lactulose
b),d)
0.009 <0.001 <0.001 ↑ ↑ ↑
scyllo-Inositol 0.039 0.002 − ↑ ↑
Xylose
b)
0.049 <0.001 <0.001 ↓ − −
Erythronic acid 0.036 ↑↓ ↑ ↑
Maltose
b),d)
0.032 ↑↓ ↑ ↑
U17 0.034 ↓ − ↓
Threonic acid 0.002 ↑↓ ↑ −
Significance threshold: p-value < 0.05. a)The direction of the time-dependent changes for the different volunteer groups is given, ↑↓: increase from 0 to 30 min and decrease
from 30 to 90 min; ↑ increase from 0 to 30 to 90 min; ↓ decrease from 0 to 30 to 90 min;—remain unchanged over time; b)Detectable in the OGTT test drink; c)Presence in
OGTT drink not confirmed due to low concentration and huge amounts of glucose or maltose; d)For readability only one of two detected derivatives is listed.
the direction of time-dependent changes of sugar compounds is
described. Box plots of these sugar compounds are depicted in
Figure 3.
Specifically, the selected sugar compounds could be classi-
fied depending on whether they mainly show a health status-
dependent difference, either dependent or independent of the
time course during an OGTT, or they mainly show a difference
in time course independent of health status. For example, i) tre-
halose clearly differentiated between health status and also be-
tween the time points (group and time effect), ii) sorbitol showed
a distinct difference only in health status (only group effect), and
iii) psicose distinctly increased during the OGTT independent of
the health status (only time effect). For the effects of all other
sugar compounds see Table 2.
3.3. Differentiation of Healthy, Prediabetic, and Diabetic Subjects
in the Fasted State
To ascertain whether healthy, prediabetic, and diabetic volunteers
can be separated based on their fasting plasma sugar profile, we
compared PCA scores A) and loadings B) plots (Figure 4). A sepa-
ration of healthy and diabetic subjects was observed in the scores
plot, while the prediabetic volunteers were in between. In the
loadings plot it is obvious that, in addition to glucose, a range
of other sugar compounds similarly added to the separation of
the volunteer groups observed in the scores plot.
In addition to glucose, significant differences between healthy,
prediabetic, and diabetic volunteers were revealed for maltose,
trehalose, an unknown sugar compound (U15), fructose, man-
nose, 1,5-anhydroglucitol, and sedoheptulose (Figure 5). The
highest median fold change with a factor of almost three between
healthy and diabetic volunteers (diabetic volunteers had a higher
level) was found for maltose. Sedoheptulose concentration was
almost twofold lower in diabetic volunteers than in healthy indi-
viduals.
3.4. Evaluation of Potential Confounders in Fasting Plasma
Samples in an Independent Study
To assess potential confounder effects of age, BMI, and sex
across the volunteer groups in the set of sugars with significant
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Figure 4. Separation of healthy (n = 15), prediabetic (n = 15), and diabetic (n = 11) volunteers based on fasting plasma sugar profile using a principal
component analysis (PCA). A) scores plot; B) loadings plot; glucose marked as bold, red arrow.
Figure 5. Box plots of peak areas for sugar compounds identified as significantly distinguishing between healthy (n = 15), prediabetic (n = 15), and
diabetic (n= 11) volunteers based on fasting plasma using the response screening workflow. *p≤ 0.05; **p≤ 0.01; and ***p≤ 0.001; n.s., not significant.
FC, median fold change. Only one of the two detected derivatives is shown in the case of maltose, fructose, glucose, and sedoheptulose. In the case of
glucose and 1,5-anhydroglucitol, the 2nd ANOVAwas a normal one-way ANOVA and the post-hoc test was a Tukey-HSD, while all other sugar compounds
were subjected to a Wilcoxon test as the 2nd ANOVA and a Steel–Dwass as post-hoc test.
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Table 3. Results of the correlation analysis and unpaired hypothesis tests for verification of potential relevant sugar compounds using fasting plasma of
a selected subgroup of the KarMeN cohort.
Sugar compounds Correlation t-test
a)
Age BMI Age BMI Sex
Spearman’s rho p-value Spearman’s rho p-value p-value Median fold change p-value Median fold change p-value Median fold change
Threonic acid −0.286 0.029 −0.297 0.024 0.008 −1.25 0.023c) −1.15 0.283 −1.07
Sedoheptulose
b) −0.229 0.084 −0.144 0.282 <0.001 −1.57 0.417 −1.08 0.018 1.33
U07 −0.102 0.448 −0.066 0.624 0.232 −1.08 0.303 1.01 0.269 −1.02
1,5-Anhydroglucitol −0.074 0.580 0.070 0.601 0.604 1.03 0.546 1.02 <0.001c) 1.42
Trehalose −0.038 0.778 0.238 0.072 0.605 −1.11 0.634 1.14 0.077 1.25
scyllo-Inositol −0.002 0.987 −0.172 0.196 0.430 −1.17 0.133 −1.34 0.831 1.04
U18 −0.001 0.992 −0.044 0.744 0.572 −1.02 0.836 −1.00 0.8272 1.06
Sorbitol 0.043 0.746 0.026 0.849 0.660 −1.02 0.517 −1.05 0.686 −1.10
Maltose
b)
0.055 0.682 0.173 0.193 0.976 −1.05 0.150 1.09 0.944 −1.04
Fructose
b),d)
0.058 0.667 0.092 0.492 0.433 1.03 0.549 1.06 0.926 1.01
U16 0.075 0.578 0.315 0.016 0.171 −1.05 0.170 1.13 0.054 1.10
Glucose
b)
0.121 0.368 0.128 0.340 0.572 1.01 0.290 −1.00 0.233 1.01
U01 0.188 0.158 0.120 0.369 0.812 1.01 0.917 1.02 0.133 −1.11
Ribitol
d)
0.245 0.064 −0.068 0.610 0.060 1.12 0.247 −1.03 0.017 −1.14
U15
d)
0.252 0.057 0.264 0.045 0.137 1.32 0.164 1.40 0.343 1.26
Psicose
d)
0.267 0.043 0.270 0.041 0.389 1.02 0.130 1.15 0.016 1.15
Arabinose 0.292 0.026 0.283 0.031 0.226 1.07 0.808 1.09 0.349 1.05
Mannose 0.297 0.024 0.161 0.229 0.086 1.17 0.178 1.12 0.050 1.04
Xylose
d)
0.327 0.012 0.246 0.063 0.327 1.04 0.101 1.05 0.437 1.03
U17 0.374 0.004 0.099 0.461 0.123 1.24 0.701 1.06 0.891 1.00
Threitol
d)
0.415 0.001 0.302 0.021 0.078 1.10 0.070 1.08 0.828 −1.05
Erythronic acid 0.441 <0.001 0.467 <0.001 0.239 −1.00 0.002 1.14 0.185 1.05
meso-Erythritol
d)
0.477 <0.001 0.443 <0.001 0.021 1.11 0.012 1.16 0.815 −1.01
Glucuronic acid
b)
0.547 <0.001 0.418 0.001 0.059 1.18 0.016 1.13 0.058 1.08
a)For the t-test the following groups were defined for comparison: age: 21–30 years (n = 10) against 50–72 years (n = 23); BMI: 19–23.9 kg m−² against 24–30 kg m−² (each
n = 29) and sex: male (n = 28) against female (n = 30). Significant values (p < 0.05) with rho > │0.3│ or with median fold changes higher │1.25│are highlighted in bold;
b)For readability only one of two detected derivatives is listed; c)In these cases a Welch’s t-test was applied due to unequal variances; d)t-test was a non-parametric Wilcoxon
test, while for the other sugar compounds normal one-way ANOVA was used (depending on normality and homogeneity of variances).
differences between groups, fasting plasma samples selected
from the KarMeN cohort were analyzed for comparison. Spear-
man correlation coefficients as well as results for hypothesis
tests with variables such as age, BMI, and sex covering ranges
similar to those of the volunteers in the present study are shown
in Table 3. They revealed a significant correlation with age for
xylose and the unknown sugar U17, in the case of threitol,
erythronic acid, meso-erythritol, and glucuronic acid for both age
and BMI, and in the case of unknown sugar U16 for BMI (Figure
S4, Supporting Information File 1). Significant differences in the
hypothesis testing were found for threonic acid regarding age,
sedoheptulose regarding age and sex, and for 1,5-anhydroglucitol
regarding sex (Figures S5 and S6, Supporting Information File
1). Thus, for some sugar compounds (xylose, threonic acid,
threitol, meso-erythritol, glucuronic acid, sedoheptulose, and
1,5-anhydroglucitol) an extended general model accounting
for the confounders, as suggested in Supporting Information
File 2, would be more suitable and especially should be taken
into consideration for subsequent studies. Since all other sugar
compounds were not significantly affected by these variables
(age, BMI, and sex) or had weak correlations (rho < │0.3│)
or median fold changes below │1.25│, it is likely that these
variables (age, BMI, and sex) are not confounding results for
these sugar compounds and the simpler model applied in this
pilot study (Supporting Information File 3) should be sufficient.
3.5. Analysis of the Ingested OGTT Test Drink and Further
Commercial OGTT Solutions
To ascertain whether some of the significant sugar compounds
listed in Table 2 might be occurring or also increase in plasma
due to their presence in the test drink used for the OGTT, this
test drink was analyzed using the samemethod as for the plasma
sugar profiling. U18, one of the two sugar compounds show-
ing a distinct time-dependent increase after the OGTT (Figure 3)
was detected in the test drink. Furthermore, we found large
amounts of tagatose, an epimer of fructose. Other sugar com-
pounds were also detectable in the test drink, but in compara-
tively small amounts relative to glucose and maltose (Table 2).
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Figure 6. GC × GC-MS chromatograms from the start to 68 min of the maltodextrin-drink, and two commercial OGTT solutions. In the maltodextrin
the additionally added acetaminophen and lactulose are highlighted. Some of the major differences between the OGTT solutions were also identified.
The part of the chromatogram from 68 to 80 min was excluded due to many artifacts arising in this region.
Additionally, a general comparison of compounds occurring
in the test drink applied in this study and further commercially
available OGTT solutions was performed using GC × GC-MS
measurements to assess whether the occurrence of other sugars
and non-sugar compounds in OGTT solutions is common. Chro-
matograms of the GC × GC-MS measurements clearly show
that the test drink and commercial OGTT solutions contained
additional compounds to glucose, such as maltose, galactose,
fructose, tagatose, and many more, even non-sugar compounds
such as citric acid (Figure 6). In the case of the test drink from this
study, one can also see the added acetaminophen and lactulose.
4. Discussion
4.1. Plasma Sugar Profile
Around 40 different sugar compounds, 27 known and 13 un-
known, were reliably and reproducibly detected in plasma.
Among the known mono- and disaccharides, polyols and sugar
acids, we also detected a variety of rare sugar compounds such as
psicose, trehalose, or xylonic acid. Interestingly, amounts of dis-
accharides such as sucrose, lactose, maltose, trehalose, and lac-
tulose found in plasma were similar to other monosaccharides
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(except glucose), challenging the dogma of complete hydrolysis
of disaccharides by mucosal disaccharidases prior to absorption
of monomers. Transfer of disaccharides into systemic circulation
was already described decades ago,[40,41] but has recently received
new attention since passive permeation of disaccharides such as
lactulose across the epithelium can serve as a measure of gut
permeability.[42] We here demonstrate the appearance of lactu-
lose from the test drink (assessment of oral-cecal transit time)
in peripheral blood. We also detected lactose, which in urine has
been described as candidate marker for dairy consumption[19,43]
and similarly, sucrose in urine was proposed as a marker for total
dietary sugar intake.[44] The origin of the other detected disaccha-
rides is currently amystery. Theymay come from the diet, or they
might be generated endogenously, for example by degradation of
heteroglycans, or as by-product of other metabolic processes.
4.2. Sugar Compounds and Diabetes
The fasting plasma sugar profile already allowed a separation of
healthy and diabetic volunteers, with prediabetic volunteers in
between. The loadings plot revealed that other sugar compounds
are just as relevant for this separation as the “key separator” glu-
cose. Although glucose is a good and easily assessable clinical
biomarker for both diabetic and prediabetic states, a metabo-
lite profile may enable simpler detection of disease subtypes,
for example to better predict complications or optimize preven-
tive measures.[1] In addition to known marker compounds, such
as 1,5-anhydroglucitol,[45] mannose,[46,47] and fructose,[12,48] other
sugar compounds such as maltose,[11] trehalose, sedoheptulose,
and an unknown sugar-like compound (U15) were found to sig-
nificantly distinguish between healthy, prediabetic, and diabetic
volunteers based on their fasting plasma levels. They thus repre-
sent promising biomarker candidates for IR and type 2 diabetes
worth to be further explored in population studies. Suchmarkers
are important in the light of the ever-increasing incidence of dia-
betes mellitus type 2, as tools for diagnosing and preventing the
disease as early as possible.[2,10,11,49]
1,5-anhydroglucitol is used as an indicator of short-term
glycemic control in type 2 diabetes.[45] When the tubular load
of glucose is high, 1,5-anhydroglucitol is rapidly excreted
in urine due to competition for reabsorption via the renal
brush-border membrane glucose transporters.[45] However,
1,5-anhydroglucitol plasma levels differed in males and females
in the KarMeN cohort, suggesting that different threshold levels
for diagnostic purposes may be needed.[50] Other sugar com-
pounds such as xylose, threitol, sedoheptulose, meso-erythritol,
erythronic acid, threonic acid, glucuronic acid, and two unknown
sugars (U16, U17) were also associated with age, BMI, or sex
in the KarMeN plasma sample set, and therefore, should be
interpreted with caution when conducting subsequent studies.
Recently, sedoheptulose was reported to decrease with age in
urine sample data from the same cohort,[51] which suggests that
differences found between healthy, prediabetic, and diabetic
volunteers are mainly due to differences in age. The correlation
of meso-erythritol with BMI is interesting with regard to a recent
publication where erythritol was described as associated with
weight gain in young adults.[52]
Other confounders could be the diet on the day before the in-
tervention or more generally the habitual diets with respect to
high or low sugar intake or consumption of sugar substitutes (by
prediabetic and diabetic volunteers) such as sorbitol, mannitol,
or erythritol. However, overnight fasting (12 h) minimizes the
influence of the diet on the day before due to the fast clearance
and excretion of the very polar sugar compounds. For those sugar
compounds whose plasma levels changed during the OGTT, the
effects of previous consumption can in essence be ruled out.
The disaccharide trehalose was found in higher levels in fast-
ing plasma of diabetic volunteers, and plasma levels also changed
differently during the OGTT. Although the changes mimic those
of glucose, with a transient peak at 30min and a decline at 90min
in healthy, and a steady increase over time in prediabetic and
diabetic individuals, it cannot be confirmed that these changes
are similarly affected by insulin and IR as known for glucose. To
our knowledge, such effects on plasma trehalose have not been
reported before, but an increased activity of plasma trehalase
was described in diabetic states [53,54] and single nucleotide
polymorphisms in the trehalase gene were recently found to be
associated with type 2 diabetes.[55] Additionally, in a study on di-
abetic retinopathy, trehalose was detectable in most diabetic, but
not in non-diabetic participants.[23] However, neither the origin
of trehalose in plasma, nor the cause of the differences found
between healthy and diabetic individuals are currently known.
Trehalose could not be detected in the test drink, and thus its
appearance and time-profile in plasma argues for an endogenous
origin. That maltose as a degradation product of maltodextrin
provided in the test drink becomes detectable in plasma is in
line with a significant permeation of intact disaccharides across
the intestinal epithelium. What makes the findings on the dis-
accharides even more interesting is that their change over time
in plasma during the OGTT is similar to the pattern of glu-
cose, suggesting similar underlying insulin-dependent processes
in clearance. This also holds true for mannose, fructose, xylose,
sorbitol, scyllo-inositol,meso-erythritol, threitol, ribitol, arabinose,
and two of the unknown sugar-like compounds (U07, U15). An
endogenous production from glucose cannot be confirmed for
these compounds as a result of the detection of trace quanti-
ties of fructose, sorbitol, xylose, sedoheptulose, and arabinose in
the test drink itself. Nonetheless, the differences over time based
on health status suggest underlying insulin-dependent processes
and therefore these sugar compounds might be interesting for
further exploration as biomarkers of IR and type 2 diabetes.
A comparison of the test drink applied in this study and
further commercial OGTT solutions depicts clearly that further
sugar and non-sugar compounds in addition to glucose can
commonly be found in such test solutions. The additional sugar
compounds likely arise from the commercial maltodextrin or
glucose syrup used for production of OGTT solutions. This urges
for care when interpreting postprandial changes of metabolites
in plasma when using such test agents, as the occurrence of
additional compounds might influence the metabolism of the
compounds of interest and an endogenous production of addi-
tionally found compounds cannot be assumed. Therefore, a good
characterization of the test products is an important step in any
intervention study. More intensive work for the harmonization
of the preparation of different OGTT solutions is desirable for
comparable results in OGTT’s.
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Xylose has to our knowledge not been described as a metabo-
lite that changes during the OGTT in volunteers with IR or dia-
betes. However, a recent analysis described different plasma lev-
els in obese and lean individuals.[15] Xylose can be produced in
the pentose phosphate pathway (PPP), which frequently shows
impaired activity in diabetic states.[23] Although we detected se-
doheptulose in plasma, further intermediates of the PPP such as
ribulose and xylulose were only found in traces, and thus could
not prove that PPP per se is altered. Similarly, arabinose could be
a by-product of an epimerase reaction in PPP, but its production
in human metabolism has not been confirmed.
Mannose is produced from glucose via fructose-6-phosphate,
and has previously been identified as a diabetes metabolite
marker.[11,20,56] Fasting mannose levels correlate with fasting
plasma glucose, and mannose seems to be only minimally in-
fluenced by meals.[46] Early in vitro studies[57] demonstrated that
mannose shares the uptake system of glucose in muscle, likely
via Glut4, which is insulin-dependent. Consequently, mannose
has a diagnostic marker quality, especially in the case of border-
line diabetes,[46,47] and our data with the pronounced difference
in mannose levels after the OGTT across the groups also demon-
strates this special quality.
Two conspicuous sugar compounds, an unknown sugar-like
compound U18 (possibly a C4 sugar acid) and psicose, showed a
uniform strong increase after theOGTT, dependent on health sta-
tus for U18 and independently of health status for psicose (U18
by 18.5-fold and psicose by sevenfold; Figure 3). Whereas U18
was detectable in the test drink, psicose was not, but we found
high amounts of tagatose, which like psicose is an epimer of
fructose. It may well be that tagatose was completely converted
to psicose in human metabolism, explaining the steep postpran-
dial increase in plasma psicose. Alternatively, psicose may also
be produced endogenously from glucose via fructose in glycol-
ysis by an epimerase in response to the glucose load. We also
showed that fructose in plasma increases upon the glucose load,
which requires that a fraction of the cytosolic fructose-phosphate
pool is dephosphorylated, resulting in efflux of free fructose via a
Glut-transporter system. Thus, it appears plausible that psicose
as a fructose-epimer is generated from glucose in cells. Further
research on the origin of psicose will be especially interesting in
light of its proposed anti-hyperglycemic and anti-hyperlipidemic
effects.[58–61]
Major limitations of our pilot study are the limited sample size,
and the unbalanced design of the study, especially with respect
to sex and age. A complex general modelling would have been
able to adjust for these confounders. However, due to the limited
sample size, a general model would result in overfitting. There-
fore, to address the limitation of the unbalanced design as best
as possible and generally assess the influence of age, BMI, and
sex on sugar compounds of interest, an independent, external
study was taken into account. Overall, our study can be viewed
as a pilot study, which led to highly interesting and unexpected
results about the influence of the diabetic state on the sugar pro-
file after an OGTT. In subsequent studies with a larger sample
size and amore balanced design, a general modelling accounting
for confounders, interactions, random slope and intercept will
be possible. Moreover, with a larger sample size, multivariate
statistical analyses could additionally be conducted to focus on
the different relationships between the sugar compounds.
5. Concluding Remarks
The 40 different sugar and sugar-like compounds we detected in
human plasma were almost all recently identified by us as nor-
mal constituents of human urine.[19] This is an important find-
ing with respect to large cohort studies, where often only plasma
samples are available; meaning plasma sugar compounds are
similar to 24 h urine samples, although concentrations in plasma
are generally lower. In volunteers with IR or type 2 diabetes nu-
merous sugar compounds show characteristic plasma profiles
that mimic those of glucose, with rapid clearance during the
OGTT in healthy individuals, but not in an IR or diabetic state.
This suggests that, like glucose, many more sugar compounds
are subject to insulin-dependent removal from plasma after ab-
sorption or when produced endogenously. Although we could
not confirm that compounds such as psicose, trehalose, man-
nose, and others are indeed produced from glucose in metabolic
pathways during the OGTT, for some this appears likely, sug-
gesting an avenue for additional research, preferentially using
stable-isotope labeled glucose. However, we demonstrated that
the source of glucose for the OGTT, here in form ofmaltodextrin,
can contain other sugars and additional compounds. We found
this also holds true for commercial OGTT solutions, highlighting
the need for good characterization of the test product and care in
interpreting postprandial metabolite changes.
Supporting Information
Supporting Information is available from the Wiley Online Library or from
the author.
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1. Materials and methods 
1.1. Study design and subjects 
 
Figure S1. Flow chart including the number of individuals in the MIPROMET study screened during recruitment 
and reasons for non-inclusion. 
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1.2. Semitargeted GC-MS sugar profiling 
1.2.1. Plasma sample preparation 
Table S1. Internal standard stock solution 
Internal standard Concentration (µmol/L in H2O) Manufacturer Purity 
1-O-Methyl-2-deoxy-D-ribose 175 Sigma-Aldrich 96% 
Phenyl-β-D-glucopyranoside 85 Sigma-Aldrich 95% 
D-Pinitol 175 ABCR 99% 
 
1.2.2. GC-MS analysis 
Table S2. GC-MS instrument and components 
Instrument component / software Name Manufacturer 
Gas chromatograph GC-2010 Shimadzu Corp, Kyoto, Japan 
Mass spectrometer QP2010 Ultra Shimadzu Corp, Kyoto, Japan 
Auto sampler AOC-20s Shimadzu Corp, Kyoto, Japan 
PTV Injector OPTIC-4 GL Sciences, Eindhoven, The Netherlands 
GCMS instrument software GCMSSolution 4.11 Shimadzu Corp, Kyoto, Japan 
PTV software Evolution Workstation 4.1 GL Sciences, Eindhoven, The Netherlands 
 
 
Table S3. Method parameters; whenever measurement parameters differed during measurement of KarMeN 
fasting plasma samples, the changed parameters are listed separately. 
Parameter Setting / value 
GC parameters 
Carrier gas Helium 
GC mode MIPROMET: Constant pressure (256 kPa) 
KarMeN: Constant pressure (180 kPa) 
Liner type Deactivated split liner with quartz wool 
Column MIPROMET: Restek Rxi-5SilMS; L = 60 m plus 10 m of an 
integrated pre-column; dc = 0.25 mm; df = 0.25 µm 
KarMeN: Restek Rxi-5SilMS; L = 57 m plus 2 m of an integrated 
pre-column; dc = 0.25 mm; df = 0.25 µm 
GC temperature ramp 150 °C  4 °C/min  180 °C  7 °C/min  200 °C  
2.25 °C/min  235 °C  10 °C/min  270 °C  5.25 °C/min  
310 °C  20 °C/min  330 °C (3,97 min). Run time: 42 min. 
Injection mode Cold split 
Injection volume 1.2 µL 
Split ratio 1:5 
PTV temperature ramp 90 °C  60 °C/s 280 °C, hold until end of run 
Interface temperature 300 °C 
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Table S3 continued. 
MS parameters 
Ion source temperature 200 °C 
Ionization mode EI (70 eV) 
MS Mode Scan/SIM 
Scan speed 20.000 u/s 
Scan range m/z 60-600 
Event time (scan) 40 ms 
SIM time frame 1 (6.50-15.10 min) 
 
 
 
                             (6.50-15.86 min) 
MIPROMET: Event time: 620 ms; m/z 147.05, 204.10, 217.10, 
307.15, 319.20, 117.00, 160.10, 292.15, 277.20, 333.10, 245.00, 
218.00, 329.00, 314.00, 220.00, 310.00, 104.00, 323.00, and 
295.00 
KarMeN: Event time: 620 ms; m/z 204.10, 217.10, 307.15, 319.20, 
117.00, 160.10, 292.15, 277.20, 333.10, 245.00, 218.00, 329.00, 
220.00, and 295.00 
SIM time frame 2 (15.10 - 20.17 min)  
 
 
 
 
                             (15.86-21.19 min) 
MIPROMET: Event time: 680 ms; m/z 147.05, 204.10, 217.10, 
307.15, 319.20, 117.00, 160.10, 318.20, 205.10, 333.10, 361.15, 
220.00, 202.10, 260.00, 345.00, 255.00, 156.00, 206.00, 105.00, 
310.15, 323.70, 162.05, 104.15, 337.00, and 308.00 
KarMeN: Event time: 680 ms; m/z 204.10, 217.10, 307.15, 319.20, 
117.00, 160.10, 318.20, 205.10, 333.10, 361.15, 220.00, 202.10, 
260.00, 345.00, 308.00, and 156.00 
SIM time frame 3 (20.17-31.75 min)  
 
 
                             (21.19-32.57 min) 
MIPROMET: Event time: 600 ms; m/z 147.05, 204.10, 217.10, 
307.15, 319.20, 318.20, 205.10, 333.10, 299.00, 202.10, 361.15, 
441.00, 382.00, 357.00, 321.30, 220.20, 192.15, and 266.20 
KarMeN: Event time: 620 ms; m/z 204.10, 217.10, 307.15, 319.20, 
318.20, 205.10, 333.10, 299.00, 202.10, 361.15, 441.00, 382.00, 
220.20, and 192.15 
SIM time frame 4 (31.75-41.99 min)  
 
                             (32.57-41.99 min) 
MIPROMET: Event time: 400 ms; m/z 147.05, 204.10, 217.10, 
307.15, 319.20, 361.15, 367.00, 442.00, 220.00, 174.00 
KarMeN: Event time: 400 ms; m/z 204.10, 217.10, 307.15, 319.20, 
and 361.15 
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1.2.3. Data treatment and evaluation 
Table S4. Integration and identification parameters 
Parameter Setting/value 
Slope 100/min 
Width 1 s 
Drift 0/min 
T.DBL 1000 min 
Minimal area 0 
Smoothing none 
Default bandtime 0.1 min 
Spectrum confirmation use ratios of target and reference ionsa 
Reference ion mode absolute 
Ratio deviation allowance 30%* 
aIn some cases it became necessary to use a higher allowance, or to use only one or no  
reference ion due to overlapping peaks with similar MS spectra. 
After automatic integration a manual check of peak assignment and occurrence of coelution was performed. The 
repeatability was checked by CV’s of QC samples and the internal standards. 
1.3. Study design and subjects 
Table S5. Participant characteristics (range and mean in brackets) in the KarMeN study. 
 n Sex (n) Age (years) BMI (kg/m²)  Male Female m f all m f all 
Male 28 - - - - 21-80 (50.6) - - 
20.0-29.9 
(24.9) 
Female 30 - - - - 23-80 (50.4) - - 
19.4-29.2 
(23.6) 
All 58 28 30 - - 21-80 (50.5) - - 
19.4-29.9 
(24.2) 
Age (21-30 years) 10 5 5 21-30 (25.4) 
23-29 
(26.0) 
21-30 
(25.7) 
20.0-29.8 
(24.3) 
20.1-22.3 
(21.1) 
20.0-29.8 
(22.7) 
Age (50-72 years) 23 11 12 50-71 (61.2) 
50-72 
(61.7) 
50.72 
(61.5) 
22.5-29.2 
(25.2) 
20.9-29.2 
(24.9) 
20.9-29.2 
(25.0) 
BMI (19-23.9 kg/m²) 29 12 17 23-71 (44.8) 
23-69 
(40.7) 
23-71 
(42.4) 
20.0-23.9 
(22.5) 
19.4-23.8 
(21.5) 
19.4-23.9 
(21.9) 
BMI (24-30 kg/m²) 29 16 13 21-80 (54.9) 
42-80 
(63.0) 
21-80 
(58.5) 
24.0-29.9 
(26.7) 
24.0-29.2 
(26.3) 
24.0-29.9 
(26.5) 
 
1.4. Analysis of the ingested test drink for the OGTT and further commercial OGTT solutions 
In addition to the GC instrument and components listed in Supporting Information Table S3, the ZX2 modulator 
from ZOEX Corp. (Houston, USA) was used for the GC×GC-MS measurement. The method parameters are listed 
in Supporting Information Table S6. The GC×GC-MS chromatograms were visualized using GC ImageTM GC×GC 
Software version 2.5 (GCImage, LLC Lincoln NE, USA). 
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Table S6. Method parameters for GC×GC-MS measurement. 
Parameter Setting / value 
GC parameters 
Carrier gas Helium 
GC mode Constant velocity (29.7 cm/s) 
Liner type Deactivated split liner with quartz wool 
1D-Column Restek Rxi-5SilMS; 1L = 30 m plus 10 m of an integrated pre-
column; 1dc = 0.25 mm; 1df = 0.25 µm 
2D-Column SGE BPX50; 2Ltotal = 2.2 m including a “separation segment” of 
2Lsep = 0.7 m; 2dc = 0.15 mm; 2df = 0.15 µm 
Column connector SilTite MiniUnion (Trajan/SGE) 
GC temperature ramp 90 °C  3 °C/min  300 °C  15 °C/min  320 °C (7.67 min). 
Run time: 80 min. 
Injection mode Cold split 
Injection volume 1 µL 
Split ratio 1:10 
PTV temperature ramp 90 °C  60 °C/s 280 °C, hold until end of run 
Interface temperature 300 °C 
Modulation parameters 
Modulator type Cryogenic, air-based, loop-type 
Modulation period (PM) 3 s 
Cold jet temperature -90 °C 
Hot jet temperature Programmed stepwise, at least 100 °C above oven temperature 
Hot jet duration 250 ms 
MS parameters 
Ion source temperature 200 °C 
Ionization mode EI (70 eV) 
MS Mode Scan 
Scan speed 20.000 u/s 
Scan range m/z 56-550 
Event time 30 ms 
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2. Results 
Table S7. Summary of all measured known and unknown (U) sugar compounds, occurrence of partial or total chromatographic coelution, the corresponding target and reference ions, 
their ratios, the median, minimum and maximum peak area in study samples, frequency in all study samples, and intra- and inter-day repeatabilities (before and after signal intensity 
drift/batch correction) in QC samples and intermediate precision of internal standards over all samples (QC plus study samples). 
Sugar compoundsa Coelutionb Target ion Reference ions 
Ratios 
target/reference 
ionsc 
Median 
peak area 
Minimum 
peak area 
Maximum 
peak area 
Detection 
frequency 
(%) 
Intra-
dayuncorr 
(mean)d 
Inter-
dayuncorr 
Intra-
daycorr 
(mean)d 
Inter-
daycorr 
Xylose partialchrom 307.15 204.10, 117.00 551.59, 2477.54 1.38E+04 6.44E+03 5.38E+04 100.0 14.7 24.5 6.0 5.5 
Arabinose  307.15 117.00, 204.10 4096.49, 577.05 2.28E+04 1.35E+04 4.41E+04 100.0 13.4 24.5 6.6 6.0 
Psicose partialmass 307.15 117.00, 205.10 107.59, 25.49 2.84E+04 3.37E+03 1.99E+05 100.0 16.1 24.8 7.6 6.8 
Fructosee  307.15 205.10, 117.00 19.25, 23.67 9.25E+04 1.84E+04 5.34E+05 100.0 18.9 38.5 6.8 6.4 
Mannose  319.20 205.10, 160.10 57.41, 35.51 3.07E+06 1.03E+06 6.80E+06 100.0 14.4 24.5 6.7 5.7 
Glucosee  319.20 205.10, 160.10 49.79, 31.68 3.50E+07 1.96E+07 6.75E+07 100.0 7.3 13.6 3.4 2.8 
Sedoheptulosee  319.20 205.10 110.76 9.81E+03 5.16E+03 3.87E+04 100.0f 16.1 25.7 7.0 6.3 
Sucrose  361.15 319.20, 307.15 5.21, 0.51 9.42E+04 2.59E+04 1.76E+06 100.0 34.8 58.0 6.3 6.0 
Lactosee  361.15 307.15, 319.20 23.03, 46.14 1.46E+04 3.84E+03 4.03E+05 100.0f 18.8 27.8 7.0 7.2 
Lactulosee  361.15 204.10, 307.15 229.84, 13.98 3.02E+04 5.60E+03 6.89E+05 66.1 17.8 33.3 10.5 8.8 
Maltosee  361.15 319.20, 204.10 20.42, 57.63 6.12E+04 9.00E+03 2.32E+06 100.0 43.2 55.1 21.2 17.8 
Trehalose partialchrom 361.15 319.20, 307.15 0.29, 0.11 2.36E+04 8.93E+03 9.98E+04 100.0 23.2 39.3 12.2 11.0 
Threitol  204.10 160.10, 117.00 145.47, 328.36 9.66E+03 4.13E+03 4.90E+04 100.0f 12.2 16.7 7.6 6.0 
meso-Erythritol  204.10 117.00, 307.15 237.66, 59.72 3.17E+04 1.61E+04 8.67E+04 100.0 13.4 21.1 7.5 6.5 
Arabitol  307.15 319.20, 117.00 104.80, 304.61 3.37E+04 1.55E+04 9.47E+04 100.0 13.2 23.0 6.9 5.8 
Ribitol partialchrom 307.15 319.20, 204.10 11.00, 47.72 4.93E+03 2.61E+03 1.08E+04 100.0f 12.9 20.2 3.6 3.3 
1,5-Anhydroglucitol partialchrom 260.00 319.20, 117.00 138.81, 326.62 1.64E+05 3.57E+04 4.52E+05 100.0 13.4 21.8 7.7 6.0 
Mannitol partialchrom 319.20 205.10, 117.00 47.70, 13.30 1.29E+05 2.71E+04 9.90E+05 100.0 19.6 25.1 10.7 10.7 
scyllo-Inositol partialchrom 318.20 307.15, 204.10 25.76, 1307.79 9.33E+04 3.61E+02 3.31E+05 100.0 14.0 25.1 7.0 5.6 
myo-Inositol partialchrom 318.20 204.10, 192.15 79.61, 21.14 8.03E+05 5.46E+05 1.70E+06 100.0 14.1 24.1 7.1 5.5 
Sorbitol partialchrom 319.20 307.15 10.50 2.67E+04 1.07E+04 2.63E+05 100.0 17.1 30.0 8.1 7.5 
Erythronic acid  292.15 117.00, 319.20 74.53, 9.81 8.71E+04 1.33E+04 1.65E+05 100.0 14.2 23.8 7.8 6.1 
Threonic acid partialchrom 292.15 117.00, 319.20 35.78, 12.41 3.79E+05 6.72E+04 9.42E+05 100.0 18.0 30.3 8.3 6.9 
Glucuronic acide partialchrom 333.10 205.10, 160.10 75.48, 82.80 6.06E+04 3.13E+04 2.36E+05 100.0 14.4 24.5 6.8 6.2 
Xylonic acid  292.15 333.10 22.92 1.92E+03 7.23E+02 1.55E+04 100.0f 27.7 36.7 15.0 12.7 
Ribonic acid  292.15 333.10 42.52 2.32E+03 8.87E+02 7.03E+03 100.0f 31.7 36.0 17.7 16.4 
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Arabonic acid  292.15 333.10 25.24 6.41E+03 8.96E+02 4.24E+04 100.0f 36.7 43.7 19.5 15.8 
U16  117.00 204.10, 160.10 18.46, 3.83 1.95E+04 1.73E+03 2.11E+05 99.2 52.2 93.5 15.7 15.0 
U01  277.20 292.15, 117.00 43.45, 2.59 1.01E+05 3.06E+04 2.24E+05 100.0 37.2 60.9 12.5 10.4 
U03 partialmass 361.15 319.20, 204.10 10.20, 39.56 9.57E+04 2.85E+04 3.13E+05 100.0 16.8 24.7 9.1 7.2 
U07  319.20 117.00, 204.10 187.95, 106.63 9.34E+03 3.59E+03 3.29E+04 100.0f 26.1 32.5 15.1 13.4 
U08  307.15 319.20, 333.10 146.17, 225.20 3.01E+04 1.06E+04 1.12E+05 100.0 31.5 37.7 14.0 12.7 
U10  361.15 299.00, 204.10 0.89, 1.83 3.34E+04 5.32E+03 1.59E+06 100.0 65.4 78.2 33.8 30.8 
U11  361.15 204.10, 299.00 25.22, 7.59 8.26E+03 2.72E+02 1.23E+06 100.0f 101.3 108.6 41.8 38.4 
U12  202.10 333.10, 319.20 16.02, 14.37 5.24E+04 8.49E+03 2.95E+05 100.0 15.4 24.3 9.2 6.8 
U15 partialchrom 319.20 205.10, 217.10 117.18, 217.79 6.02E+03 1.91E+03 2.06E+04 100.0f 22.3 36.2 14.8 13.9 
U17  292.15 333.10 27.96 4.19E+03 1.42E+03 1.48E+04 100.0f 24.4 32.9 12.2 10.3 
U18  117.00 204.10, 217.10 46.34, 18.22 7.71E+04 3.94E+03 4.44E+05 90.9 13.2 20.4 8.5 7.0 
U19  319.20 204.10 23.42 7.29E+03 3.06E+02 3.56E+05 100.0f 90.6 93.3 47.9 48.7 
U20  319.20 204.10 187.22 2.28E+03 1.93E+01 4.70E+05 98.3f 117.8 116.9 47.4 47.2 
Methyl-2-
deoxyribose e, g partialchrom 160.10 117.00, 204.10 4383.23, 197.83    100.0 9.7 16.5 8.7 8.9 
Pinitolg  260.00 318.20, 204.10 77.15, 16.16    100.0 9.0 20.0 7.8 8.2 
Phenyl-β-
glucopyranosideg  361.15 319.20, 204.10 7.31, 7.71    100.0 10.5 22.5 8.4 9.0 
aAll named sugar compounds were unambiguously identified using co-chromatography with standard substances; the remaining unknowns could be assigned to a 
substance class according to mass spectra. bpartialmass.: total chromatographic coelution, separation through masses possible; partialchrom.: partial chromatographic 
coelution and separation through masses possible. cRatios of reference ions to target ion, deviation allowance was usually 30%. dMean of 5 measurement days intra-
day precision. eOnly first of two derivatives is shown. fTrace analytes. gInternal standards. 
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Figure S2. Mass spectra of the unknown sugar-like compounds.  
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Figure S3. Boxplots for the measured time points (0, 30 and 90 min) of lactulose grouped into healthy (n = 15), 
prediabetic (n = 15) and diabetic (n = 11) volunteers. 
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2.1. Verification of findings in fasting plasma samples in an independent study 
 
Figure S4. Scatterplots of glucuronic acid, meso-erythritol, threitol, and xylose showing significant Spearman correlation 
coefficients with age and/or BMI in KarMeN fasting plasma samples (n = 58). 
 
 
 
 
 
Figure S5. Boxplots of threonic acid and sedoheptulose with significant differences between 20-30 years old (n = 10) 
and 50-72 years old (n = 23) KarMeN participants. 
3 PUBLICATIONS  
118 
 
  
Supporting Information for online publication - File 1 
 
 
Figure S6. Boxplots of sedoheptulose and 1,5-anhydroglucitol with significant differences between male (n = 28) and 
female (n = 30) KarMeN participants. 
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Online Supporting Material File 2
The plasma ”sweet” component: Exploring the diversity of sugar
compounds in healthy, prediabetic and diabetic volunteers
Statistical Analyses
Aim
The aim is to analyse the longitudinal data of the metabolites in dependence
of the variable ”group” and the variable ”time”, after finding a proper fitting
model. Interactions terms betwenn group and time are considered, as well
as models corrected for the confounders ”age” and ”BMI”. A general model
is proposed and compared with the simpler model considering only ”group”
and ”time” as independent variables.
library("knitr")
library("XLConnect")
library("lattice")
library("lmerTest")
library("multcomp")
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1 Sedoheptulose.deriv..1: Example of potential con-
founding by age
print(bwplot(Sedoheptulose.deriv..1~as.factor(Time..min.)|Group,data,xlab="Time"))
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mod1<-lmer(Sedoheptulose.deriv..1~Group+Time..min.+(1|Participants),data)
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mod2<-lmer(Sedoheptulose.deriv..1~Group+Time..min.+(1|Participants)+Age..years.,data)
anova(mod1,mod2)
## refitting model(s) with ML (instead of REML)
## Data: data
## Models:
## object: Sedoheptulose.deriv..1 ~ Group + Time..min. + (1 | Participants)
## ..1: Sedoheptulose.deriv..1 ~ Group + Time..min. + (1 | Participants) +
## ..1: Age..years.
## Df AIC BIC logLik deviance Chisq Chi Df Pr(>Chisq)
## object 7 2312.3 2331.8 -1149.1 2298.3
## ..1 8 2311.0 2333.3 -1147.5 2295.0 3.2941 1 0.06953 .
## ---
## Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
res1<-glht(mod1,linfct=mcp(Group="Tukey"))
par("mai" = par("mai") * c(1, 2.2, 1, 1))
plot(res1)
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res2<-glht(mod2,linfct=mcp(Group="Tukey"))
plot(res2)
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2 Glucose.deriv..1: Example of model considering
interaction terms
print(bwplot(Glucose.deriv..1~as.factor(Time..min.)|Group,data,xlab="Time"))
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mod1<-lmer(Glucose.deriv..1~Group*Time..min.+(1|Participants),data)
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mod2<-lmer(Glucose.deriv..1~Group+Time..min.+(1|Participants),data)
anova(mod1,mod2)
## refitting model(s) with ML (instead of REML)
## Data: data
## Models:
## ..1: Glucose.deriv..1 ~ Group + Time..min. + (1 | Participants)
## object: Glucose.deriv..1 ~ Group * Time..min. + (1 | Participants)
## Df AIC BIC logLik deviance Chisq Chi Df Pr(>Chisq)
## ..1 7 4152.4 4171.9 -2069.2 4138.4
## object 11 4083.4 4114.1 -2030.7 4061.4 77.027 4 7.423e-16 ***
## ---
## Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
The choice of the proper test remains open.
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3 Threitol: Example of general model considering
interaction terms and potential confounders
print(bwplot(Threitol~as.factor(Time..min.)|Group,data,xlab="Time"))
## subject-specific slopes, intercepts as random effects; interactions
mod1<-lmer(Threitol~Group*Time..min.+(Time..min.|Participants)
+Age..years.+BMI..kg.mš.,data)
## subject-specific slopes and intercepts as random effects
mod2<-lmer(Threitol~Group+Time..min.+(Time..min.|Participants)
+Age..years.+BMI..kg.mš.,data)
## only intercepts as random effects, interactions
mod3<-lmer(Threitol~Group*Time..min.+(1|Participants)
+Age..years.+BMI..kg.mš.,data)
## only intercepts as random effects
mod4<-lmer(Threitol~Group+Time..min.+(1|Participants)
+Age..years.+BMI..kg.mš.,data)
anova(mod1,mod2)
anova(mod1,mod3)
anova(mod2,mod4)
anova(mod3,mod4)
Such a model could be considered in a future, larger study.
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essential information of this file is summarized in Table 2 and Figure 3 of the main 
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Online Supporting Material File 3 of
The plasma ”sweet” component: Exploring the diversity of sugar
compounds in healthy, prediabetic and diabetic volunteers
Statistical Analyses
Aim
The aim is to screen sugar compounds associated with health status (healthy,
prediabetic, diabetic)
library("knitr")
library("XLConnect")
library("lattice")
library("lmerTest")
library("multcomp")
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1 Threitol
print(bwplot(Threitol~as.factor(Time..min.)|Group,data,xlab="Time"))
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mod1<-lmer(Threitol~Group+Time..min.+(1|Participants),data)
res<-glht(mod1,linfct=mcp(Group="Tukey"))
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par("mai" = par("mai") * c(1, 2.2, 1, 1))
plot(res,main="Threitol")
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summary(res)
##
## Simultaneous Tests for General Linear Hypotheses
3
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##
## Multiple Comparisons of Means: Tukey Contrasts
##
##
## Fit: lme4::lmer(formula = Threitol ~ Group + Time..min. + (1 | Participants),
## data = data)
##
## Linear Hypotheses:
## Estimate Std. Error z value Pr(>|z|)
## Healthy - Diabetic == 0 -3730 2481 -1.503 0.2889
## Prediabetic - Diabetic == 0 1206 2481 0.486 0.8778
## Prediabetic - Healthy == 0 4935 2283 2.162 0.0777 .
## ---
## Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
## (Adjusted p values reported -- single-step method)
res<-glht(mod1,linfct=mcp(Time..min.="Tukey"))
plot(res,main="Threitol")
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summary(res)
##
## Simultaneous Tests for General Linear Hypotheses
##
## Multiple Comparisons of Means: Tukey Contrasts
##
##
## Fit: lme4::lmer(formula = Threitol ~ Group + Time..min. + (1 | Participants),
## data = data)
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##
## Linear Hypotheses:
## Estimate Std. Error z value Pr(>|z|)
## 30 - 0 == 0 2059.58 487.13 4.228 <1e-04 ***
## 90 - 0 == 0 2132.77 491.61 4.338 <1e-04 ***
## 90 - 30 == 0 73.19 487.13 0.150 0.988
## ---
## Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
## (Adjusted p values reported -- single-step method)
print(qqmath(~resid(mod1)|Group,data))
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4 FURTHER DEVELOPMENT OF THE SUGAR PROFILING METHOD 
4.1 Background 
Although the semitargeted one-dimensional GC-MS sugar profiling method already 
enabled detection and separation of 55 known and unknown sugar compounds in 
human urine (section 3.2), we still observed further trace signals of compounds that 
exhibited mass spectra characteristic for sugar compounds. Additionally, in a number 
of cases the specificity in the one-dimensional GC-MS method is based not on 
chromatographic resolution, but on the detection of characteristic mass fragments. 
For targeted approaches with exhaustive sample clean-up the separation via m/z is 
usually sufficient. However, in the case of metabolite profiling approaches with only 
minimal sample clean-up (as for the semitargeted GC-MS sugar profiling method), 
the risk exists that unknown matrix compounds and non-sugar compounds with 
similar mass fragments interfere with the detection of the targeted compounds. 
Another relevant point with respect to separation of sugar compounds based on MS 
is that the mass spectra of stereoisomers are highly similar to identical and therefore, 
separation based on MS is problematic. As a consequence, further optimization of 
the sugar profiling method with respect to sensitivity and separation performance is 
desirable. GC×GC-MS enables both an improved sensitivity (via band focusing in the 
modulator) and an improved separation performance (via separation on two 
orthogonal columns). 
For the transformation of the one-dimensional GC-MS method towards a two-
dimensional GC×GC-MS method, several points have to be addressed: i) the column 
set-up; ii) the MS mode; and iii) the data processing strategy. With respect to the 
column set-up, the 60 m long Rxi-5SilMS column used in the one-dimensional GC-
MS method was chosen as 1D-column and for the 2D-column a classical medium 
polar BPX50 column with a separation length of 1 m was utilized, leading to a typical 
orthogonal unpolar × medium polar column combination (introduction section 1.1.3). 
The one-dimensional GC-MS method is performed in Scan/SIM mode, enabling both 
detection and elucidation of unknown compounds using Scan mode and the sensitive 
and selective detection using SIM mode. However, Scan/SIM mode is no longer an 
option using GC×GC-MS due to the necessity to achieve a fast data acquisition rate 
for an adequate reconstruction of the narrow GC×GC peaks (introduction 
section 1.1.3). To improve sensitivity and selectivity, characteristic SIM masses were 
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considered as the mode of choice for the GC×GC-MS method. The usage of SIM 
mode for two-dimensional GC×GC-MS is unusual and has only rarely been described 
so far [88-90]. The characteristic m/z for sugar compounds were chosen based on 
experiences from the one-dimensional GC-MS method (section 3.3 results). Finally, 
as mentioned in section 1.1.3, processing of two-dimensional data is more complex 
than in the case of one-dimensional data and necessitates dedicated software and 
algorithms. In our workgroup, a peak-feature based approach for GC×GC-Scan-MS 
was established by Björn Egert and Christoph Weinert [31, 91]. This approach so far did 
not enable the evaluation of SIM data and usage of targeted ions. With the help of 
Björn Egert the peak-feature based approach was extended towards GC×GC-SIM-
MS data. The applicability of the optimized GC×GC-SIM-MS method and the 
advantages over the so far utilized one-dimensional method are shown exemplarily 
based on data of a cross-over intervention study (FoodBAll) with multiple urine 
collections after the consumption of apple, coke, and water as control. The focus of 
this chapter lies on the further technical development of the sugar profiling method in 
comparison to the one-dimensional method. Nonetheless, some preliminary 
impressions on the biological results of the FoodBAll intervention study are 
presented. 
4.2 Material and methods 
Chemicals 
Methanol (GC; ≥ 99.9%) was purchased from Carl Roth (Karlsruhe, Germany). 
Heptane (GC) and acetone (GC) were from Merck (Darmstadt, Germany). Pyridine 
(anhydrous, 99.8%) was supplied by Sigma-Aldrich (Steinheim, Germany). O-
Methoxylamine hydrochloride was obtained from Chemos (Regenstauf, Germany). N-
Methyl-N-(trimethylsilyl)trifluoroacetamide (MSFTA) with 1% trimethylchlorosilane 
(TMCS) was from Macherey-Nagel (Düren, Germany). Supplemental Table S4.1 lists 
all used standard substances. 
Consumables 
Consumables utilized in this study are listed in Supplemental Table S4.2. 
Study design and samples 
The samples were generated during the FoodBAll study at the MRI in February 2016. 
The study was a randomized crossover intervention study with the aim to identify 
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potential markers of apple and coca cola consumption, including water as a control 
food and a reference meal (Keto-Drink, Tavarlin GmbH, Pfungstadt, Germany), which 
was ingested together with the test foods (apple (Elstar), Coca Cola® and water) in 
three separate arms of the study. For the detailed insight on the study design, see 
Figure 4.1. 
 
Figure 4.1. Study design of the FoodBAll MRI study.  
In total, 11 participants (5 males and 6 females), aged between 21-33 years, BMI 
19.7-27.1 kg/m², who gave their written consent, were recruited. Participants were 
included, if they were healthy male or female, between 18 and 40 years, had a BMI 
between 18.5 and 30 kg/m², were free from prevalent diseases, had no history of a 
chronic disease, were non-smokers, did not take any medication (e.g. hormonal 
contraceptive), or did not take supplements within the last four weeks, did not take 
antibiotics within the last six months, donated blood within the last three months, in 
case of women were not pregnant or lactating, did not have an allergy or intolerance 
for one of the test food or reference meals and were willing and able to perform the 
study. The ethics committee of the State Medical Chamber of Baden-Württemberg, 
Stuttgart, Germany, approved the study, which was in accordance with the 1964 
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Helsinki declaration and its later amendments. The study was registered at the 
German Clinical Study Register (DRKS00008787) and has the Universal Trial 
Number U1111-1177-1536.  
For optimization and development of the GC×GC-MS sugar profiling method only the 
urine samples were used. Participants provided spot urine samples before the intake 
of the test food, at 48 hours after the intervention and collected their urine during the 
periods described in Figure 4.1. During collection periods the bottles were kept on 
ice, until samples were processed. After recording urine volume, samples were 
centrifuged (10 min, 1850 × g, 20 °C), and aliquoted, frozen at -20 °C and after one 
day stored at -80 °C. 
A QC sample was prepared by mixing urine samples from all participants, all 
interventions and all time points. Separate aliquots were frozen at -80 °C until 
analysis. Osmolality of the QC sample and study samples was determined in 
duplicate after centrifugation by using an Advanced® Osmometer Modell 2020 
(Advanced Instruments, Massachusetts, USA). 
Sample preparation 
First, 40 µL of urine sample (study and QC samples) were diluted with water (dH2O) 
to adjust osmolality to 60 mOsmol/kg. 20 µL of IS solution (composition see 
Supplemental Table S4.1) were pipetted to a screw thread vial with a 300 µL fused 
insert and 40 µL of the diluted urine sample were added. After mixing, the samples 
were evaporated in a Speedvac-concentrator (Heto maxi dry plus, Jouan Nordic) for 
1 h at 40 °C and maximal vacuum (p < 1 mbar). To remove remaining traces of 
water, 20 µL of methanol were added followed by an additional evaporation step 
(30 min). After evaporation, a two-step derivatization protocol was performed. First, 
methoximation was conducted by adding 15 µL of methoxylamine-hydrochloride 
solution (20 mg/mL in anhydrous pyridine) at 40 °C for 1 h under shaking (1000 rpm). 
Second, trimethylsilylation was carried out by adding 50 µL of MSTFA with 1% TMCS 
at 75 °C for 1.5 h. Each day, a solvent blank was prepared similarly to urine samples, 
but with water instead of urine. At the end of the reaction, 10 µL of the FAME solution 
for RI were added (Supplemental Table S4.1). For the sugar compound reference 
standard samples (Supplemental Table S4.1) measured at the end of the 
measurement series, 50 µL of the 25 µMol/L standard solutions were evaporated to 
dryness in a two-step procedure as described before. Derivatization conditions were 
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the same as for study samples, however 10 µL methoxylamine-hydrochloride solution 
and 30 µL MSTFA with 1% TMCS were used. 
GC×GC-MS analysis 
To correct drift and offset effects during the measurement due to shifts in equipment 
performance, analyte degradation and also prolonged derivatization reactions or 
changes in the system (e.g. change of septum), the regular measurement of QC 
samples is necessary, enabling an analyte-wise correction of these effects. 
Therefore, each day started with the daily solvent blank sample followed by 11 study 
samples in three groups of four/three samples framed by six QC samples, with two in 
the beginning and in the end. In the beginning and in the end of each measurement 
week, a QC sample was measured in Scan mode (m/z 60-550), this run can later be 
used for identification based on the full scan. At the end of the measurement series, 
reference standards of sugar compounds (Supplemental Table S4.1) were 
measured, so that they could be aligned with the study and QC samples and thus 
enable an a priori identification of known sugar compounds. Every measurement 
week, the liner and injector septum were replaced and the qMS was tuned, followed 
by six equilibration runs with QC samples. Table 4.1 lists the GC×GC-MS system and 
software utilized in this study. In Table 4.2, the GC, modulation and MS parameters 
are shown. 
Table 4.1. GC×GC-MS system and software. 
Instrument component/ 
software 
Name Manufacturer 
Gas chromatograph GC-2010 Shimadzu Corp, Kyoto, Japan 
Mass spectrometer QP2010 Ultra Shimadzu Corp, Kyoto, Japan 
Autosampler AOC-20i+s Shimadzu Corp, Kyoto, Japan 
PTV Injector OPTIC-4 GL Sciences, Eindhoven, The 
Netherlands 
Modulator ZX2 ZOEX Corp., Houston, USA 
GCMS instrument software GCMSSolution 4.11 Shimadzu Corp, Kyoto, Japan 
PTV software Evolution Workstation 4.1 GL Sciences, Eindhoven, The 
Netherlands 
GC×GC visualization software ChromSquare 2.1 Chromaleont Srl, Messina, Italy 
FiehnLib database FiehnLib Agilent, Santa Clara, USA 
NIST database NIST2014 NIST, Gaithersburg, MD, USA 
 
4 FURTHER DEVELOPMENT OF THE SUGAR PROFILING METHOD  
142 
 
Table 4.2. Method parameters including consumables. 
Parameter Setting/value 
Autosampler parameters 
Syringe 10 µL, conical 
Injection volume 1.2 µL 
Pre Clean with Solvent (heptane, acetone) 3 
Post Clean with Solvent (heptane, acetone) 6 
Pre Rinses with Sample 1 
Plunger Speed (Suction) High 
Viscosity Comp. Time 0.2 s 
Plunger Speed (Injection) High 
Syringe Insertion Speed High 
Pumping Times 3 
Injection Port Dwell Time 0.3 s 
GC parameters 
Carrier gas Helium 
GC mode Constant velocity 
Initial column head pressure 210.3 kPa 
Liner type Deactivated split liner with quartz wool (CS 
chromatography, Langerwehe, Germany) 
Injector septum Septa Thermolite® Shimadzu Plug (Restek, Bad 
Homburg, Germany) 
1D-column Rxi-5SilMS; 1L = 60 m plus 10 m of an integrated pre-
column; 1dc = 0.25 mm; 1df = 0.25 µm (Restek, Bad 
Homburg, Germany) 
2D-column BPX50; 2Ltotal = 2.4 m, including a “separation 
segment” of 2Lsep = 1.0 m; 2dc = 0.15 mm, 2df = 
0.15 µm (SGE, Milton Keynes, United Kingdom) 
Column connector SilTite MiniUnion (SGE, Milton Keynes, United 
Kingdom) 
GC temperature ramp 80 °C → 8 °C/min → 140 °C → 1.75 °C/min → 220 °C 
→ 8 °C/min → 255 °C → 4 °C/min → 300 °C 
(6.16 min). 
Run time: 75 min. 
Injection mode Cold split 
Split ratio 1:5 → 1:20 (1 min) 
PTV temperature ramp 90 °C → 60 °C/s → 280 °C, hold until end of run. 
Interface temperature 280 °C 
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Table 4.2 continued. 
Modulation parameters 
Modulator type Cryogenic, air-based, loop-type 
Modulation period (PM) 2.4 s 
Cold jet temperature -90 °C 
Hot jet temperature Programmed stepwise, at least 100 °C above oven 
temperature 
Hot jet duration 200 ms 
MS parameters 
Ion source temperature 200 °C 
Ionization mode EI (70 eV) 
MS Mode SIM 
Event time 30 ms 
SIM m/z 160.00, 277.00, 292.00, 305.00, 307.00, 318.00, 
319.00, 333.00, 361.00, 421.00, 437.00 
Data acquisition frequency 33 s-1 
 
Data processing 
Data processing is a complex and labor-intensive process involving different steps 
and different softwares (GCMSSolution, R modules, Microsoft Excel). The original 
workflow for a peaklet-based generic analysis of untargeted GC×GC-MS data was 
developed by Björn Egert and Christoph Weinert [31, 91]. This strategy is based on full 
scan data. However, for the sugar profiling, the measurement was performed in SIM 
mode with 11 selected m/z. To address the differences between full scan and SIM 
data, the workflow was adjusted with the help of Björn Egert. In the following 
paragraphs, a short description of the relevant points is given, a flow diagram can be 
found in Supplemental Figure S4.1:  
• Raw data processing: 
As a first step, raw data was submitted to automated integration. For this, 
overall 44 integration methods were created, four for each measured m/z 
(integration parameters see Supplemental Table S4.3). This was necessary 
due to the limitation of the GCMSSolution software (designed for the 
processing of one-dimensional GC-MS data) being able to handle only a 
maximum of 1000 peaks per run. Therefore, the chromatogram had to be 
integrated within timeframes for each of the 11 measured m/z with an overlap 
of 1 min between the time frames (Supplemental Figure S4.1, part A). A batch 
4 FURTHER DEVELOPMENT OF THE SUGAR PROFILING METHOD  
144 
 
process resulted in one txt-file per run (overall 470 runs: QC samples, study 
samples, technical replicates and standard substances) including the 44 
integration methods. Each retention time can be reported up to 11 times 
depending on the number and size of peaks for each of the m/z. 
• Import and restructuring of data: 
Each txt-file consisted of peak lists for four time frames of one m/z followed by 
the time frames of the next m/z and so on in a block-wise structure; 
information such as retention times (apex, start and end time), area, height 
and RI are included. Additionally, after each time frame block, the mass 
spectra consisting of maximally 11 masses for each listed peak are reported 
(Supplemental Figure S4.1, part B). The txt-files were imported and 
reorganized towards a tabular structure. Therefore, the 11 m/z were assigned 
to their respective block peak list based on a heuristical approach. The 
overlapping time frames of 1 min were removed based on exactly the same 
retention time and mass spectra. Additionally, based on the modulation time 
the retention time (RT) of the raw data was converted to 1D- and 2D-RT’s. To 
compensate RT-shifts for the modulations (Supplemental Figure S4.1, part C), 
runs were shifted batch-wise for maximally two modulations to the left or right. 
Which batches or measurement days were shifted and in which direction was 
decided based on the median RT’s for the highest modulation of three 
randomly chosen sugar compounds in the QC samples of each day. The 
result of this step was a first global data matrix with a continuous peak list for 
each m/z and run. 
• Filtering and data reduction: 
In the next step, a data reduction was performed based on several filters. All 
peaks with peak heights below 5000, and less than five data points were 
deleted. Based on the 2D-chromatogram obvious noise peaks and 
background peaks were deleted by adding their mass spectra to a noise 
database. Additionally, all peaks were deleted that could not find a matching 
peak (RT and mass spectral similarity) in any other run. 
• Alignment: 
The alignment is performed to combine all modulations in one run and to 
combine matching peaks over all runs. In a first step, a clustering algorithm 
combined peaks based on their 1D- and 2D-retention times and mass spectral 
4 FURTHER DEVELOPMENT OF THE SUGAR PROFILING METHOD  
145 
 
similarity (ε < 0.015) by comparing peaks pair-wise (Supplemental Figure 
S4.1, part D). In a second step, each resulting cluster was evaluated again by 
calculating a hierarchical cluster analysis of the mass spectra within each 
cluster. If the height cut (HC)-value was above 275, the cluster was cut into 
two separate clusters (Supplemental Figure S4.1, part E). These steps were 
first performed for six QC samples and nine study samples comprising all 
study groups leading to a representative reference alignment. Such a 
reference alignment was necessary to cope with the huge amount of data due 
to limits in main memory for the computational calculation. Therefore, the 
processing of large cohorts with many samples is enabled. Then for each 
peak in each run, the mass spectral similarity was calculated against this 
reference alignment. The third and last step was the separation of clusters 
based on their peak height profile. Here, modulations of two separate peaks 
were combined due to their mass spectral similarity although being two 
separate peaks (Supplemental Figure S4.1, part F). To find the optimal split 
between such peaks, the cumulative heights of all runs were calculated. If 
adding a modulation results in an increase of less than 1.5%, this modulation 
was assigned to the first of the two peaks and all other modulations build their 
own cluster. 
• Demodulation: 
First, the quantifying ion was determined, which is the m/z with the highest 
signal intensity in most modulations of a cluster. Then, for each run, the signal 
intensities of the modulations of the quantifying ion were summed up to 
receive one signal intensity for one analyte in each run. 
• Drift correction: 
As a result of long measurement series, drift or batch effects can occur due to 
increasing contamination of the injector and column by matrix compounds, 
due to batch-wise derivatization (e.g. instability of derivatives, prolonged 
derivatization) or due to maintenance (e.g. changing of liner or septum). 
Representative QC samples were injected six times per batch/measurement 
day to correct such effects. Therefore, analyte-specific correction functions 
were calculated based on QC samples, and the signal intensities of study 
samples were adjusted accordingly (Supplemental Figure S4.1, part G). In this 
step, analytes were separated in correctable and uncorrectable analytes. If an 
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analyte was found with less than 15% of the QC samples per 
batch/measurement day in more than 50% of all batches/measurement days, 
then the analyte was defined as uncorrectable. No correction of drift effect was 
performed because neither a batch-wise nor an analyte-specific correction 
function is possible with so few QC samples. For measurement days/batches 
with less than 15% QC samples or where the first and/or last QC samples 
were missing, only a global batch correction via the mean of the QC samples 
was performed. For all other batches/measurement days, where the frequency 
of the analyte in the QC samples was high enough, analyte-specific correction 
functions were calculated. The result was a final data matrix for each 
correctable and uncorrectable analytes, where analytes were listed in columns 
and samples in rows. 
• Identification: 
For identification purposes two steps were performed. First, at the beginning 
and at the end of each measurement week QC samples were measured in 
Scan mode. Thus, it was possible to perform a comparison of the mass 
spectrum of a compound with mass spectral libraries (in-house database, 
NIST14, FiehnLib). Second, overall 111 sugar reference standards were 
measured in 35 runs at the end of the measurement series (Supplemental 
Table S4.1). Therefore, the alignment of these reference standards with the 
QC and study samples and thus the identification of known sugar compounds 
was enabled. 
• Evaluation:  
After the data processing, an evaluation of the analytes had to be performed 
with respect to the choice of quantifying ion, with respect to a correct 
alignment and height profile split, with respect to the repeatability and with 
respect to the occurrence of partial or complete coelution with matrix 
compounds, non-sugars or other sugar compounds. 
4.3 Results and Discussion 
The optimized two-dimensional GC×GC-MS method enabled the detection and 
separation of 52 known sugar compounds, all identified by reference compounds. 
Furthermore, 28 sugar compounds that could be tentatively identified (e.g. as 
deoxypentitol or deoxysugar acid) or classified as one of the subclasses of sugar 
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compounds (e.g. polyol, sugar acid or similar) were detected. Additionally, further 
compounds were detected that exhibited typical mass spectra of sugar compounds 
(also section 3.2-3.3), of which only those were evaluated that showed biologically 
interesting time courses during the intervention with apple and coke or were detected 
also with the one-dimensional GC-MS method (4 compounds). It is to be expected 
that about 10-20 further unknown sugar compounds might be detectable in urine 
using the two-dimensional GC×GC-MS method based on the mass spectra. Overall, 
84 known and unknown sugar compounds were detected. In panel A of Figure 4.2, a 
typical two-dimensional GC×GC-MS chromatogram of a urine QC sample is 
displayed exemplarily.  
The tentative identification and/or classification of 28 as yet unknown sugar 
compounds was possible as a result of the mass spectra and also of the so-called 
structured retention effect, which results from the separation of compounds on two 
columns with independent/orthogonal separation mechanisms. In addition to the 1D-
separation based on volatility, and thus more or less on molecular weight, 
compounds were separated on the 2D-column based on additional polar interactions. 
Consequently, the number of C-atoms and the subclass (i.e. polyols, 
monosaccharides, sugar acids or sugar acid lactones; Figure 4.2 panel B) of an 
unknown sugar compound can be deduced based on the chromatographic position in 
the 2D-chromatogram, especially in conjunction with the mass spectra.  
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Figure 4.2. A: GC×GC-SIM-MS chromatogram of a urine QC sample. C4-C7 marks 
the regions, where tetroses, pentoses, hexoses and heptoses elute. B: Image section 
including chromatographic regions for sugar acid lactones, sugar acids, 
monosaccharides, polyols and disaccharides. 
In the Supplemental Tables S4.4-S4.8, the sugar compounds detected in human 
urine with the one-dimensional GC-MS method and the two-dimensional GC×GC-MS 
method are listed separately for the subclasses monosaccharides, disaccharides, 
polyols, sugar acids and others/unknowns. The known sugar compounds from the 
one-dimensional GC-MS sugar profiling were taken from Supplemental Table 3 of 
Publication No. 2 (section 3.2). In general, due to the improved sensitivity and 
separation performance a higher number of sugar compounds in all subclasses could 
be detected using the GC×GC-MS method in comparison to the GC-MS method 
(Figure 4.3). All the known sugar compounds and most of the unknown ones found 
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with the one-dimensional GC-MS method were also detected with the GC×GC-MS 
method, except for some unknown sugar compounds. Only two compounds (ribonic 
and xylonic acid) were separated using the one-dimensional GC-MS method, but 
coeluted using the two-dimensional method. 
 
Figure 4.3. Number of detected sugar compounds in each subclass of sugar 
compounds for the GC×GC-MS and the GC-MS method. 
The improved sensitivity is a result of both the usage of GC×GC-MS and the 
utilization of characteristic mass fragments of sugar compounds. As a result of the 
band focusing in the modulator before the short separation on the 2D-column, the 
analytes reach the detector as very narrow peaks (50-200 ms peak base width), and 
therefore the signal-to-noise ratio and consequently sensitivity is improved 
(section 1.1.3). Another factor playing a role for the increased sensitivity of two-
dimensional GC×GC-MS is that chemical or chromatographic noise (result of column 
bleed and/or solvent tail) is separated as a compressed band from most of the 
analytes [92]. Typically, the sensitivity is increased by a factor of 10, which has been 
discussed exhaustively in the literature [92-94].  
Next to the GC×GC method in general, the usage of the MS in SIM mode enables an 
improved sensitivity through longer dwell times for each selected mass. 
Consequently, a larger number of selected ions reach the electron multiplier and the 
signal intensity, and thus signal-to-noise (S/N) ratio, is increased. To highlight the 
difference in sensitivity between scan and SIM analysis, the mean S/N ratio was 
calculated for the major modulation of 15 selected sugar compounds measured in 
four urine QC samples each. As shown in Table 4.3, sensitivity was on average 
3.2 times higher in SIM mode, compared to Scan mode. Figure 4.4 depicts an 
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overlay of chromatograms of a urine QC sample, which have been recorded in Scan 
and SIM mode while keeping all other parameters constant. The signal intensity of 
the sugar compounds was clearly higher in SIM mode compared to the intensity of 
the same mass traces extracted from Scan data. Therefore, an overall increased 
sensitivity (S/N) by a factor of approximately 32 can be assumed by combining the 
increased sensitivity through the GC×GC method (factor 10) and the SIM mode 
(factor 3.2). Although SIM mode enables an increased sensitivity, there are some 
disadvantages or problems connected to using only a limited number of mass 
fragments. First, identification of compounds is complicated and necessitates 
measurement of reference substances and/or measurement of additional samples in 
Scan mode for identification purposes. Both was performed for this study and proved 
useful in identifying and classifying 84 sugar compounds, although the measurement 
of overall 111 reference substances in 35 runs was somewhat costly in terms of 
measurement time. Another possibility for the future might be a mass spectral 
database of sugar compounds measured with the selected characteristic 11 mass 
fragments, enabling a direct annotation during the processing of data, together with 
RI’s. 
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Table 4.3. Comparison of S/N ratio of the highest modulation of 15 selected sugar compounds in four urine QC samples measured in 
SIM mode and four urine QC samples measured in Scan mode, while keeping all other parameters constant. 
Sugar compounds 
S/N ratio SIM mode S/N ratio Scan mode Average S/N ratio S/N ratio factor 
SIM/Scan 
QC001a QC016b QC017a QC036b 
Scan 
QC01 
Scan 
QC02 
Scan 
QC03 
Scan 
QC04 
SIM Scan 
Arabinose 2127 1126 718 1460 245 262 447 186 1358 285 4.8 
Fucose deriv. 2 193 173 192 1088 50 93 156 81 411 95 4.3 
Fructose deriv. 2 1714 2144 737 874 462 795 657 276 1367 547 2.5 
Glucose deriv. 1 3299 3656 984 1952 1458 1683 1822 1990 2473 1738 1.4 
Sedoheptulose deriv. 1 5794 3393 2641 3525 175 1056 564 444 3838 560 6.9 
Sucrose 1602 1437 789 503 973 445 96 130 1083 411 2.6 
Lactose deriv. 1 469 344 776 496 62 55 73 260 521 112 4.6 
Threitol 2306 3402 1188 2768 246 869 2372 435 2416 981 2.5 
Ribitol 2920 4203 1357 2336 662 1783 687 327 2704 865 3.1 
Sorbitol 949 897 789 1510 306 248 440 386 1036 345 3.0 
scyllo-Inositol 1354 2153 896 2500 1193 555 963 928 1726 910 1.9 
Erythronic acid 1576 2782 1155 1078 1080 1550 2622 910 1648 1540 1.1 
Arabonic acid 1229 1388 754 3361 366 664 556 579 1683 542 3.1 
Glucuronic acid deriv. 1 1346 2277 888 3652 508 594 1277 713 2041 773 2.6 
Levoglucosan 855 691 656 828 66 216 348 264 758 223 3.4 
Average of S/N ratio factor between SIM/Scan for selected sugar compounds   3.2 
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Figure 4.4. Overlay of GC×GC-MS raw data chromatograms of a urine QC sample 
measured in Scan mode (red) and SIM mode (black). All measurement parameters 
except the MS mode (Scan/SIM) were the same. For a comparable depiction of Scan 
mode with SIM mode an extraction of the same 11 m/z used for SIM was utilized. 
Below a section of the chromatogram is increased depicting three sugar compounds 
(mannitol, glucuronic acid and sorbitol; from left to right). 
Second, and maybe most critical, is the choice of the fragments for SIM analysis. As 
a consequence of the set event time of 0.03 s and the acquisition speed of the qMS 
instrument, only 11 mass fragments can be utilized for the GC×GC-SIM-MS 
measurement. The event time was chosen to achieve similar conditions as for the 
GC×GC-Scan-MS workflow for data processing, which was previously established in 
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our lab. The 11 characteristic mass fragments were chosen based on the knowledge 
gained from the semitargeted GC-MS (Scan/SIM) sugar profiling method 
(sections 3.2-3.3). Some characteristic masses such as m/z 204 or 205 were not 
feasible, because their usage would have led to interferences with non-sugar 
compounds and consequently a decreased separation performance. In the end, the 
following m/z were chosen: 160, 277, 292, 305, 307, 318, 319, 333, 361, 421 and 
437 (Table 4.3). However, the chosen 11 mass fragments define the coverage of 
sugar compounds detected in human urine. Rarer sugar compounds, which were not 
in the beginning expected to be detected in human urine, such as 2-deoxyribonic 
acid-1,4-lactone, exhibited none of the chosen 11 masses in their mass spectra, and 
therefore could not be detected using SIM mode. While in case of 2-deoxyribonic 
acid-1,4-lactone, it was possible to detect the corresponding free acid, something 
similar might not be the case for other unusual sugar compounds. One such example 
is methyl-α-glucopyranoside, which was detected in traces in the QC samples 
measured in Scan mode, but not in SIM mode. Most of the masses were used and 
necessary as quantifying ion for at least some compounds. However, both m/z 421 
and 437 were not used as quantifying ions, because for all detected sugar 
compounds other more intense fragments were available. Therefore, in future they 
could be exchanged for other masses, e.g. to detect as yet not covered sugar 
compounds like 2-deoxyribonic acid-1,4-lactone or methyl-α-glucopyranoside. 
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Table 4.3. Selected mass fragments characteristic for sugar compounds [12]. 
Mass fragment Characteristic for Structure 
m/z 160 
C2 fragment of aldoses, absent in 2-
ketohexoses 
 
 
 
 
m/z 292 
sugar acids with 2,3-dihydroxy 
structure, formed by rearrangement 
 
 
 
m/z 305 inositols 
 
 
 
 
m/z 307 
sugars, especially C6 ketoses and 
C5 sugars 
 
 
 
m/z 318 inositols 
 
 
m/z 319 sugars 
 
 
 
 
m/z 333 
sugar acids, often combined with 
m/z 292 
 
 
 
 
m/z 361 disaccharides and glycosides 
 
 
 
m/z 437 
disaccharides, non-methoximated 
TMS derivatives of aldoses 
 
 
 
 
 
Third, an important aspect in relation with the interpretation of the so far relative 
quantitative SIM data, is that no comparison of amounts between sugar compounds 
can be made, because not only response factors of the detector are different (as is 
the case for normal Scan data), but also the heights of mass fragments are not 
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comparable for different sugar compounds. Therefore, as is typically the case for any 
metabolomics experiment with relative quantitative data, the signal intensities of each 
sugar compound are only comparable within different study groups. This problem can 
only be avoided by optimizing the method towards an absolute quantification. 
However, due to the high number of sugar compounds, including even unknown 
sugar compounds, their broad concentration range, the differential influence of the 
background matrix and the limited number of isotopically labeled standard 
compounds, the development of a quantitative method is complex. The only 
reasonable possibility might be to optimize the method for quantification of a selected 
number of well-known and relevant sugar compounds. However, the relevance of 
sugar compounds is highly dependent on the research questions. Therefore, sugar 
compounds for quantification have to be chosen with respect to the aim of an 
investigation. In the end, it has to be stated that the semitargeted sugar profiling 
method has to be viewed as a hypothesis-generating metabolite profiling approach, 
where only in a second step a quantitative method would be developed to prove the 
hypothesis and gain further biological insight. 
Another important reason for the larger number of detected sugar compounds with 
the GC×GC-MS method in comparison to the GC-MS method is the separation 
performance. As mentioned in section 1.1.3 the peak capacity of a two-dimensional 
GC×GC method is increased in a multiplicative way in comparison to one-
dimensional GC. Therefore, separation performance is improved considerably; in 
Figure 4.5, examples for compounds separated in the 2D are depicted. For example, 
ribitol and fucose derivative 1 would completely coelute, if measured one-
dimensional. The same is true in the case of 1-deoxyhexitol and ribonic/xylonic acid, 
glucono-δ-lactone, fructose derivative 2 and mannose derivative 1 and in case of 
neo-inositol and glucose derivative 1 (Figure 4.5). Additionally, the effect of the 
structured retention is observable, i.e. polyols eluting early from the 2D, followed by 
monosaccharides, sugar acids and sugar acid lactones.  
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Figure 4.5. The additional value of the 2D-separation. Compounds only separated in 
the second dimension would coelute in the one-dimensional analysis. 
Although separation performance is considerably improved for the two-dimensional 
method in comparison with the one-dimensional method, in some cases still the 
usage of the SIM masses for separation from matrix compounds and/or other sugar 
compounds is necessary (Figure 4.6). However, the choice of characteristic masses 
enables a sufficient separation from non-sugar compounds and the matrix. While 1-
deoxyhexitol A0494_H2_H1 and the unknown sugar acid U09/A0510 coeluted 
completely, if measured in Scan mode (panel A, 1.-2.), a separation based on the 
independent mass fragments m/z 292 (unknown sugar acid U09/A0510) and m/z 319 
(1-deoxyhexitol A0494_H2_H1) could be achieved (panel A, 4.). Another example is 
the separation of psicose derivative 1 from the non-sugar compound quinic acid, 
which are both partially coeluting in 1D, i.e. at least 1-2 modulations are completely 
overlapping in Scan mode (panel B, 1.-2.). Nonetheless, using the characteristic 
mass fragment m/z 307 for psicose derivative 1, a complete separation from quinic 
acid can be achieved (panel B, 4.).  
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Figure 4.6. Panel A: 1. Absolute coelution of 1-deoxyhexitol A0494_H2_H1 (green 
line) and unknown sugar acid U09/A0510 (blue line) depicted as TIC chromatogram. 
2. MIC chromatogram of the same compounds with the mass fragments m/z 277, 
292, 319 and 333 measured in Scan (red line) and SIM (black line) mode. 3. Mass 
spectra measured in Scan mode for 1-deoxyhexitol A0494_H2_H1 and unknown 
sugar acid U09/A0510. 4. Chromatogram measured in SIM mode, depicting 
separation via m/z 292 and 319. Panel B: 1. Partial coelution of psicose derivative 1 
(green line) and quinic acid (blue line) depicted as TIC chromatogram. 2. MIC 
chromatogram of the same compounds with the mass fragments m/z 277, 307, 421, 
437, 255 and 345 measured in Scan (red line) and SIM (black line) mode. 3. Mass 
spectra measured in Scan mode for psicose derivative 1 and quinic acid. 4. 
Chromatogram measured in SIM mode, depicting separation via m/z 307.  
Further important aspects for the comparison of the optimized GC×GC-MS method 
and the GC-MS sugar profiling method are repeatability and robustness during long 
measurement series. For the one-dimensional GC-MS measurement of the KarMeN 
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study urine samples, 312 study samples and 144 QC samples were measured. With 
264 study samples and 144 QC samples, the GC×GC-MS sugar profiling method is 
comparable with respect to the number of samples. However, the one-dimensional 
method has a much shorter run time with 42 min in comparison to 75 min with the 
two-dimensional method, which resulted in 14 batches for the GC-MS method and 24 
batches for the GC×GC-MS method. Retention times for both methods were 
comparably stable and within an acceptable range. While in the case of the one-
dimensional method the peak integration time frames had to be adjusted during data 
processing, in the case of the two-dimensional method a shifting of retention times 
(no more than two modulations) was performed to ensure reliable alignment of 
clusters. In the Supplemental Table S4.9, the inter- and intra-day coefficients of 
variation (CV’s) of all sugar compounds for the GC×GC-MS method are listed 
together with information on trace and saturated analytes, occurrence of coelution, 
median heights and frequency in the QC and study samples. The distributions of 
intra- and inter-day CV’s before drift/batch correction for the sugar compounds 
detected with the two-dimensional GC×GC-MS method is depicted in Figure 4.7. 
Although the repeatability of the two-dimensional method is slightly worse in 
comparison to the one-dimensional method (Supplemental Table 4 in section 3.2), it 
is still sufficient for a semitargeted metabolite profiling approach with intra-day CV’s 
below 15% for 87% of the sugar compounds (Figure 4.7). The slightly better 
repeatability of the one-dimensional method might be related to the number of data 
points for each peak: while with the GC-MS method most sugar compounds had 
about 9-15 data points, in the case of the GC×GC-MS method only 5-9 data points 
were achieved due to the narrow peaks (Supplemental Table S4.10). For an 
adequate and precise recording of a peak about 7-10 data points per peak are 
necessary [28, 33]. While this criterion is easily fulfilled in the one-dimensional method, 
the data acquisition speed of the qMS does not allow an optimal reconstruction of the 
narrow two-dimensional peaks. Nonetheless, next to an improved sensitivity and 
separation performance, a good repeatability over the measurement series with 
overall 431 samples was achieved for the two-dimensional GC×GC-MS method.  
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Figure 4.7. Distribution of CV’s in QC samples without correction, left: inter-day CV; 
right: mean intra-day CV.  
The data processing for the GC×GC-MS measurement had to be adjusted for the 
usage of SIM mode. Therefore, the peaklet-based generic analysis of untargeted 
GC×GC-Scan-MS data [31, 91] was taken as a basis for the development of a SIM-
adapted workflow. A number of problems had to be addressed for this optimization:  
• One run essentially consists of 11 specific ion mass chromatograms leading to 
up to 11 mass fragment peaks reported for one modulation (peak). It is clear 
that this acquisition mode may result in very large data, especially in the case 
of complex samples. 
• The parameters for the alignment and especially the calculation of mass 
spectral similarity for Scan data were optimized for a m/z range of 
approximately 500 amu, while for SIM-data only 11 m/z are available. 
Therefore, a step-wise adjustment of different parameters (such as mass 
spectral similarity ε or HC value) in different steps during the alignment is 
necessary. 
• The fact that only 11 fragments are available causes more often the necessity 
of a height profile splitting due to the highly similar mass spectra of isomeric 
sugar compounds (Supplemental Figure S4.1, part E). So far, the height 
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profile splitting is based on the cumulative heights of all runs and results in 
one split time over all runs. The RT-shifting in modulations during long 
measurement series can lead to a faulty split for individual samples 
(Figure 4.8), and this even though a rudimentary shifting of RT was already 
performed. There are two potential future solutions for this problem, i) a more 
complex correction of the RT-shifting (including non-linear shifting depending 
on chromatographic region); or ii) performing the splitting based on each 
individual run. However, both solutions necessitate complex bioinformatics 
processes and cannot be easily implemented. 
Figure 4.8. Height profile of psicose derivative 2 and fructose derivative 1 for the 
aggregated modulations of all runs and for two individual runs during the 
measurement series. Due to their identical mass spectra they were combined in one 
cluster and had to be splitted using their height profile. In red the global split time is 
depicted and in green the split time if performed individually for each run. 
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4.4 Conclusions 
The optimization of the so far one-dimensional GC-MS sugar profiling towards a two-
dimensional GC×GC-SIM-MS method was successful, and has a number of 
advantages, the two most important being the improved sensitivity and separation 
performance leading to the detection of overall 84 sugar compounds. Method 
repeatability was good with mean intra-day CV’s (uncorrected) of less than 15% for 
87% of the sugar compounds over a long measurement series with overall 
431 samples and 24 measurement days. The GC×GC-SIM-MS sugar profiling 
method will in future enable the reliable measurement of a large number of sugar 
compounds in biological samples. Some optimization of the data processing 
procedure is still necessary. However, good results can already be achieved with the 
workflow described here. In future, this method can have an important contribution to 
investigate the metabolism of sugar compounds and will enable the identification of 
further dietary markers. In Figure 4.9, some first impressions of the biological results 
of the FoodBAll study are depicted. A number of sugar compounds (e.g. threitol, 
fructose, sucrose, etc.) increased after the interventions with apple and/or coca cola, 
but not in the water control. Some of the sugars increase solely after the 
consumption of the apples and therefore might be promising candidates as markers 
of apple consumption. 
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Figure 4.9. Line plots for a number of sugar compounds increasing after apple and/or coca cola intake in urine samples, but not in the 
control. Each colored line stands for one participant. 
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5 DISCUSSION AND CONCLUDING REMARKS 
Within this thesis, putative markers for dietary intake (sections 3.1, 3.2 and 4) and 
health status (sections 3.2 and 3.3) were identified using two different GC-MS based 
metabolite profiling approaches: a semitargeted sugar profiling and a broader, more 
untargeted VOC analysis. This section aims for an overarching discussion, starting 
with the classification of the applied GC-MS based metabolite profiling approaches 
within the broader concept of metabolomics in general. Thereafter, aspects of the 
discovery of dietary markers are discussed, followed by an outlook with respect to 
validation of the putative dietary markers identified in this thesis. Last, the application 
of the semitargeted sugar profiling method towards the discovery of markers for 
health status, especially with respect to changes in the plasma sugar profile of 
participants with type 2 diabetes mellitus is addressed. 
General classification of the applied GC-MS based metabolite profiling approaches 
In general, targeted analysis, metabolite profiling, untargeted metabolomics and 
metabolite fingerprinting can be differentiated. By definition metabolite profiling 
approaches, as applied in this thesis, lie in between targeted analysis and untargeted 
metabolomics approaches. Important aspects for the differentiation of those three 
approaches are sample preparation, quantification and identification. 
While for targeted analysis always an absolute quantification and for untargeted 
metabolomics so far mostly a relative quantification is performed, in the case of 
metabolite profiling approaches both relative and absolute quantification is possible. 
However, more and more scientists demand absolute quantification as the standard 
for all metabolomics approaches [36, 41], although this will confront the analytical 
scientists with a number of challenges. These challenges were also the reason that 
the metabolite profiling approaches developed and utilized in this thesis were of a 
relative quantitative nature. In general, absolute quantification can be performed 
using i) calibration curves either in solvent or in matrix; ii) standard addition 
approach; or iii) isotopically labelled standards (e.g. isotope dilution analysis). Given 
the sheer number of metabolites, including a huge number of unknown or unusual 
compounds for which no standards are available, their broad concentration range, 
the relevant influence of the background matrix on quantification and also the limited, 
and cost-intensive assortment of commercially available isotope-labeled 
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standards [95], the effort for the development of an absolute quantification method is 
enormous and time-consuming. In addition, a number of compromises and potential 
biases most likely will be included, such as e.g. using an isotopically labelled 
standard A for a chemically different compound B. A first question here is, whether 
the advantages of an absolute quantification will outweigh the necessary effort and 
potential biases and the second question is, whether these biases are comparable to 
those resulting from a relative quantification. In metabolomics investigations of plant 
material or microorganisms, another possible, yet cost- and time-intensive, approach 
is the accurate normalization on a whole isotopically labelled metabolome, which is 
added as a kind of internal standard. Such an isotopically labelled metabolome is 
generated by cultivation on fully labelled substrates with 13C, 15N or 18O [96, 97]. 
However, this is not possible for investigations of human samples, but an interesting, 
yet also cost- and time-intensive, alternative might be the application of isotopically 
labelled reagents to create for example an isotopically labelled urine sample [98]. 
Within the scope of the semitargeted sugar profiling, an absolute quantification would 
be feasible, especially for selected biologically important sugar compounds, to 
investigate a defined scientific question. The most important advantage of an 
absolute quantification in contrast to relative quantification would be that a 
comparison of amounts between sugar compounds (e.g. glucose and fructose) is 
possible (section 4). 
Identification is one of the other important aspects for differentiation of metabolomics 
approaches. While in the case of targeted analysis all measured compounds are 
clearly defined and known, in the case of metabolite profiling approaches additionally 
to a priori known compounds, unknown compounds belonging to the targeted 
substance class or selected pathway are included (see semitargeted sugar profiling 
approach, sections 3.2-3.3, 4). In contrast, for untargeted metabolomics, 
identification is most often performed after statistical analysis for those compounds 
showing e.g. significant p-values. In this respect, and with respect to the range of 
chemically diverse substance classes belonging to VOC’s, the applied VOC method 
(section 3.1) might on the one hand be considered an untargeted metabolomics 
(volatilomics) analysis. On the other hand, in contrast to an untargeted metabolomics 
analysis, the sample preparation was specific for volatile compounds and as a result 
limited to a subclass of metabolites showing a certain characteristic or property (in 
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this case volatility). Therefore, the VOC analysis might also be considered a 
metabolite profiling approach.  
Identification is one of the most essential aspects in any metabolomics approach and 
at the same time one of the major challenges [12]. Without identification, no biological 
interpretation or mechanistic elucidation is possible. To ensure proper identification, 
the Metabolomics Standard Initiative (MSI) proposed a classification of metabolite 
identification into four levels ranging from unknown compounds to absolutely 
identified compounds [99]. The most important resources for identification in GC-MS 
based metabolomics approaches are comprehensive EI-MS based spectral 
databases, such as NIST, Fiehn Lib, Golm Metabolom Database (GMD) or Wiley 
database, which include both mass spectral and RI information (based on alkanes or 
FAME) for library matching of derivatized and underivatized compounds [2, 12, 100]. 
Those can successfully be utilized across different laboratories due to highly 
reproducible mass spectra with a standardized ionization energy of 70 eV [100, 101]. In 
this thesis, identification of volatile marker candidates was performed using such EI-
MS based spectral databases with mass spectral and RI information (section 3.1). 
However, library matching and spectral similarity can lead to ambiguous 
identification: 
• due to problems resulting from signal deconvolution, chemical derivatization or 
column degradation [100];  
• due to indistinct mass spectra as a result of trace analytes or saturated 
analytes; 
• in the case of RI comparison due to subtle differences in stationary phases [12];  
• additionally, erroneous and misdirecting entries in mass spectral databases, 
such as NIST or Fiehn Lib, are possible; 
• and especially due to uninformative, identical or highly similar mass spectra 
e.g. in case of isomeric compounds.  
Consequently, in the case of the sugar profiling with many structurally similar isomers 
and almost identical mass spectra, unambiguous identification was performed using 
standard compounds (section 3.2-3.3, 4). Even so, both in case of the sugar profiling 
and VOC analysis several compounds remained unknown. Dunn et al. [102] found that 
using EI-MS based databases only about half of the detected metabolites can be 
annotated using library matching. So, how can the number of annotated metabolites 
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be increased? In principal, mass spectral databases have to be expanded in future 
with more and more metabolites and this not only for EI-MS based databases, but 
also for new instrumental set-ups like high-resolution/high accuracy mass analyzers, 
for example Orbitrap or Q-TOF, as well as CI-MS based databases [100]. In general, 
EI-MS spectra can give hints for elucidation of the structure of an unknown 
compound (e.g. about functional groups) [2, 12, 100], especially if additional information 
such as RI or structured retention in the case of GC×GC (section 4) is available. 
However, this requires time and considerable chemical and analytical expertise 
regarding fragmentation reactions and fragment structure [12]. Otherwise, high-
resolution MS (such as Orbitrap, TOF or Q-TOF) enable the calculation of the 
empirical chemical formula of a metabolite via accurate mass and relative isotopic 
abundance. Together with the fragmentation, structural elucidation of unknown 
compounds is possible. Similarly, MS/MS experiments can be used to gain 
information on the fragmentation behavior and therefore about the structure. Both, 
calculation of the empirical chemical formula and also MS/MS experiments 
necessitate an abundant detection of the molecular ion or pseudo-molecular ion, 
which is usually of low intensity or not present at all in EI-MS spectra of trimethylsilyl 
derivatives. Consequently, alternative soft ionization methods resulting in an 
abundant molecular ion are necessary, such as positive ion chemical ionization CI(+), 
cold or soft EI (lower ionization energy), field ionization, photo ionization, electrospray 
ionization or atmospheric pressure chemical ionization (APCI) [101]. Nevertheless, all 
the above mentioned possibilities will reach their limits in the case of structural 
isomers such as sugar compounds, because e.g. glucose and galactose will result in 
the same molecular ion and highly similar fragmentation patterns. In principal, ion 
mobility spectrometry (IMS) coupled to MS, enabling separation of ionized molecules 
depending on their mobility in a carrier buffer gas, might be an interesting method for 
the separation of such isomers [103, 104]. Nonetheless, these problems of structural 
isomers highlight the necessity of chromatographic separation, which is the reason 
why the original one-dimensional GC-MS sugar profiling method was transformed 
towards a two-dimensional GC×GC-MS method, which enabled better separation 
performance, higher sensitivity and additional information on subclasses due to 
structured retention (e.g. polyol vs. monosaccharide vs. sugar acid; section 4). 
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Comparing physiological and mechanistic links revealed by untargeted 
metabolomics, metabolite profiling approaches and targeted analysis, Sévin et al. [7] 
found that most mechanistic links were revealed by hypothesis-driven targeted 
analysis or narrower metabolite profiling approaches. This can most likely be 
attributed to the narrower perspective on a specific pathway or substance class in 
hypothesis-driven approaches. Therefore, a deeper elucidation and interpretation of 
metabolic pathways is possible, a typical example is the usage of lipidomics [42]. 
Often metabolite profiling approaches enable a more coherent interpretation of the 
relations between the covered metabolite profile and a biological question [7, 41]. 
Subtle changes in the metabolome due to, for example the diet, are unlikely to be 
discovered using standard untargeted metabolomics approaches, these often 
necessitate more specified metabolite profiling approaches [53]. Nonetheless, 
untargeted metabolomics approaches often reveal unexpected and important 
insights, but strategies for the interpretation of highly complex metabolic patterns and 
integration of results into mechanistic physiological pathways still need to be 
developed and expanded, e.g., by using novel computational approaches [7]. 
Additionally, untargeted metabolomics is considered as a hypothesis-generating 
approach and most often results will lead to the development of a targeted method to 
confirm a hypothesis generated by an untargeted metabolomics approach.  
Discovery of markers for dietary intake 
The putative markers identified in this work (e.g. mannoheptulose and perseitol for 
avocado consumption, lactose and galactose for dairy product consumption, 3,4-
dimethyl-2,5-furandione for coffee consumption or trehalose for the differentiation of 
time-courses after an OGTT in healthy, prediabetic and diabetic volunteers; sections 
3.1-3.3) were identified in a data-driven or hypothesis-generating approach. While so 
far most markers used in practice were identified hypothesis-driven, this might 
change in the future and more and more markers will be identified using hypothesis-
generating metabolomics approaches. However, metabolomics approaches can help 
also for hypothesis-driven identification of potential dietary markers by building 
databases with metabolite profiles of the foods themselves. Using such databases, 
marker candidates might be identified by comparing the occurrence of a potentially 
specific food component with its occurrence in other foods. An example for such a 
database is the FooDB, which is so far the presumably most comprehensive 
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resource on food constituents, chemistry and biology, covering more than 25 000 
native food compounds (macro- and micronutrients), additives and compounds 
derived from food processing [105, 106]. A crucial point of such databases is the 
question, whether the information in these databases are only “collected” using 
algorithms or whether the information is also checked for reliability, which is a 
demanding and labor-intensive part. Other relevant databases are national nutrient 
databases such as the German nutrient database, which is supervised and quality-
controlled by the Max Rubner-Institut [107]. Furthermore, more specified databases 
such as the Phenol-Explorer for polyphenols exist [108]. In the metabolomics 
workgroup of the MRI, also first steps towards building a metabolite profile database 
of fruit and vegetables were performed by a comprehensive screening of primary 
metabolites in overall 33 fruit varieties and 41 vegetable varieties (see list of 
supervised master and diploma theses). A good example, how such metabolite 
profile databases might enable the hypothesis-driven identification of dietary 
markers, is pinitol for soy. During the comprehensive screening of 41 vegetable 
varieties in our workgroup, it was detected in high amounts in soy beans, but not in 
other vegetable varieties (data not shown). Within one of the intervention studies of 
the FoodBAll consortium, Münger et al. [70] were able to identify pinitol as a candidate 
marker for a soy drink. This clearly demonstrates the benefits of expanding the 
application of metabolite profile databases. 
Validation of markers for dietary intake 
Validation is a vital step before any marker can be used in practice, e.g., to 
objectively measure dietary intake or as a clinical marker. As described in the 
introduction (section 1.2.2), validation serves to ascertain, which confounding factors 
contribute and how strong their contribution to the variability of the marker is, 
meaning the consumed amount of a certain food. Dragsted et al. [74] proposed the 
first comprehensive scheme for validation of dietary markers within the frame of the 
FoodBAll project. The scheme is meant to demonstrate both, the current level of 
validation and also the necessity for additional studies for full validation of a 
candidate marker. The validation concept includes eight criteria (section 1.2.2) 
provided as questions, which can be answered with yes, no or data not available 
(Supplemental Table S5.1). However, answering these questions unambiguously 
might be difficult and the particular value of each criterion depends on the intended 
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purpose of the marker. Therefore, explanatory comments and conditions under which 
these questions were answered, should be added to substantiate the degree of the 
validation [74]. The exemplary application of the validation scheme on selected 
candidate markers identified in this thesis (mannoheptulose and perseitol for 
avocado consumption, galactose and lactose for dairy product consumption, xylitol 
and ethyl-β-glucuronide for alcohol consumption and 3,4-dimethyl-2,5-furandione for 
coffee consumption) is depicted in Figure 5.1. Additionally, in Supplemental Table 5.1 
the concrete answering of the validation questions is provided, exemplified for 
mannoheptulose and perseitol as putative markers for avocado consumption (section 
3.2). In the figure, some critical points are marked by half circles, because an 
unambiguous answer with yes, no or no data available was not possible here. 
 
Figure 5.1. Application of the validation scheme developed by Dragsted et al. [74] on 
a selection of putative markers identified in this thesis. The eight validation criteria 
are depicted in columns and the putative markers in rows. Green circles: validation 
question answered with yes; red circles: validation question answered with no; grey 
circles: no data available; half circles: conditional yes, but more data necessary; 
answer is dependent on the strictness in application of the scheme. 
In general, the proposed eight criteria meet the most important aspects to validate 
candidate markers of dietary intake. Some ambiguities with respect to the application 
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of the validation scheme are discussed in the following paragraphs together with the 
general applicability and advantages. 
As pointed out above, building and expanding comprehensive metabolite profile 
databases will help to establish plausibility and specificity of putative markers in the 
future. It is somewhat surprising that specificity as such, has not been included as a 
separate criterion in the validation scheme of Dragsted et al. [74], but it is included 
within the criteria plausibility and robustness. This might cause confusion with 
respect to the definition and application of these criteria. For example, mannitol was 
associated with mushroom intake in the cross-sectional KarMeN study (300 free-
living individuals with a highly diverse diet) and therefore can be considered as 
robust (section 3.2). Additionally, as a compound naturally occurring in mushrooms, it 
can also be considered as plausible. However, it cannot be considered as specific, 
due to its occurrence in a number of other fruit and vegetables (screening of fruit and 
vegetables, section 3.2), therefore, neither a quantitative nor a qualitative 
assessment of mushroom consumption is possible. In this respect, it would be more 
conclusive to classify specificity as a separate criterion to avoid confusion. 
With respect to specificity, another interesting aspect is the use of single markers vs. 
multiple markers for a certain food, which so far is practically unexplored [56]. In the 
case of multiple markers, specificity, reliability and robustness might be achieved 
through the combination of compounds. Statistical methods enabling the inclusion of 
multiple compounds as potential markers for one food should both help to select new 
panels of markers and also to strengthen their validity through complementary 
combination. For example, stepwise logistic regression analysis enables the inclusion 
of more than one metabolite in marker panels and regression against dietary intake 
data for identification of multiple marker panels; other approaches include 
multivariate strategies such as PCA, PLS, random forest or support vector machine 
algorithms [56]. Multiple marker panels will enable more accurate estimation of dietary 
intake, especially if additionally combined with data from traditional dietary 
assessment methods [56]. Within this thesis, multiple markers for one food were also 
detected, e.g., mannopheptulose and perseitol for avocado consumption. 
Mannoheptulose is less specific than perseitol due to its occurrence in other foods. 
However, it is more abundant in urine and thus detected more frequently. Therefore, 
the complementary combination of both avocado markers might result in a more 
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accurate quantification, where the lower specificity of mannoheptulose is attenuated 
by additional consideration of perseitol. However, statistical approaches in this 
direction still need to be developed. 
A criterion causing ambiguities in its interpretation and application is reliability. 
Dragsted et al. [74] require confirmation studies with highly controlled settings (e.g. 
supervised intake with known exact amounts) to compare the performance of the 
putative marker to indicate true dietary intake against a gold standard. However, in 
practice, for almost no newly discovered dietary marker, a gold standard or reference 
method for comparison is available. Thus, the current best practice is comparison 
with traditional dietary assessment methods or, if several putative markers for the 
same food were discovered at the same time, they may be validated for reliability 
against each other [74]. However, Dragsted et al. urge for care in interpreting reliability 
in such cases, as both approaches are not without pitfalls, e.g. misreporting in case 
of comparison against traditional dietary assessment methods (see introduction 
section 1.2.1 and 1.2.2). Consequently, the question on how to exactly apply the 
criterion reliability remains unclear. 
In general, more rigid criteria to unambiguously answer the validation questions with 
yes or no for each criterion might be helpful to decide, if a criterion can be considered 
as fulfilled or not (Figure 5.1). For example, in the case of dose-response 
relationship, it should be differentiated between the establishment of the criterion in a 
cross-sectional study or in an intervention study, especially in the light of the 
quantitative assessment of dietary intake. In a cross-sectional study, bias through the 
background diet, the utilization of self-reported intake and the necessity to define 
food variables (e.g., not only black coffee, but also milk coffee, cappuccino etc. were 
included for coffee consumption; section 3.1) influence quantification of dietary 
intake. In contrast, the study food during an intervention is well-defined and different 
intake amounts are compared with a normally not interfering background diet. 
Therefore, a classification within each criterion, together with more rigid criteria is 
necessary to determine validity. Such criteria were already mentioned by Dragsted et 
al.; however, further work will be necessary to define such a classification, depending 
on the different intended purposes of markers [74]. Another aspect that should be 
considered to define whether a criterion can be classified as fulfilled, is the quality 
and the significance of the studies used for validation. This includes aspects such as 
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e.g., number of study participants, well-defined intervention food, standardization of 
the background diet, run-in and wash-out periods during a study, etc. For example, 
mannoheptulose and perseitol as putative markers for avocado consumption were 
identified in the cross-sectional KarMeN study and therefore, can be considered as 
robust; however, only nine out of 300 participants consumed avocado. Also, with 
respect to the criteria time- and dose-response, the intervention study with avocado 
by Wamelink et al. [109] was performed with only three volunteers. Considering the low 
number of volunteers in both studies, the need for studies with more volunteers 
should be highlighted here (see half circles Figure 5.1).  
Another ambiguity concerns the last three validation criteria addressing the validity of 
the analytical method and the clear differentiation from the first five validation criteria 
addressing biological validity. Within their validation scheme, Dragsted et al. [74] 
address both biological and analytical validity; however, both should be viewed as 
independent aspects. On the one side, the first five criteria and in part also the 
criterion stability (chemical and biological) might be considered as intrinsic criteria of 
a putative marker, addressing whether a metabolite fulfills biological validity. On the 
other side, the analytical performance addresses requirements, which are necessary 
to obtain valid results while discovering new markers and also while applying a 
biologically valid marker. Therefore, analytical performances (i.e. analytical validity) is 
a requirement for both, the method used for marker discovery (likely untargeted), and 
the method used for application of a biologically valid marker (likely targeted). 
However, Dragsted et al. [74] consider analytical performance mainly related to the 
question, whether qualitative or quantitative analysis is possible using a putative 
marker or whether the development of a quantitative targeted method is feasible. Yet, 
this remains unclear, if only the validation questions (see Supplemental Table 5.1) 
are considered. Despite the fact that analytical validity should be viewed as an 
independent step, some aspects of the criteria for biological validity are also 
dependent on the actually used analytical method. For example, defining the range of 
intake that could be measured with a certain putative marker does not only depend 
on the marker itself, but also on the limit of detection and linearity range of the 
applied analytical method. Overall, the application and interpretation of the criterion 
analytical performance seems incomplete and unclear. Combining different methods 
in the literature to validate a putative marker has to be reviewed and interpreted 
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critically, because a full validation, both biologically and analytically, should be 
carried out with the method intended for use in practice. Overall, all aspects causing 
ambiguities (as discussed in the paragraphs above) should be addressed in a further 
development of the validation scheme.  
After discussion of the general applicability of the scheme [74], the practical 
application of the validation scheme on the putative marker candidates identified in 
this thesis, are discussed in the following paragraph. The scheme clearly revealed 
the necessity for further studies to validate the candidate markers discovered in this 
thesis (Figure 5.1 and Supplemental Table 5.1). So far, all marker candidates might 
only be considered as plausible qualitative markers of dietary intake, with the 
exception of ethyl-β-glucuronide, which is routinely and quantitatively used for the 
proof of abstinence [110]. However, its application is questionable due to problems 
with respect to robustness, reliability and stability (section 3.2). For evaluation of the 
putative markers identified in this thesis as quantitative markers of dietary intake, 
further controlled intervention studies with different doses of food intake and no 
influencing background diet will be necessary. So far, dose-response was 
established in a cross-sectional study, thus only half circles were applied in 
Figure 5.1. With the exception of 3,4-dimethyl-2,5-furandione and xylitol, time-
response after a single meal was established for the candidate markers in the 
literature [70, 109, 111] (also sections 3.1-3.2), although in the case of mannoheptulose 
and perseitol only a limited number of participants was available (Figure 5.1). No 
literature can be found about the influence of repeated intake on the putative markers 
(e.g. inhibition or activation of enzymes, accumulation etc.), therefore highlighting the 
need for further investigations in this respect. Robustness can be assumed to a 
certain degree for all putative markers, due to the establishment within the cross-
sectional KarMeN study with unrestricted background diet, except for 
mannoheptulose and perseitol (limited number of participants) and ethyl-β-
glucuronide (section 3.2). Additionally, reliability (i.e. comparison of the marker 
performance with other described markers or a dietary assessment method) has to 
be evaluated in the future. For example, in the case of coffee, reliability might be 
assessed via measuring caffeine metabolites or trigonelline [68] and in the case of 
milk via measuring pentadecanoic acid in serum and adipose tissue for total dairy fat 
intake [112]. Considering analytical validity (stability, analytical performance and inter-
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laboratory reproducibility), first targeted methods for the application of the candidate 
markers have to be developed for all candidate markers. 
Overall, it can be concluded that in principle both metabolite profiling approaches 
(sugar profiling and VOC analysis) applied in this thesis enabled the detection of 
putative markers for dietary intake, which after further validation might be applied for 
a more objective measurement of dietary intake, monitoring of compliance in studies 
or validation of traditional dietary assessment methods. Using these metabolite 
profiling approaches, further potential dietary markers will be discovered in the future 
(section 3.1 Table 4: e.g. 2-pentylfurane for bread, section 3.2 Table 4 and Figure 4, 
or see section 4 Figure 3.9: putative markers for apple and coke consumption). 
Expanding the number of available validated dietary markers is imperative to improve 
the understanding of the influence of the diet on health and disease. For example, 
measurement errors in self-reported intake of sugar (due to misreporting) prevent 
finding consistent epidemiologic evidence on the association between sugar and 
disease risk (e.g. for cardiovascular disease (CVD), type 2 diabetes and cancer links 
have been ambiguous and inconclusive) [58]. Here, dietary markers for sugar intake 
might enable obtaining objective and accurate estimates of intake and circumvent 
problems associated e.g. with underreporting [113, 114].  
Another point relevant for obscured and inconsistent associations between diet and 
health is the complexity of the diet itself. Any food consists of several hundred 
compounds, and each of them might have positive, negative, synergistic or 
cumulative health effects that may depend on the food matrix composition. 
Therefore, it is highly recommended to analyze the composition of any food under 
investigation for a health effect. Metabolomics approaches (untargeted metabolomics 
or metabolite profiling approaches) can help to facilitate the understanding of the 
complex and dynamic responses of the human metabolism to nutrition in two 
complementary ways. First, metabolite profile databases of the food itself will help 
understanding the complexity of the food itself (see above).  
Discovery of markers for health status 
Second, metabolomics approaches are of high interest to identify new biomarkers for 
defining or describing health status and early disease states. To demonstrate this, 
the developed semitargeted sugar profiling method was applied to investigate the 
sugar profile in plasma of healthy, prediabetic and diabetic volunteers after an OGTT 
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(section 3.3). Interestingly, although type 2 diabetes is primarily characterized by a 
disturbance in glucose metabolism, other sugar compounds have only rarely been 
investigated. The application of the sugar profiling method enabled the detection of a 
complex plasma sugar profile and revealed further sugar compounds next to glucose 
showing characteristic differences depending on health status (section 3.3). 
One could argue whether new biomarkers for diagnosis of T2DM are required, given 
that well-established and easily measurable biomarkers such as glucose and HbA1C 
already exist. However, metabolomics approaches enable generating whole 
signatures of multiple metabolites, and therefore have the potential for sensitive and 
accurate detection of a disease state [7]. This is especially relevant for early diagnosis 
of disease, where additional parameters might result in a better prediction of the risk 
for certain diseases. Early diagnosis of T2DM is highly relevant, because during this 
period effective preventive measures are available; remarkably enough, still half of 
the people having T2DM remain undiagnosed for years [86] and during this time many 
of the later emerging complications already develop. The prediction of the 
development and severity of these complications might be further facilitated by 
metabolomics approaches. In multifactorial diseases such as T2DM, the phenotype 
is highly dynamic and complex because various factors (genetic, life style, 
environmental, etc.) have an influence on manifestation and lead to several different 
subtypes [3]. The classification of metabolic subtypes of a disease via multiple 
metabolite signatures might open up the possibility of personalized treatment. 
Detecting metabolic subtypes in a dynamic system is best evaluated during a 
metabolic challenge, such as the OGTT performed for diagnosis of diabetes [3]. 
Performing the OGTT with healthy, prediabetic and diabetic subjects and measuring 
the resulting response in the sugar profile showed that, contrary to expectations, a 
number of further sugar compounds showed characteristic health status-dependent 
changes (section 3.3), which in future may serve as biomarkers of early stage T2DM. 
Additionally, using the sugar profile might enable the differentiation of subtypes in the 
disease or the likelihood for certain complications, enabling better prevention, 
monitoring and therapy. To investigate this, an intervention study with a large 
collective of participants (prediabetic and diabetic) performing an OGTT would be 
necessary. In our study, no assessment of subtypes was possible due to the limited 
number of volunteers (only 15 healthy, 15 prediabetic and 11 diabetic volunteers). 
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And similarly to dietary markers, an extensive evaluation and validation of the 
changes in the sugar profile has to be performed, before the sugar profile as a whole, 
or single sugar compounds might be used as biomarkers. The first and most 
important step would be the investigation of the causal link/plausibility between the 
characteristic differences in health status observed, for example for mannose, 
trehalose or xylose (section 3.3) and therefore, the understanding of how they might 
serve as biomarkers. Additional research/interventions with stable-isotope labeled 
glucose will help to verify, whether these compounds were derived from glucose 
during the OGTT and give first hints on the mechanistic links of these sugar 
compounds and T2DM disease state. Further validation criteria address similar 
aspects as those for dietary markers [53]: specificity for the disease, defining threshold 
levels for disease stage, defining time-lines/levels/thresholds for progression of the 
disease, robustness in the population, reliability of diagnosing a disease and 
analytical aspects (stability of the marker compounds, analytical performance and 
inter-laboratory reproducibility of the final biomarker-assay) need to be considered.  
Overall, the sugar profiling method enabled unexpected insights into human 
physiology, even though no explanation of the underlying mechanisms can be 
provided yet. Maltose enabled the differentiation of the menopausal state in women 
(section 3.2), but the link with vaginal glycogen and Lactobacilli counts in vaginal fluid 
as a result of reduced estrogen concentrations needs to be confirmed in future. The 
occurrence of psicose in urine and also the increase of psicose after an OGTT, the 
causality underlying the excretion of xylitol after alcohol consumption, and also the 
above mentioned sugar compounds potentially indicating diabetic state, both in 
fasting state and after an OGTT (e.g. trehalose; section 3.3), raise a number of 
questions with respect to the depth of our understanding of carbohydrate metabolism 
in health and disease.  
In conclusion, both metabolite profiling approaches developed in this thesis, the 
semitargeted sugar profiling and the VOC analysis, are valuable and useful tools 
allowing the identification of markers of dietary intake and also markers of health 
status and disease states as demonstrated in application studies.  
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7 SUPPLEMENT 
Supplemental Table S1.1. Overview of several definitions and classifications of biomarkers/markers used in nutritional research [50-53]. 
Classification Definition 
Based on function Biomarkers of dietary exposure: assess dietary intake of different foods, nutrients, non-nutritive components or dietary patterns 
Biomarkers of nutritional status: reflect not only dietary intake but also metabolism of nutrients and possible effects from disease 
processes  
Biomarkers of health/disease: related to different intermediate phenotypes of a disease or even to the severity of the disease 
Based on application Exposure/intake biomarker: reflects level of extrinsic variables that humans are exposed to, such as diet or food compounds  
Food compound intake biomarkers: divided in nutrient and non-nutrient intake biomarkers, have distinctive dose- and time-dependent 
response after intake  
Food or food component intake biomarkers: measure intake of specific food groups, foods or food components (such as ingredients), 
have distinctive dose- and time-dependent response after intake  
Dietary pattern biomarkers: reflect the average diet of an individual, distinguish different dietary habits 
Effect biomarker: divided in functional response biomarkers and risk-effect biomarkers; monitor changes in biochemical, physiological 
or psychological state as a response to nutritional exposures 
Susceptibility biomarker: measurable indicator including genetic or acquired host factors and intrinsic factors, individual susceptibility or 
resilience to an exposure predicting intensity of its effect on the individual  
Food compound status biomarkers: divided in nutrient and non-nutrient intake biomarkers, reflect the current body burden or status of 
compounds from food  
Physiological or health state biomarkers: divided into host factor biomarkers (personal intrinsic quality or trait influencing susceptibility 
to disease) and risk (personal intrinsic quality or trait influencing susceptibility to develop a disease) biomarkers 
Based on temporality Short-term/acute biomarkers: reflecting intake over past hours/days  
Medium-term biomarkers: reflecting intake over weeks/months  
Long-term biomarkers: reflecting intake over months/years 
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Supplemental Table S1.1 continued. 
Based on correlation 
with intake/ biokinetics 
Recovery biomarkers: excretion is highly correlated with intake (not subject to homeostasis, no substantial inter-individual differences in 
metabolism) 
Concentration biomarkers: excretion is correlated with intake, affected by metabolism or personal characteristics (e.g. sex, age, 
smoking, obesity,..) 
Replacement biomarkers: serve as proxy for intake when it is not possible to capture intake due to limited nutrient databases to assess 
intake 
Predictive biomarkers: show dose-response relationship with intake levels, are sensitive, time-dependent, may be affected by personal 
characteristics (see above) but distinction is that overall recovery is lower 
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Supplemental Table S4.1. List of all used standard substances, including their purity 
and manufacturer. In a separate column additionally combination of standard 
substances and their concentrations for the used standard solutions are included. 
FAME standards for RI 
Substance Purity Manufacturer FAME solution 
Methyl octanoate (C8) GC Merck, Darmstadt, Germany 
Each FAME 
250 µMol/L in 
heptane. 
Methyl decanoate (C10) 99% Sigma-Aldrich, Steinheim, Germany 
Methyl dodecanoate (C12) 99% Sigma-Aldrich, Steinheim, Germany 
Methyl tetradecanoate (C14) > 99% Sigma-Aldrich, Steinheim, Germany 
Methyl hexadecanoate (C16) > 99% Sigma-Aldrich, Steinheim, Germany 
Methyl octadecanoate (C18) > 99% Merck, Darmstadt, Germany 
Methyl eicosanoate (C20) > 99% Sigma-Aldrich, Steinheim, Germany 
Methyl docosanoate (C22) > 99% Sigma-Aldrich, Steinheim, Germany 
Methyl tetracosanoate (C24) > 99% Sigma-Aldrich, Steinheim, Germany 
Methyl hexacosanoate (C26) 95% Sigma-Aldrich, Steinheim, Germany 
Internal standards 
Substance Purity Manufacturer IS solution 
1-O-Methyl-2-desoxy-D-ribose 96% Sigma-Aldrich, Steinheim, Germany • 100 µMol/L 
• 50 µMol/L 
• 50 µMol/L in 
MeOH/dH2O. 
Phenyl-β-D-glucopyranoside 99% ABCR, Karlsruhe, Germany 
D-Pinitol 95% Sigma-Aldrich, Steinheim, Germany 
Sugar compounds 
Substance Purity Manufacturer 
Standard solutions 
(each 25 µMol/L) 
D-Threitol 99% Sigma-Aldrich, Steinheim, Germany 
Solution AA 
Galactaric acid 97% Sigma-Aldrich, Steinheim, Germany 
L-Threonic acid >97% Sigma-Aldrich, Steinheim, Germany 
Lacto-N-biose - Carbosynth, Berkshire, UK 
meso-Erythritol - Sigma-Aldrich, Steinheim, Germany 
Solution AB 
Glucono-δ-lactone >99% Sigma-Aldrich, Steinheim, Germany 
N-Acetyl-D-glucosamine >99% Carl Roth, Karlsruhe, Germany 
Lactose 99.5% Sigma-Aldrich, Steinheim, Germany 
Ribitol >99% Sigma-Aldrich, Steinheim, Germany 
Solution AC 
Eryhtronolactone >98% TCI Chemicals, Tokyo, Japan 
Gluconic acid >99% Sigma-Aldrich, Steinheim, Germany 
N-Acetyl-D-mannosamine >98% Sigma-Aldrich, Steinheim, Germany 
Xylitol >99% Sigma-Aldrich, Steinheim, Germany 
Solution AD 
2,3-Dihydroxybutyric acid - Sigma-Aldrich, Steinheim, Germany 
Isosaccharinic acid-1,4-lactone - Carbosynth, Berkshire, UK 
N-Acetyl-D-galactosamine >99% Carl Roth, Karlsruhe, Germany 
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Supplemental Table S4.1 continued.  
D-Arabitol >98% TCI Chemicals, Tokyo, Japan 
Solution AE 
3,4-Dihydroxybutyric acid - Sigma-Aldrich, Steinheim, Germany 
α-D-Glucoheptonic acid >99% Sigma-Aldrich, Steinheim, Germany 
D-Ribose-5-phosphate >99% Sigma-Aldrich, Steinheim, Germany 
1,5-Anhydroglucitol - Sigma-Aldrich, Steinheim, Germany 
Solution AF 
2,4-Dihydroxybutyric acid ≥95% Sigma-Aldrich, Steinheim, Germany 
D-Erythrose ≥75% Sigma-Aldrich, Steinheim, Germany 
D-Fructose-6-phosphate ≥98% Sigma-Aldrich, Steinheim, Germany 
L-Fucitol - Sigma-Aldrich, Steinheim, Germany 
Solution AG D-Erythrulose ≥85% Sigma-Aldrich, Steinheim, Germany 
Glucose-1-phosphate >98% Carl Roth, Karlsruhe, Germany 
D-Mannitol a.g. Sigma-Aldrich, Steinheim, Germany 
Solution AH 
1-Deoxy-D-xylulose-5-
phosphate 
>99% Sigma-Aldrich, Steinheim, Germany 
Glucose-6-phosphate >98% Merck, Darmstadt, Germany 
D-Sorbitol - Merck, Darmstadt, Germany 
Solution AI 2-Desoxy-D-ribose 99% Sigma-Aldrich, Steinheim, Germany 
Methyl-β-D-glucuronide - Carbosynth, Berkshire, UK 
Galactitol >99% Sigma-Aldrich, Steinheim, Germany 
Solution AJ D-Ribose >98% Carl Roth, Karlsruhe, Germany 
Methyl-α-D-glucopyranoside 99% Sigma-Aldrich, Steinheim, Germany 
L-Iditol - Carbosynth, Berkshire, UK 
Solution AK D-Arabinose >98% Sigma-Aldrich, Steinheim, Germany 
Ethyl-β-D-glucuronide - Carbosynth, Berkshire, UK 
Perseitol - Carbosynth, Berkshire, UK 
Solution AL D-Xylose r.g. Sigma-Aldrich, Steinheim, Germany 
Ethylglucoside - Chemos GmbH, Altdorf, Germany 
Maltitol 97% ABCR, Karlsruhe, Germany 
Solution AM D-Lyxose 99% Sigma-Aldrich, Steinheim, Germany 
Lactulose - Carl Roth, Karlsruhe, Germany 
Galactinol >98% Sigma-Aldrich, Steinheim, Germany 
Solution AN D-Apiose - Carbosynth, Berkshire, UK 
Laminaribiose - Carbosynth, Berkshire, UK 
allo-Inositol 97% Sigma-Aldrich, Steinheim, Germany 
Solution AO D-Ribulose 97% Sigma-Aldrich, Steinheim, Germany 
Maltose r.g. Sigma-Aldrich, Steinheim, Germany 
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Supplemental Table S4.1 continued.  
chiro-Inositol 98% ABCR, Karlsruhe, Germany 
Solution AP D-Xylulose - Carbosynth, Berkshire, UK 
Maltulose - Carbosynth, Berkshire, UK 
L-Fucose >99% Sigma-Aldrich, Steinheim, Germany 
Solution AQ 
Melibiose - Merck, Darmstadt, Germany 
myo-Inositol - Sigma-Aldrich, Steinheim, Germany 
Solution AR L-Rhamnose >99% Merck, Darmstadt, Germany 
D-Leucrose - Carbosynth, Berkshire, UK 
scyllo-Inositol 98% ABCR, Karlsruhe, Germany 
Solution AS Levoglucosan 99% ABCR, Karlsruhe, Germany 
Neohesperidose - Carbosynth, Berkshire, UK 
1-D-4-O-Methyl-myo-inositol 
 Carbosynth, Berkshire, UK 
Solution AT D-Galactose r.g. Serva, Heidelberg, Germany 
Neotrehalose ≥98% Sigma-Aldrich, Steinheim, Germany 
D-Glucose a.g. Sigma-Aldrich, Steinheim, Germany 
Solution AU 
Nigerose ≥94% Sigma-Aldrich, Steinheim, Germany 
cis-Inositol - Carbosynth, Berkshire, UK 
Solution AV D-Mannose >98.5% Carl Roth, Karlsruhe, Germany 
Palatinose ≥99% Sigma-Aldrich, Steinheim, Germany 
epi-Inositol - Carbosynth, Berkshire, UK 
Solution AW D-Allose - Carbosynth, Berkshire, UK 
Rutinose - Carbosynth, Berkshire, UK 
neo-Inositol - Carbosynth, Berkshire, UK 
Solution AX D-Altrose - Carbosynth, Berkshire, UK 
Xylobiose ≥90% Sigma-Aldrich, Steinheim, Germany 
2-Deoxy-D-ribonic acid-1,4-
lactone 
- Carbosynth, Berkshire, UK 
Solution AY 
D-Gulose - Carbosynth, Berkshire, UK 
Turanose 98% ABCR, Karlsruhe, Germany 
5-Deoxy-L-arabonic acid-1,4-
lactone 
- Carbosynth, Berkshire, UK 
Solution AZ 
D-Psicose >95% Sigma-Aldrich, Steinheim, Germany 
Galactosamine >97% Carl Roth, Karlsruhe, Germany 
D-Arabino-1,4-lactone - Carbosynth, Berkshire, UK 
Solution BA D-Fructose 99% Sigma-Aldrich, Steinheim, Germany 
α-Sophorose - Carbosynth, Berkshire, UK 
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Supplemental Table S4.1 continued.  
D-Ribono-1,4-lactone 95% ABCR, Karlsruhe, Germany 
Solution BB L-Sorbose - Sigma-Aldrich, Steinheim, Germany 
β-Gentiobiose 96% ABCR, Karlsruhe, Germany 
D-Xylonic acid - Carbosynth, Berkshire, UK 
Solution BC D -Tagatose 99% Sigma-Aldrich, Steinheim, Germany 
D-Trehalose >99% Sigma-Aldrich, Steinheim, Germany 
D-Galacturonic acid - Merck, Darmstadt, Germany 
Solution BD L-Idose - Carbosynth, Berkshire, UK 
D-Cellobiose >98% Carl Roth, Karlsruhe, Germany 
D-Glucaric acid >98.5% Sigma-Aldrich, Steinheim, Germany 
Solution BE D-Glycero-D-galacto-heptose - Carbosynth, Berkshire, UK 
D-Sucrose a.g. Sigma-Aldrich, Steinheim, Germany 
D-Glucaric acid-1,4-lactone - Sigma-Aldrich, Steinheim, Germany 
Solution BF D-Sedoheptulose ≥95% Sigma-Aldrich, Steinheim, Germany 
Epilactose - Carbosynth, Berkshire, UK 
D-Glucuronic acid >98% Carl Roth, Karlsruhe, Germany 
Solution BG D-Mannoheptulose - Carbosynth, Berkshire, UK 
Isomaltose 97% ABCR, Karlsruhe, Germany 
D-Mannonic acid-1,4-lactone - Carbosynth, Berkshire, UK 
Solution BH D-Glucosamine >99% Sigma-Aldrich, Steinheim, Germany 
Isoprimeverose - Carbosynth, Berkshire, UK 
D-Galactono-1,4-lactone - Carbosynth, Berkshire, UK 
Solution BI D-Mannosamine >98% Sigma-Aldrich, Steinheim, Germany 
Kojibiose - Carbosynth, Berkshire, UK 
a.g.: analytical grade; r.g.: research grade 
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Supplemental Table S4.2. Consumables utilized in this study. 
Consumable Manufacturer 
1.5 mL Reaction tubes (safe-lockTM) Eppendorf, Hamburg, Germany 
Molecular sieve 0.3 nm, type 564 Carl Roth, Karlsruhe, Germany 
Syringe, PTFE (25 µL, 50 µL) Trajan Scientific, Ringwood, Australia 
10 µL Syringe for CTC analytics systems, fixed needle, 
conical 
Trajan Scientific, Ringwood, Australia 
9 mm Screw thread vial 300 µL, fused insert, clear Thermo Scientific, Langerwehe, Germany 
9 mm Open top short screw AVCS cap, 6 mm hole, 
blue, Polypropylene, white silicone/Red PTFE 
Thermo Scientific, Langerwehe, Germany 
Pipette (0.1-10 µL, 0.5-20 µL, 10-100 µL, 2-200 µL, 50-
1000 µL, 500-5000 µL) 
Eppendorf, Hamburg, Germany 
2.0 mL Crimp vial, amber WICOM, Heppenheim, Germany 
11 mm Aluminium crimp cap, Butylgummi/PTFE WICOM, Heppenheim, Germany 
16.0 mL Glass screw thread bottle with cap, 
Butylgummi/PTFE-septum 
WICOM, Heppenheim, Germany 
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Supplemental Figure S4.1. Workflow of data processing. 
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Supplemental Table S4.3. Automated integration parameters. 
Parameter Setting/value 
Integrated m/z 160.00, 277.00, 292.00, 305.00, 307.00, 318.00, 319.00, 
333.00, 361.00, 421.00, and 437.00 
Timeframe Each ~ 16 min 
Mode Detail 
Slope 2500 min-1 
Width 0.04 s 
Drift 1000 min-1 
T.DBL 1000 min 
Min Height 3000 
Smooting None 
Spectrum process (Raw spectrum) Peak Top Spectrum/apex 
Spectrum process (Background 
spectrum) 
None 
 
Supplemental Table S4.4. Monosaccharides detected in human urine with the one-
dimensional GC-MS method and the two-dimensional GC×GC-MS method. 
Sugar compounds GC-MS GC×GC-MS 
Apiose 
 
X1 
Xylose X X 
Arabinose X X 
Ribose X X 
Ribulose/Xylulose 
 
X2 
Fucose X X 
Rhamnose 
 
X 
Tagatose 
 
X 
Psicose X X 
Fructose X X 
Allose X X 
Galactose X X 
Glucose X X 
Mannose X X 
Sorbose 
 
Traces3 
Mannoheptulose X X 
Unknown monosaccharide A0986_H2 
 
X 
Sedoheptulose X X 
Unknown monosaccharide U03/A0408 X X 
Unknown monosaccharide U21/A1005_H1 X X 
1
 no drift correction; 2 not separable, could be either or both; 3 identification unsure due to low signal 
intensity 
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Supplemental Table S4.5. Disaccharides detected in human urine with the one-
dimensional GC-MS method and the two-dimensional GC×GC-MS method. 
Sugar compounds GC-MS GC×GC-MS 
Sucrose X X 
Lactose X X 
Maltose X X 
Isomaltose 
 
Traces3 
Unknown disaccharide U26/A1254 X X 
Unknown disaccharide U27/A1307 X X 
Unknown disaccharide U28 X 
 
Unknown disaccharide U29 Traces 
 
Unknown disaccharide A1235 
 
X 
Unknown disaccharide A1283 
 
X 
Unknown disaccharide A1289 
 
X 
Unknown disaccharide A1302 
 
X 
3
 identification unsure due to trace amounts 
Supplemental Table S4.6. Polyols detected in human urine with the one-
dimensional GC-MS method and the two-dimensional GC×GC-MS method. 
Sugar compounds GC-MS GC×GC-MS 
Threitol X X 
meso-Erythritol X X 
1-Deoxypentitol A0220 
 
X 
1-Deoxypentitol A0226 
 
X 
2-Deoxypentitol 
 
X 
Unknown polyol U02/A0402 X X 
Xylitol X X 
Arabitol X X 
Ribitol X X 
1-Deoxyhexitol A0494_H1 X X 
1-Deoxyhexitol A0494_H2_H1 
 
X 
1,5-Anhydroglucitol 
 
X 
Fucitol  X X 
Mannitol X X 
Sorbitol X X 
Galactitol X X 
Perseitol  X X 
chiro-Inositol  X X 
scyllo-Inositol X X 
myo-Inositol X X 
allo-Inositol 
 Traces4 
cis-Inositol 
 Traces4 
4
 trace amounts, no analyte cluster detected 
  
7 SUPPLEMENT  
195 
 
Supplemental Table S4.7. Sugar acids detected in human urine with the one-
dimensional GC-MS method and the two-dimensional GC×GC-MS method. 
Sugar compounds GC-MS GC×GC-MS 
Glyceric acid 
 
X 
4-Deoxyerythronic acid 
 
X 
4-Deoxythreonic acid 
 
X 
2-Deoxytetronic acid 
 
X 
Erythronic acid X X 
Threonic acid X X 
Deoxy sugar acid A0250 
 
X 
2-Deoxyribonic acid/Unknown sugar acid U01 X X 
Deoxy sugar acid A0279_H1  X 
Deoxy sugar acid A0279_H2_H1  X 
5-Deoxyarabonic acid 
 
X 
Unknown sugar acid U06/A0471 X X 
Xylonic acid X X5 
Ribonic acid X X5 
Unknown sugar acid U09/A0510 X X 
Arabonic acid X X 
Unknown sugar acid A0532 
 
X 
Unknown sugar acid A0564 
 
X 
Glucuronic acid X X 
Mannonic acid X Traces 
Galactonic acid X X 
Glucaric acid 
 
X 
Gluconic acid X X 
5
 coeluting in the GC×GC-MS method. 
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Supplemental Table S4.8. Other sugar compounds and unknown sugar-like 
compounds detected in human urine with the one-dimensional GC-MS method and 
the two-dimensional GC×GC-MS method. 
Sugar compounds GC-MS GC×GC-MS 
Levoglucosan X X 
Ethyl-β-D-glucuronide X Traces4 
Methylglucopyranoside  Traces4 
N-Acetyl-D-glucosamine 
 
X5 
N-Acetyl-D-mannosamine 
 
X5 
N-Acetyl-D-galactosamine 
 X 
Glucosamine 
 
X 
Unknown U05/A0461_H1 X X 
Unknown U12/A0569 X X 
Unknown U24 X 
 
Unknown U25 X 
 
Unknown A0286 
 
X 
Unknown A0664 
 
X 
4
 trace amounts, no analyte cluster detected; 5 coeluting in the GC×GC-MS method. 
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Supplemental Table S4.9. All measured sugar compounds are listed together with their inter- and mean intra-day CV, median peak 
height, frequency in samples (Pr%) and QC’s (QC%), quantifying ion and the occurrence of coelution or partial coelution. Additionally, 
sugar compounds that only occur in traces or were saturated are marked. 
Sugar compounds 
Corrected Uncorrected 
median 
peak height Pr% QC% m/z Coelution 
inter-
day 
CV 
mean 
intra-day 
CV 
inter-
day CV 
mean intra-
day CV 
Apiose1 12.6 
 
12.6 
 
1.17E+04 33.0 22.9 307 
 
Xylose deriv. 1 4.9 3.7 22.0 8.1 5.53E+05 100 100 307 
 
Xylose deriv. 2 4.5 3.8 17.8 6.8 2.94E+06 100 100 307 partial coelution 
Arabinose 5.0 4.0 21.5 8.2 6.36E+06 100 100 307 
 
Ribose 5.3 4.3 21.5 8.0 2.48E+06 100 100 307 
 
Ribulose/Xylulose 6.4 5.4 22.7 11.3 8.10E+04 100 100 333 coelution 
Fucose 5.3 4.4 21.3 8.4 5.78E+05 100 100 277 
 
Rhamnose 5.6 4.8 20.5 8.3 1.50E+05 100 100 160 
 
Tagatose1 6.0 5.3 25.4 10.8 3.46E+04 98.1 99.3 307 
 
Psicose deriv. 1 4.7 3.6 23.4 9.0 1.10E+06 100 100 307 
 
Psicose deriv. 2 5.1 4.2 23.4 9.2 1.88E+06 100 100 307  
Fructose deriv. 1 4.9 4.2 23.7 9.4 8.32E+05 100 100 307  
Sorbose 6.1 5.2 26.6 15.4 7.74E+04 100 100 307  
Fructose deriv. 2 5.3 4.3 23.1 9.4 5.49E+05 100 100 307 
 
Allose deriv. 1 4.8 4.0 22.8 8.3 2.73E+06 100 100 319 
 
Mannose deriv. 1 5 4.1 23.1 8.5 6.31E+05 100 100 319 
 
Galactose deriv. 1 5.1 4.1 22.1 9.0 7.99E+05 100 100 319 
 
Glucose deriv. 12 1.9 1.6 8.4 3.6 1.53E+07 100 100 319 
 
Mannose deriv. 2/Allose deriv. 2 5.3 4.5 22.3 8.7 8.26E+04 100 100 319 coelution 
Galactose deriv. 2/Glucose deriv. 2 5.8 5.1 22.3 8.4 1.80E+05 100 100 319 coelution 
Mannoheptulose 5.0 4.1 26.6 11.6 7.56E+05 100 100 319 
 
Unknown monosaccharide A0986_H2 6.4 5.8 24.6 10.9 1.50E+06 100 100 319 
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Sedoheptulose 5.4 4.7 26.6 9.5 7.86E+06 100 100 319 
 
Unknown monosaccharide U03/A0408 4.9 3.9 23.3 8.0 9.14E+05 100 100 307 
 
Unknown monosaccharide U21/A1005_H1 5.9 5.3 26.6 9.9 6.98E+05 100 100 319 
 
Sucrose 6.1 5.4 53.9 16.7 8.24E+05 100 100 361 
 
Lactose deriv. 1 6.4 5.3 26.6 11.7 7.55E+05 100 100 361 
 
Lactose deriv. 2 7.1 6.2 24.9 11.4 1.70E+05 100 100 361 partial coelution 
Maltose deriv. 1 6.6 5.5 28.9 13.0 3.47E+05 100 100 361 coelution 
Maltose deriv. 2 5.5 4.8 26.2 10.9 2.09E+05 100 100 361 coelution 
Isomaltose1 9.4 8.1 36.6 17.0 3.45E+04 95.5 100 361 
 
Unknown disaccharide U26/A1254 9.1 7.0 28.0 13.0 2.18E+05 79.2 99.3 319 
 
Unknown disaccharide U27/A1307 6.5 5.6 20.2 9.9 1.93E+05 100 100 305 
 
Unknown disaccharide A12351 20.2 19.8 44.0 25.3 3.41E+04 15.9 83.3 319 partial coelution 
Unknown disaccharide A1283 7.2 6.5 29.7 13.0 3.78E+05 99.6 100 319 partial coelution 
Unknown disaccharide A1289 8.1 7.8 35.4 15.7 8.37E+04 73.1 99.3 319 
 
Unknown disaccharide A1302 9.4 7.9 31.1 14.7 8.49E+04 99.2 100 361 
 
Threitol 4.9 3.9 24.5 10.1 1.41E+06 100 100 307 
 
meso-Erythritol 4.7 3.9 22.4 6.3 5.98E+06 100 100 307 
 
1-Deoxypentitol A0220 5.4 4.6 21.6 8.0 5.15E+05 100 100 307 
 
1-Deoxypentitol A0226 4.8 3.9 21.5 8.0 6.97E+05 100 100 307 
 
2-Deoxypentitol1 6.7 5.8 25.9 11.6 3.96E+04 100 100 307 
 
Unknown polyol U02/A0402 5.2 4.5 24.0 8.7 1.77E+05 100 100 307 
 
Xylitol 5.5 4.3 22.9 7.9 1.48E+06 100 100 307 
 
Arabitol 4.9 4.4 22.0 7.0 8.11E+06 100 100 307 
 
Ribitol 5.2 4.7 22.3 8.1 2.27E+06 100 100 319 
 
1-Deoxyhexitol A0494_H1 7.7 6.2 45.8 13.8 3.37E+05 100 97.9 319 partial coelution 
1-Deoxyhexitol A0494_H2_H1 5.6 4.6 24.2 8.5 9.59E+05 100 100 319 partial coelution 
1,5-Anhydroglucitol 6.6 6.1 22.9 10.2 6.09E+04 100 100 319 
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Fucitol 6.0 5.4 23.3 8.8 3.09E+05 100 100 319 
 
Mannitol2 2.5 2.0 9.9 4.7 2.13E+07 100 100 319 
 
Sorbitol 5.8 5.0 22.4 8.2 5.74E+06 100 100 319 
 
Galactitol 5.6 4.9 23.2 8.1 1.47E+06 99.6 100 307 
 
Perseitol1 30.6 
 
53.0 
 
1.11E+04 48.1 86.1 319 
 
chiro-Inositol 4.5 3.3 22.9 7.5 3.58E+05 100 100 318 
 
scyllo-Inositol2 5.4 4.6 21.5 7.8 1.07E+07 100 100 318 
 
myo-Inositol2 3.9 3.7 15.5 7.0 1.29E+07 100 100 305 
 
epi-Inositol 5.4 4.7 21.7 8.5 1.56E+05 100 100 305 
 
neo-Inositol 10.6 6.7 23.4 10.7 1.98E+06 100 100 318 
 
Glyceric acid 5.0 4.5 16.1 7.9 5.87E+05 100 100 292 
 
4-Deoxyerythronic acid 3.4 2.9 15.4 6.5 6.43E+06 100 100 292 
 
4-Deoxythreonic acid2 2.2 1.8 10.4 6.0 1.33E+07 100 100 292 
 
2-Deoxytetronic acid 6.6 6.1 24.0 11.8 5.63E+04 98.5 100 305 partial coelution 
Erythronic acid2 1.6 1.4 6.9 3.7 2.01E+07 100 100 292 
 
Threonic acid 4.9 4.1 18.6 7.1 8.67E+06 100 100 292 
 
Deoxy sugar acid A0250 5.3 4.5 19.2 8.0 8.64E+05 100 100 292 
 
2-Deoxyribonic acid/Unknown sugar acid 
U01 4.9 4.1 20.8 7.9 7.20E+05 100 100 333 partial coelution 
Deoxy sugar acid A0279_H1 10 8.3 36.6 20.9 1.85E+04 93.5 100 292  
Deoxy sugar acid A0279_H2_H1 7.4 6.5 25.1 15.4 2.45E+04 99.6 100 292  
5-Deoxyarabonic acid 4.5 3.5 20 7.9 1.02E+05 100 100 292 
 
Sugar acid A0471/Unknown sugar acid U06 6.3 5.9 21.7 9.2 1.90E+05 100 100 292 
 
Xylonic acid/Ribonic acid 5.5 4.6 21.1 8.5 4.62E+06 100 100 292 coelution 
Sugar acid A0510/Unknown sugar acid U09 5.2 4.2 21.3 7.7 1.53E+06 100 100 292 
 
Arabonic acid 5.0 4.2 22.1 8.2 5.25E+06 100 100 292 
 
Sugar acid A05321 40.7 41.0 63.6 50.5 1.22E+04 61.4 81.3 292 partial coelution 
7 SUPPLEMENT  
200 
 
Supplemental Table S4.9 continued.        
Sugar acid A0564 5.6 4.6 22.9 9.2 1.28E+05 100 100 292 
 
Glucuronic acid deriv. 12 3.6 3.1 12.9 5.1 1.85E+07 100 100 333 
 
Glucuronic acid deriv. 2 5.2 4.1 21.2 8.2 2.92E+06 100 100 333 
 
Mannonic acid1 7.5 6.7 26.5 12.6 3.39E+04 98.9 100 305 
 
Galactonic acid1 23.7 23.2 40.1 29.1 9.32E+03 41.7 86.8 305 partial coelution 
Glucaric acid 6.3 5.1 24.9 10.0 2.44E+06 100 100 333 
 
Gluconic acid 5.2 4.2 22.6 7.9 9.50E+06 100 100 333 
 
Glucono-δ-lactone 6.4 5.5 21.2 9.4 1.98E+06 100 100 319 
 
Glucono-γ-lactone 5.3 5.0 24.2 10.8 7.38E+04 100 100 305 
 
Levoglucosan 4.9 4.1 22.3 9.7 8.69E+05 100 100 333 
 
N-Acetyl-D-glucosamine/N-Acetyl-D-
mannosamine 5.7 4.5 25.6 9.4 6.80E+05 100 100 319 coelution 
N-Acetyl-D-galactosamine 5.8 4.7 25.1 10.1 4.08E+05 100 100 319 
 
Glucosamine 26.4 22.6 48.8 32.7 7.42E+04 
  
160 partial coelution 
Unknown U05/A0461_H1 4.1 3.5 20.1 6.2 3.46E+06 100 100 305 
 
Unknown U12/A0569 5.3 4.2 24.0 8.3 5.51E+05 100 100 307 
 
Unknown A02861 23.6 16.1 47.0 27.2 2.14E+04 34.1 92.4 307 
 
Unknown A06641 8.8 8.1 29.5 15.9 2.19E+04 66.7 99.3 319 partial coelution 
Methyl-desoxyribose deriv. 1 3.3 2.4 13.8 5.1 
   
160 
 
Methyl-desoxyribose deriv. 2 2.2 1.7 11.0 4.5 
   
160 
 
Pinitol 3.0 2.0 19.5 4.3 
   
318 
 
Phenylglucopyranoside 10.5 6.9 32.0 12.0 
   
319 
 
1
 Trace amount (peak height < 5.00E+04); 2 saturated analyte (peak height > 1.00E+07) 
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Supplemental Table S4.10. Data points of 15 selected sugar compounds for both 
the one-dimensional GC-MS sugar profiling method and the two-dimensional 
GC×GC-MS method. 
Sugar compounds GC-MS GC×GC-MS 
Arabinose 15 7 
Fucose deriv. 2 11 6 
Fructose deriv. 2 11 7 
Glucose deriv. 1 12 7 
Sedoheptulose deriv. 1 14 5 
Sucrose 13 9 
Lactose deriv. 1 11 8 
Threitol 10 6 
Ribitol 10 5 
Sorbitol 10 6 
scyllo-Inositol 12 7 
Erythronic acid 9 8 
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Supplemental Table S5.1. Application of the validation scheme by Dragsted et al. [74] on the putative avocado consumption markers 
mannoheptulose and perseitol (section 3.2). 
Validation questions [74] Avocado – mannoheptulose and perseitol 
1. Plausibility: Is the marker compound plausible as a specific biomarker 
of food intake for the food or food group? 
- variability of (parent) compound in food or food group is limited 
 
- level of compound in other food is comparatively low or presence 
only in other foods not commonly consumed 
Yes - both occur naturally in avocados (sugar profiling of 75 fruit and 
vegetables section 3.2 and literature [115-117]) 
- only one variety (Hass avocado) typically consumed, but 
concentrations may vary depending on ripening stage [116] 
- mannoheptulose occurs in other fruit and vegetables, perseitol only in 
traces in a few fruit and vegetables (section 3.2) 
2. Dose-response: Is there a dose-response relationship at relevant 
intake levels of the targeted food (quantitative aspect)? 
- established using several intake levels (meal study) or different meal 
studies with comparable results or cross-sectional or longitudinal 
observational study 
- background level is 0 or low 
Yes - dose-response relationship not yet evaluated with respect to 
quantitative consumption of avocado 
- qualitative dose-response established in cross-sectional 
observational study (section 3.2) and in a meal study with several 
intake levels [109] 
- low for mannoheptulose; traces for perseitol (section 3.2) 
3. Time-response: Is the biomarker kinetics described adequately to 
make a wise choice of sample type, frequency and time window? 
- single-meal time response relationship has been described for 
defined sample type and time window in a meal study 
- kinetics after repeated intakes has been described for defined 
sample type in a meal study or accumulation in certain sample types 
has been observed 
Yes - kinetics in urine see [109], excretion within 16 hours after consumption: 
short-term or acute marker 
- yes, see above 
 
- no, however, both sugars are highly polar and as such unlikely to 
accumulate in the human body 
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Supplemental Table S5.1 continued.   
4. Robustness: Has the marker been shown to be robust after intake of 
complex meals reflecting dietary habits of the targeted population? 
- robust after intake of complex meals in intervention studies or 
observational studies 
- no confounding food observed or its level is low or confounding foods 
are not commonly consumed 
 
Yes - KarMeN study is an observational cross-sectional study with 
participants on an unrestricted and diverse diet (section 3.2) 
- intervention study not available; observational study (section 3.2) 
 
- no confounding food observed for perseitol (section 3.2), minor 
confounding for mannoheptulose possible (occurs in other food as 
well; section 3.2) 
5. Reliability: Has the marker been shown to compare well with other 
markers or questionnaire data for the same food/food group? 
- marker has compared well with other biomarkers of same food or 
food group or with dietary assessment instruments or with data in 
studies with highly controlled setting and supervised intake 
partially1 - in KarMeN study self-reported intake of a 24 hour recall was used to 
establish correlation (section 3.2), but no objective comparison 
between the 24 hour recall and the marker was performed 
- no other markers known and no studies with controlled setting 
available 
6. Stability: Is the marker chemically and biologically stable during 
biospecimen collection and storage, making measurements reliable and 
feasible? 
partially - no data available 
7. Analytical performance: Are analytical variability (CV%), accuracy, 
sensitivity and specificity known as adequate for at least one reported 
analytical method? 
- protocol of method has been well described and could be repeated 
- method has been compared with validated method or reference 
Yes - see section 3.2 for KarMeN study and [109] 
 
 
- see section 3.2 for KarMeN study and [109] 
- no data available 
8. Reproducibility: Has the analysis been successfully reproduced in 
another laboratory? 
partially - no data available 
- however, at least two laboratories with different methods identified 
both sugars as potential dietary marker (see section 3.2 and [109] 
1
 partially: not enough or no data available to fully answer with yes or no. 
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